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Abstract
Protein -  carbohydrate recognition is an important target for inhibitor development 
Improved inhibitor design requires a fundamental molecular basis of these interactions. 
This thesis describes the preliminary structural studies on three carbohydrate processing 
enzymes, UDP-galactopyranose mutase, a-D-glucose-1-phosphate thymidylyltransferase and 
TDP-glucose 4,6-dehydratase. These enzymes are found in important human pathogens 
such as Mycobacterium tuberculosis and Salmonella typhimurium.
The major focus of the thesis has been on UDP-galactopyranose mutase, the enzyme 
responsible for catalysing synthesis o f the thermodynamically unfavourable 5 membered 
ring form of galactose, UDP-galactofuranose from the thermodynamically favoured 6 
membered ring form, UDP-galactopyranose. UDP-galactofuranose plays a key role in 
mycobacterial cell walls.
This thesis also describes work with concanavalin A. This legume lectin is an invaluable 
model for the study of protein -  carbohydrate interactions. Two concanavalin A complexes 
are discussed. Both structures clear up misunderstandings in the literature and provide an 
insight into designing enzyme inhibitors.
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Chapter 1
Tuberculosis and the Mycobacterial Cell Wall.
21
1.1 Summary
Tuberculosis is a dangerous disease caused by infection with Mycobacterium tuberculosis. It 
is responsible for around 3 million deaths annually and is estimated to infect as many as one 
third of the world’s population. Established methods of treating infection are in increasing 
danger of becoming obsolete as new multi-drug resistant strains of the disease emerge. 
These factors combine to make the requirement for new anti-tuberculosis drugs urgent.
One method of destroying the bacterium is to dismpt the cell wall. This can be achieved by 
targeting the enzymes responsible for cell wall biosynthesis. The mycobacterial cell wall is 
uniquely complex: its biosynthesis affords novel targets for drug intervention.
The successful development of new drugs is greatly aided by a three-dimensional picture of 
the target enzyme active site. This can be obtained by protein crystallography. This chapter 
describes the re-emergence of the mycobacterial infection tuberculosis and the strategies 
being adopted to over come this. Particular emphasis is placed on the structure and 
biosynthesis of the mycobacterial cell wall and the targets it presents for novel drug 
intervention.
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1.2 Introduction
There are over 70 different strains of mycobacteria. All are non-capsulated, acid fast, 
obligate aerobes with characteristic cell walls containing an unusually high percentage of 
lipids. Most appear as harmless saprophytic inhabitants of soil, however there are notable 
exceptions, the most important of which is Mycobacterium tuberculosis {M. tuberculosis). 
Figure 1.1. This infects one third of the worlds population (Dolin et al, 1998). Other 
pathogenic mycobacteria include Mycobacterium leprae (M. leprae) which causes leprosy, 
and a class of rarely occurring species termed the ‘Atypical Mycobacteria’. The remaining 
mycobacteria are primarily environmental organisms collectively known as MOTTS 
(Mycobacteria Other Than Tuberculosis) (Elliot et al, 1997).
Figure l . l :  M. tuberculosis.
(htto://\v'ww.act.iict.ac.7.a/depTs/mmi/iste\u/lecTure.html)
Pathogenesis of Tuberculosis
Pulmonary tuberculosis (TB) is the most common form of the disease and is transmitted in 
the form of aerosol droplets that may be inhaled by the lungs. The most obvious symptoms 
of pulmonary TB include fatigue, weight loss, chest pains and night fevers. Once the 
bacterium has gained entry to the body it activates the body’s defence mechanisms and is
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engulfed by macrophages. Macrophages phagocytose foreign objects and destroy them upon 
release of toxic enzymes. For reasons not yet fully understood M, tuberculosis infections 
evade this attack and survive. If the invading bacterium survives it can follow one of two 
available routes proceeding to latent infection or active disease. In both scenarios the 
macrophages fail to eradicate the infection and it is the immune system’s ability to contain 
the bacterium which determines the route the infection. In the clinical disease, the 
mycobacteria divide inside the macrophages until the macrophage ruptures spilling not only 
the mycobacteria but also toxic enzymes. This process results in lesions in the lung where 
the mycobacteria multiply freely, eventually destroying the lung tissue and rupturing blood 
vessels; this is the active form of the disease and results in the blood stained sputum. 
Alternatively the host immune system may halt the spread of the disease by containing 
infected macrophages behind a barrier of white blood cells and phagocytes known as 
granulomas. This is the latent form of the disease, and unless the immune system is 
compromised represents no danger to the individual. However, if the immune system 
becomes suppressed for example as result of an accident, viral infection etc. the otherwise 
latent mycobacterial infection may proceed to the clinical form of the disease. Figure 1.2.
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Figure 1.2. The pathogenesis o f tuberculosis
Mtb coughed or exhaled 
by active case.
Remains in the air I
Inhaled by family 
members, friends etc
Evades macrophage attack I
Macrophages attack and 
lake up bacterium.
Fails to establish infection I
Active disease, weight 
loss, fever etc
Latent Infection,
bacteria live inside 
granulomas.
History o f Tuberculosis
M. tuberculosis was first identified as the bacterium responsible for tuberculosis in 1882 
(Koch, 1882), although it is thought the disease has been around for many centuries prior to 
this discovery. Evidence for these claims was uncovered in 1994 when Salo and co-workers 
recovered DNA unique to M. tuberculosis from a lung lesion of a spontaneously mummified 
1000 year old adult female body in southern Peru (Salo et al, 1994).
The incidence of the disease in between these centuries is unclear. It is believed that almost 
all Europeans were infected with TB in the 17^ *' century, with the bacterium being 
responsible for one in four deaths at this time (http://www.brown.edu/Research/TB- 
HIV_Lab). Over the next centuiy it is thought the incidence of tuberculosis went into 
decline before a resurgence to peak levels in the early 1800’s, when the annual mortality rate 
in Europe and the U. S. was around 5000 per 1 000 000. The number of tuberculosis 
infections then went into decline, and in 1882, when Koch gave his historic lecture, its
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occurrence had fallen over 50% from the peak levels reported in the early 1800’s. This trend 
continued into the 20'^ century and was accelerated mid-century with the introduction of 
effective therapies to combat the disease. In 1969 the TB death rate in the U. S. was down to 
40 per 1 000 000 (http://www.brown.edu/Research/TB-HIV_Lab). Perhaps inevitably the 
last two decades have seen this trend reversed and incidences of TB have again started to rise 
throughout the whole world.
Current Status ofTB
In 1997 more people died from TB that any year in living history (World Health 
Organisation, 1998). A disease once thought to be confined to the realms of history, TB is 
most definitely back with a vengeance. That year there were approximately 7.25million new 
infections of TB and aiound 3 million deaths as a direct result of TB infection (World Health 
Organisation, 1998). This is more than the combined total from malaria, diarrhoea, 
HIV/AIDS and tropical diseases, conspiring to make TB one of today’s most pressing global 
problems. In addition one in every three people are hosts to a dormant TB infection, (each 
has a 10% chance of progressing from infection to clinical disease), providing a significant 
reservoir of disease for the future. Moreover, the disease is a world-wide problem and is not 
confined to poor underdeveloped nations, Table 1.1. TB occurs in every country in the 
world with the highest incidences being in Asia and Africa. In recent years it has re-emerged 
as a major heath issue in Russia where as many as 10% of Russian prisoners are infected. 
More alarmingly, 20 000 of these prisoners are infected with new emerging strains of the 
disease known as Multi-Drug Resistant - TB or MDR - TB (TB Treatment Observer, 1998). 
These deadly versions of the disease have developed a resistance to at least two of the
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frontline drugs used to treat TB. Moreover in a few isolated cases they have been found to 
be resistant to as many as seven anti - TB drugs (Frieden, 1996).
Table L I: Global distribution ofTB cases in 1997 (Dolin et al, 1998)
Region No. of Cases Deaths
Southwest Asia 2 800 000 1 095 000
Africa 1 650 000 770 000
Western Pacific 1 583 000 594 000
Americas 448 000 160 000
Eastern Mediterranean 427 000 173 000
Europe 342 000 118 000
Total 7 249 000 2 908 000
Treatment of TB
What is particularly distressing about the current death rates as a result of M. tuberculosis 
infection is that they are largely avoidable. There are several methods of overcoming 
infection by M. tuberculosis, though the efficiency of the therapeutic measures used may 
vary depending on which area of the world they are applied (Duncan, 1997). The current 
World Health Organisation (WHO) recommendation is a combination of 4 front-line anti- 
mycobacterial drugs, isoniazid, ethambutol, pyrazinamide and rifampicin, administered over 
a minimum period of two months followed up by a further four months of just two of these 
dmgs, isoniazid and rifampicin Figure 1.3. This multi-drug therapy is known as DOTS 
(Directly Observed Treatment Short course) and has cure rates of upto 95% (Dolin et al, 
1998). Furthermore, treatment by DOTS is inexpensive, a six month course costs only £25, 
allowing it to be implemented world-wide as an effective treatment of TB. Attempts to treat
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TB with a single drug often result in the selection and growth of drug resistant strains of the 
bacteria. It was this observation that catalysed the introduction of DOTS.
Figure 1.3: Three o f the WHO recommended front-line drugs used to treat TB.
HO'
OH
•OH;
Isoniazid (+)E tham butol
OHAoOi
OHOH
Me
NH
Me
OH
R ifam picin
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In addition to DOTS a vaccination against TB is also available. The bacille Calmette-Guerin 
(BCG) was first introduced in the 1950’s and involves inoculation with a live attenuated 
strain of the closely related species Mycobacterium bovis (Evans, 1998). The efficacy with 
which the BCG works seems to depend on the region of the world it is applied. 
Administration in the UK affords greater than 80% protection against infection whereas in 
Southern India protection rates are almost zero (Duncan, 1997). As to why this is the case 
no-one exactly understands. At present, the most favoured explanation involves co-infection 
with other non-pathogenic bacteria that interferes with, or masks, BCG protection (Bloom & 
Fine, 1994).
Reasons for Resurgence of TB
Despite the existence of effective TB therapies, the recent rise in numbers of TB infections is 
a problem of human making. There are many reasons for the high number of unnecessary 
deaths including a lack of easily accessible health seiwices, diagnostic facilities, delays in 
patients seeking medical attention and perhaps most importantly, the failure of patients to 
comply with prescribed regimens.
The emergence of MDR-TB is primarily a result of insufficient resources and poor patient 
compliance, that is, failing to complete a full course of therapy. This provides the selection 
mechanism needed for the development of resistance in mycobacteria. MDR-TB is 
profoundly more difficult to cure than drug sensitive mycobacteria, requiring more expensive 
and toxic drugs for treatment. Even then it is often the case that treatment is unsuccessful. It 
does not seem a coincidence that the regions throughout the world with a high prevalence of 
MDR-TB are those with a poor health care infra-structure leading to poor patient compliance
29
(WHO, 1998). Strains of MDR-TB have been known to be resistant to as many as 7 
different classes of anti-mycobacterial drugs resulting in mortality rates of patients infected 
being on a par with the pre-antibiotic era.
The Human Immunodeficiency Virus (HIV) epidemic represents an additional contributory 
factor to the resurgence ofTB. Infections with HIV compromise the host’s immune system 
increasing the likelihood, by about 1 0% per year, that a dormant mycobacterial infection 
will start to replicate and progress to the active form of the disease (Young, 1995). In turn, 
the development of an active mycobacterial infection speeds up the progression of HIV to 
AIDS. Considering approximately one third of the world’s population is host to a dormant 
mycobacterial infection, the synergy between HIV and TB, Figure 1.4, is likely to result in 
substantially increased numbers ofTB infections. The WHO estimates the HIV/TB link will 
result in an additional 750 000 cases of TB annually which otherwise would not have 
occurred (TB Treatment Observer, 1998).
Figure 1.4: Cartoon representation, taken from the WHO's 'TB treatment 
Observer o f  the co-operation displayed between TB and AIDS.
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Unfortunately research into M. tuberculosis, and the way it causes disease has been a low 
priority over the past thirty years. An over reliance on the primary frontline drugs, together 
with the belief that the disease was confined to the third world saw research funds restricted, 
and little progress made in the research and development of new anti-mycobacterial drugs. 
Furthermore, as M. tuberculosis is an extremely difficult and dangerous pathogen to work 
with, requiring specialised expensive containment facilities, it was not a particularly 
appealing organism to be working on. In addition, as M. tuberculosis cells divide only once 
in 24 hours it takes three to four weeks to form a single colony on an agar plate under ideal 
incubation conditions. This results in significant delays in diagnosis when the infection can 
be freely transmitted in the interim period.
Against this backdrop, the urgency with which new anti-mycobacterial drugs aie required is 
clear. Accordingly, recent years have seen a substantial increase in the funds being made 
available to achieve this goal. Several lines of novel research are being pursued, including 
genomics, immunotherapy, vaccination and the targeting of the mycobacterial cell wall in the 
quest for new anti-mycobacterial agents.
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1.3 New Developments in Tuberculosis Treatment 
Immunotherapy
This is an alternative line of approach, in that the host is targeted rather than the pathogen. 
Patients are treated with a heat-killed preparation of the non-pathogenic Mycobacterium 
vaccae before embarking on a course of DOTS (Stanford et al, 1990). Whilst this failed to 
improve the overall cure rate, significant improvements were made in the treatment of MDR- 
TB or where patients had failed to complete the prescribed drug course (Etemadi et al, 
1992). Why this is so is not exactly clear, but it is thought that an immune response is 
stimulated allowing the host to eliminate latent mycobacteria which are unaffected by the 
drugs. This method of treatment is currently undergoing phase II clinical trials in South 
Africa.
Vaccines
Progress is being made in different areas towai'ds generating new candidate vaccines. 
Research has primarily focused on development of attenuated strains of M. tuberculosis 
(MeAdam et al, 1995), protein subunit vaccinations (Anderson et al, 1995), nucleic acid 
vaccines (Ulmer et al, 1993) and improving the existing BCG vaccination (Maharias et al,
1996). However, despite many advances in these areas, any new vaccine would have to be 
more effective than the existing BCG. For this to be proven a method of monitoring 
protective immunity must be identified in order to avoid lengthy and expensive clinical trials.
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Genomics
The sequencing of the complete M. tuberculosis genome has been completed by Cole et al 
(1998) revealing the sequence of every potential drug target of any new anti-mycobacterial 
diug. The sequence consists of some 4.4 million base pairs being surpassed only in size by 
the E. coli genome (Blattner et al, 1997). The sequence confirms the bacteria to have the 
metabolic potential to exist in a variety of environments. This may explain how the bacteria 
survive in what is thought to be a largely anaerobic environment when the infection is 
housed in the dormant state. Indeed, Cunningham and Spreadbury (1998) have reported a 
thickening of the mycobacterial cell wall when the bacterium are starved of oxygen, possibly 
strengthening the bacteria’s ability to survive in the dormant state.
1.4 Mycobacterial Cell Wall
At the lecture of Robert Koch in 1882, when M. tuberculosis was first identified as the agent 
responsible for TB, the unusual appearance of the mycobacterial cell wall was commented 
upon (Koch, 1882). Subsequently with sequencing of the M. tuberculosis genome, its 
importance in mycobacterial physiology has been confirmed with the identification of some 
250 genes associated in lipid and polysaccharide metabolism, providing a cornucopia of 
potential new diug targets.
The structure of the cell wall itself is an elaborate one and it presents a formidable barrier to 
anti - tuberculosis drugs. Figure 1.5. It consists of several unusual polymers and is thick and 
hydrophilic in nature. This confers on their bacteria an extraordinary resistance to drugs, the 
host immune system, dehydration and acid treatment (Draper, 1982).
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Figure 1.5: The mycobacterial cell envelope. UDP-galactopyranose muta.se i.s 
located in arabinogalactan and catalyses the interconversion o f  
UDP-galpOnd UDP-galf. LAM is not shown, (Evans, 1998).
Arabinoluranos*
C#N membrane
Four classes of polymers make up the cell wall: peptidoglycan, arabinogalactan, mycolic 
acids and lipoarabinomannan (LAM). Three of these polymers make up what is the fulcrum 
of the cell wall in the mycolyl arabinogalactan-peptidoglycan complex (mAGP). The first of 
these four polymers, peptidoglycan, consists of linear polysaccharide chains extensively 
cross-linked by short peptides. Peptidoglycan is covalently linked to the next polymer in the 
cell wall, arabinogalactan, via a unique diglycosy 1 phosphory 1 bridge containing rhamnose 
and V-acetyl glucosamine. Figure 1 .6 .
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Figure L6: The linker region connecting the peptidoglycan and arabinogalactan.
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Arabinogalactan is an essential structural component of the cell wall, forming a connection 
between peptidoglycan and mycolic acids. Its backbone consists of alternating p(l, 5) and 
P(l, 6 ) galactofuranose (gal/) residues branched from which are three units each consisting of 
linear a ( l ,  5) linked arabinan. The sugars that make up the arabinogalactan are all in their 
furanose configuration, (5 membered ring structure), as opposed to the more commonly 
found 6  membered ring structure (pyranose) Figure 1.7,
35
Figure 1.7: Simplified representation o f the arabinogalactan backbone.
HO.
'ARABINANAra
t(al-5)yHO OH = \
H O  ^ a l  0  OH OH
G lcN A c-P -P ep tid og lycan
HO
HO.
HO OH
P  =  P h o sp h a teHO OH
The mycolic acids aie located in clusters of 4 on the terminal pentaarabinofurunosyl units, 
consisting of a mixture of different Ceo -  C90 branched fatty acids forming a pseudo -  outer 
membrane, making the membrane a highly hydrophilic stmcture. Approximately two thirds 
of the terminal pentaarabinofurunosyl are mycolated. In the mAGP complex, 
arabinogalactan forms an integral part of the cell wall proper whereas the fourth polymer 
LAM has been implicated as a key surface molecule involved in the virulence of 
mycobacterial disease. LAM’s complex structure comprises a core of 6  mannose residues, 
substituted to varying degrees at position 2  with single a-mannose residues, directly attached 
to position 6  of the inositol of the phosphatidyl linker. To date it is still unclear how LAM is 
associated with the cell wall; though unpublished results (P. Draper) imply the lipoglycan is 
firmly but not covalently attached. In addition, monoclonal antibodies to LAM recognise 
whole mycobacterial cells in enzyme linked immune assays suggesting at least part of the 
molecule is accessible to the outside environment (Chatterjee, 1997). Structurally, the
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macromolecular arabinan is an ensemble of oligomeric a ( l , 5)-D-ai*abinofuranose chains via 
bridging a-D-arabinofuranose residues at numerous branched points, terminating with a (32- 
D-arabinofuranose. It is postulated that the phosphatidyl-inositol acts as a linker to other 
structural elements of the cell envelope.
Although the basic salient features of the cell wall are well understood it is only in recent 
years that an understanding of its biosynthesis has emerged. Figure 1.8. There is 
considerable current research interest in this area, as it is anticipated that the cell wall will 
contain several chemically unique features offering excellent targets for novel antibiotics.
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Figure 1.8: Proposed pathway for the assembly o f  arabinogalactan, its attachment 
to peptidoglycan and subsequent mycolyation.
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1.5 Biosynthesis of Arabinan
Arabinan is central to the integrity of the mycobacterial cell wall having two important roles 
to play. In the chemical setting of the mAGP complex, arabinan is an essential structural 
component of the cell wall framework. Whereas in the context of LAM, arabinan is 
implicated as being a key surface molecule involved in the pathogenesis of mycobacterial 
disease. However, it is only in recent years that an understanding of the biosynthesis of 
arabinan has been obtained.
It is postulated that arabinan biosynthesis in mAGP and LAM is via a similar set of 
arabinosyitransferases, as each structural motif (mAGP and LAM) terminates with the same 
pentaarabinosyl structure. It follows that as each motif is unique then overall arabinan 
biosynthesis must either be enzyme regulated, compartmentalised or involve enzymes 
sufficiently distinct that will allow divergent processing.
Characterisation of lipids extracted from the membrane of Mycobacterium smegmatis (M. 
smegmatis) by Woluka and co-workers (1994) suggested that (3-D-arabinofuranosyl-1- 
monophosphodecaprenol (DPA), to be the arabinofuranose precursor in arabinan 
biosynthesis (Woluka et al, 1994). Further work with synthetically derived DPA and a 
arabinosyl transfer assay demonstrated that DPA was indeed being incoiporated into cell 
wall material (Woluka et al, 1994; Lee et al, 1995). In addition, if isotopically labelled 
polyprenylphosphate [‘‘^ C] arabinofuranose is incubated with particulate enzymes from M. 
smegmatis it is converted into arabinan, and further characterisation reveals hexa- 
arabinose and di-arabinose oligomers to be present (Schermann et al, 1996). Namely the 
two stmctural motifs found in mAGP and LAM. As arabinan is detected in both internal 
and external arrangements of arabinan suggests the donor (DPA) is unique in mycobacteria.
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It is currently uncleai* how DPA is derived biosynthetically. Initially the biosynthesis of 
DPA was anticipated to involve sugar nucleotides as polyprenylphosphate sugars are 
generally synthesised via sugar nucleotides (Shibaev et al, 1986). However, attempts to 
identify such analogues failed (Takayama & Kilbum, 1989; Singh & Hogan, 1994). As a 
result alternative routes were investigated as viable pathways to DPA biosynthesis.
Currently, it is thought that DPA is derived from 5’-phosphoribosyi-l-pyrophosphate (pRpp) 
via 5’-phosphoarabinosyl-l-pyrophosphate (pApp). Schermann and co-workers (1996) have 
shown pRpp to be a biosynthetic precursor of polyprenylphosphate-arabinose and that 
polyprenylphosphate-arabinose is formed via polyprenyl phosphate-5-phosphoarabinose. 
Figure 1.9. Inhibition of the enzyme forming polyprenylphosphate should inhibit the 
formation of pApp and subsequently arabinose, thus preventing cell wall synthesis. As D- 
arabinofurosyl is absent in humans, these enzymes become appealing therapeutic targets, as 
inhibitors would most likely be non-toxic. If this hypothesis is correct, then the crucial and 
as yet unresolved step, is the épimérisation from D-ribose to D-arabinose in the formation of 
pApp. The enzyme involved here would be an inviting subject for structure determination 
with a view to rational ding design. Alternatively, one might consider inhibiting the 
biosynthesis of pRpp as a means of ultimately inhibiting arabinan synthesis, but as pRpp is 
generated by way of the pentose phosphate pathway, inhibition at this level would ultimately 
inhibit DNA synthesis.
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Figure 1.9: The biosynthetic route to polyprenylphosphate-ribose and the proposed 
route to polyprenylphosphate-arabinose. Established pathways are in 
unbroken lines and proposed pathways in broken lines (Schermann et al, 1996).
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A recent investigation by Draper and co-workers (1997) identified galactosamine (GalN) 
bound at position 2 of arabinose in the arabinogalactan motifs. As it is present in its free un- 
N-acetylated state it is postulated that it may help stabilise mycobacterial cell walls through 
binding of anionic substances. Candidates include the phosphatidylinositol-based LAM or 
the phosphate linker itself. Similarly as glutamic acid polymers are known to be located 
within the cell walls of mycobacteria then GalN may bind free cai'boxyl groups thus
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attaching polymers to the cell wall. What is particularly significant about the presence of 
GalN is that it has only been found in the cell walls of slow growing mycobacteria; it is 
conspicuously absent in all rapid growing species. It may point to a difference in the cell 
wall structures of slow and rapid growing mycobacteria and give an insight into why only 
slow growing species are pathogenic.
The anti-mycobacterial compound ethambutol has been used in the treatment of TB since 
1961 (Thomas et al, 1961). As well as being a front-line drug recommended for TB 
treatment it is also used to treat opportunistic infections of AIDS patients caused by the 
atypical mycobacteria, Mycobacterium avium. Several lines of evidence exist to support the 
theory that the critical target for ethambutol lies in the biosynthesis of arabinogalactan. 
Mikusova et al (1995) demonstrated that addition of ethambutol to cultures of 
Mycobacterium smegmatis resulted in appreciable amounts of DPA accumulation, the 
proposed arabinan donor in both arabinogalactan and LAM. Secondly, the observations 
reported by Deng et al (1995) and Mikusova et al (1995) illustrate that although the de novo 
synthesis of arabinan may be via a similar set of arabinosyitransferases it appears its 
subsequent polymerisation is through a different route in each structural motif.
The genes encoding ethambutol resistance {emb A, B and R) have been isolated from M. 
avium and transfected into M. smegmatis. The otherwise ethambutol susceptible M. 
smegmatis was rendered resistant to ethambutol after this treatment. Characterisation of the 
genes revealed that only embAB were necessary for an ethambutol resistant phenotype. 
EmbR is expendable though an intact promoter region between embR and embAB is required. 
An ethambutol sensitive cell free assay for arabinan biosynthesis showed that overexpression
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of the embAB is associated with high level ethambutol resistant arabinosyltransferase activity 
and that embR appears to modulate the in vitro level of this activity (Belanger et al, 1996),
1.6 Biosynthesis of the Linker Region and Galactan
In contrast to the biosynthesis of arabinan, the biosynthesis of the linker region is relatively 
well understood (Mikusova et al, 1996). Pioneering work on the biogenesis of the cell wall 
of gram positive bacteria (Daffe et al, 1990; M'^Neil et al, 1991) allowed a framework to be 
established for the biosynthesis of this region of the mycobacterial cell wall. Experiments by 
Mikusova and co-workers have provided firm evidence that this framework is correct 
(Mikusova er a/, 1996).
Radiolabelling of UDP-GlcNAc and subsequent characterisation, including assaying 
tunicamycin activity, of the two glycolipids (GLi & GL2) formed after incubation with 
membranes from M. smegmatis showed the glycolipids to be polyprenyl based. Similarly, 
assaying incorporation of radiolabelled TDP-rhamnose into GL, and GL% showed TDP- 
rhamnose was only taken up in GL2, suggesting GL2 is in fact polypreny 1-P-P-GlcNAc- 
rhamnose.
Synthesis of the galactan polymer (alternating 5, 6 linked galactofuranose) has also been 
confirmed by radiolabelling experiments. Using either UDP [‘"^C]-GlcNAc or UDP-[*'^C]- 
Gal/ in incubation with mycobacterial membranes revealing 5-linked Gal/, 6 -linked Gal/ and 
(5, 6 )-linked Gal/all to be present (Nassau et al, 1995). These findings have established that 
both the linker region and galactofuranose ai*e synthesised on a polyprenyl-phosphate lipid 
carrier.
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If one looks even closer at this biogenesis, and considers the biosynthesis of dTDP-rhamnose 
and UDP-Gal/ then a plethora of potential targets become available for novel 
antimycobacterial drug development. The enzymes involved in the biosynthesis of rhamnose 
and galactan have been identified and are discussed in chapters 6  and 2  respectively. 
Similarly, as in the biogenesis of arabinan, neither rhamnose nor galactan is utilised in 
humans, so new drugs should be highly specific and non-toxic. As the mycobacterial linkage 
unit is the fulcrum of cell wall integrity, it potentially provides a singular site for target- 
directed chemotherapy, which makes inhibition of this pathway additionally appealing.
1.7 Biosynthesis of Lipoarabinomannan
LAM is not essential for mycobacterial growth in culture. Yet, as it is implicated in the 
pathogenesis of mycobacterial disease, an understanding of its biosynthesis is essential. It is 
still unclear how LAM is chemically associated with the cell walls. Extraction methods 
(boiling crude mycobacterial cell walls in 50% ethanol or Percoll gradient purification) 
suggest LAM to be firmly, but not covalently, attached to cell walls (Chatterjee, 1997). 
Furthermore, as whole mycobacterial cells are recognised by monoclonal antibodies to LAM, 
it implies a portion of the molecule is accessible to the environment (Chatterjee, 1997).
Early work by Brennan and Ballou (1967), established GDP-mannose to be the mannose 
donor in the initiation of the conversion of phosphatidylinositol (PI) to Pl-mannoside^ where 
X represents the number of added mannoses.
Radiolabelling experiments showed the synthesis of a novel a  ( l ,6 )-linked linear form of 
lipomannan, and the concomitant decrease in Cis/C50-P-mannoses. As the synthesis is 
susceptible to amphomycin, an inhibitor of polyprenyl-P requiring translocases, this suggests
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the C^g/Cjio-P-mannoses are the mannosyi donors rather than UDP-mannose, as synthesis of 
the simpler PIM2 was not inhibited by amphomycin. The source of the mannose residues is 
now established as being from UDP-mannose in the biosynthesis of the simpler PIM’s and 
from the polyprenyl-mannoses in the elongation of the mannose backbone. The origin of the 
a ( l ,  2) mannose branches is not currently known but is thought to be from GDP-mannose 
(Besraera/, 1997).
1.8 Biosynthesis of the Mycolic Acids
Mycolic acids, being unique to mycobacteria, are the major determinants of the 
impregnability of the mycobacterial cell wall. Structurally, the long chain a-alky-|3- 
hydroxyfatty acids are complimented by various glycolipids including a , a ’-trehalose 
dymycolate (TDM), and the analogous monomycoiate (TMM). It appears mycolate acids 
enable the cell to survive the hostile environment of the macrophage by forming an 
impermeable lipid bilayer (Liu et al, 1995). The biosynthetic pathway of the mycolic acids is 
understood to be the position of attack for several anti-TB drugs including the front-line drug 
Isoniazid (Banerjee etal, 1994).
The biosynthesis of mycolic acid is proposed to be via a modification of normal fatty acid 
metabolism where short chain fatty acids aie extended and altered to form lipids of the 
required length (George et al, 1995).
Research to identify the enzymes and genes responsible for mycolic acid deposition is 
ongoing in many independent laboratories, and to date has resulted in the identification of 
several targets on which to base the rational design of new anti-mycobacterial drugs.
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Belisle and co-workers (1997) have identified a mycolyl transferase that catalyses the 
transestérification of non-radioactive mycolic acids to ['"^ C] a , a ’-trehalose, yielding both 
['^C] TMM and ['^C] TDM, The enzyme responsible for this exchange has been purified 
and analysed by 2D-PAGE to reveal two proteins of identical pi and similar molecular 
weights, 31 and 34kDa, furthermore N-terminal sequencing of each protein yields an 
identical sequence (RPGLPVEY). A comparison of this sequence with that of the antigen 85 
(Ag85) complex (Ag85 A, B and C) from M. tuberculosis reveals a striking similarity 
(FSRPGLPVAY). Ag85 is a triad of gene products implicated in mycobacterial 
pathogenesis through their fibronecting binding capabilities (Peake et al, 1993). 
Investigations with the individual components of the Ag85 complex confirmed 
mycolytransferase activity. Belisle and co-workers (1997) went on to demonstrate each 
component of the Ag85 complex to show carboxylesterase activity. Interestingly, 
transestérification of mycolic acids dictates carboxylesterase activity. An analysis of the 
primary sequences of Ag85 A, B and C disclosed the consensus Gly-x-Ser-x-Gly that is 
conserved among other fatty acyl transferases. X-ray crystallography has shown serine to be 
the active residue of the catalytic triad serine, aspartic acid/glutamic acid and histidine 
(Kazlauskas, 1994). Site-directed mutagenesis (serine to alanine) destroyed the 
carboxylesterase activity to confirm the role of serine in the Ag85 component.
Given that the mycolyl transferase identified to catalyse transestérification of mycolic acids 
is reactive to monoclonal antibodies specific for the Ag85 complex further suggests the 
members of Ag85 complex have a role to play in mycolic acid metabolism (Belisle et al,
1997).
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A screen of putative competitive inhibitors of this metabolism identified 6-azide-6-deoxy- 
a ,a ’-trehalose (ADT) as being able to suppress growth of Mycobacterium aurum (an 
established surrogate of M. tuberculosis) but not of Escherichia coli. Along with this 
observation an additional unknown compound was accumulated on inhibition, presumably 
an intermediate in the mechanistics of the reaction. That ADT inhibits synthesis of TMM 
and TDM and subsequently cell wall synthesis, demonstrates that mycolate transfer is 
essential in cell wall integrity, identifying these enzymes (Ag85 A, B and C) as viable 
targets.
The major mycolic acids produced by M. tuberculosis aie defined as the a-mycolic acids 
which can be further divided into two subclasses a i and a 2. Each class averages some 78- 
80 carbons in length (Danielson and Gray, 1982). 0L\, the most abundant of the class,
contains two cis unsaturated bonds (proximal and distal) which are open to cycloprotonation 
Figure 1.10. Cycloprotonation is significantly more common in slow growing mycobacteria 
than the more rapid growing saprophytic species (Minniken, 1982). In addition, 
modification at the distal position has been shown to confer on the slow growing bacteria, a 
greater resistance to H2O2. Furthermore, differential scanning microcalorimetiy has shown 
cycloprotonation at the proximal position to raise the observed transition temperature by 3 C 
(George et al, 1995). Together these results imply that cycloprotonation of mycolic acids 
may be an important adaption of slow growing pathogenic mycobacteria.
Cycloprotonation at each position is catalysed by two independent enzymes, CMAS-1 and 
CMAS-2, and the genes responsible for expression of these enzymes have been identified 
(George et al, 1995). It is postulated that s-adenosyl-L-methionine is an enzyme cofactor, as 
analysis of the primary sequences identifies a consensus motif (V/L) LDXGXGXG which
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has been previously been proposed to play a role in binding of this co-factor (Ingrosso et al, 
1989).
The two enzymes help make up a family of foin proteins that catalyse the transfer of a 
methylene group from ^-adenosyl-L-methionine to an unsaturated lipid. The others are from 
the other mycobacterial pathogen M. leprae and E. colL As no three-dimensional structures 
of these enzymes are available no firm molecular mechanistic details exist as to how these 
enzymes function. Mammals do not cycloprotonate unsaturated lipids, making these 
enzymes appealing therapeutic targets for novel drug intervention.
Figure 1.10. : Cycloprotonation o f  the major mycolic acids in M. tuberculosis.
CMAS-1 m o  CMA.S.2
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Isoniazid, one of the front-line anti-tuberculosis drugs, has been used to treat tuberculosis 
since 1952 (Middlebrook, 1952). It is only in the last decade that an understanding o f both 
its mechanism of action and the development of resistance to it has become apparent. 
Isoniazid is a pro-drug activated by catalase peroxidase upon administration to its active 
form. Interestingly, the gene encoding catalase peroxidase (katG) is found to have deletions 
or missense mutations in around 20-30% of isoniazid resistant cases of M  tuberculosis 
(Zhang et al, 1992).
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The target for activated isoniazid has been shown to be mycolic acid biosynthesis (Quemard, 
1991). Two open reading frames {orf’s) from an isoniazid resistant mutant from M. 
smegmatis have been identified. Subcloning studies showed the second of these open 
reading frames to be sufficient in conferring the isoniazid resistance phenotype and was duly 
labelled inhA. This differed from the wild-type (wt) gene (non-isoniazid resistant) by a 
single base pair mutation, T to G, resulting in substitution of alanine 44 for serine 44. Allele 
exchange experiments confirmed drug sensitivity was directly related to the single mutation 
(Banerjee et al, 1994). Further characterisation revealed the wt protein to bind NADP and 
catalyse the reversible reaction of 2 -  trans long chain enoyl (Ci6-C2o)-acyl carrier proteins 
(ACP’S). More specifically, by following the oxidation of NADH spectrophotometrically, 
Dessen and co-workers (1995) showed the gene catalysed the reduction of 2-tra«j-octenoyl- 
ACP, confirming that inhA is involved in mycolic acid biosynthesis. Kinetic studies by the 
same group suggest the role NADH plays in the mechanism to be crucial. K,n and of the 
mutant protein were found to be similar to the wt for the reduction. However, the Michaelis 
constant for NADH was five times higher in the mutant, Table 1.2, implying the interactions 
between the enzyme and co-factor may be related to the mechanism of drug resistance 
(Dessen etal, 1995).
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Table 1.2: Kinetic evaluation o f  the wt and S94A mutant inhA catalysed reduction 
o f 2-trans-octenyl-ACP by NADH (Dessen et a l , 1995).
Enzyme
K„(nM) ^m ax
(pmol min'* mg'^)2-/ram-octenoyl NADH
Wild-type 2 ±  1 8 + 0 2.2 ±0.4
S94A 3 + 1 38 ± 2 3.1 ±0.6
To investigate these interactions further, Dessen and co-workers (1995) determined the 
three-dimensional structures of both the wild type and the mutant proteins. The structures 
are described as having an overall chairlike appearance, composed of seven p strands and 
eight a-helices. Figure 1.11. The Tegs’ and ‘seat’ of the protein are in the orientation 
typically known as the Rossman fold (Rossman, 1975), and it is here the cofactor binds to 
the protein.
Figure 1.11: Schematic ribbon representation o f  InhA complexed with one NADH 
molecule (blue) (Dessen et al, 1995).
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It is in the binding of NADH that the structures differ significantly. Figure 1.12. NADH is 
stabilised in the wild type structure by thirteen hydrogen bonds involving a combination of 
polar amino acids, backbone atoms and six water molecules. One of these hydrogen bonds, 
involving a bridging water molecule, is disrupted in the S94A structure. Figure 1.12b. In the 
wild type, a hydrogen bond exists between O of the Pn phosphate of NADH and a well 
ordered water molecule. This water molecule in turn forms a hydrogen bond with the 
hydroxyl o f serine 94, the main chain O of glycine 14 and two other main chain atoms 
(alanine 22 and isoleucine 21). In the mutant structure, glycine 14 faces the opposite 
direction, away from the NADH, curtailing the extent of hydrogen bond between NADH and 
the protein. Overall the disruption of the hydrogen bonding accounts for around two to three 
kcal mol ' of binding energy which will explain the mutants five-fold reduced affinity for 
NADH evident from kinetic studies.
Figure Ll2:a) Stereo view o f  the atoms involved in the binding o f  NADH in a) wild type 
and b) mutant InhA. N  = blue, O = red and phosphate = green. Carbons 
atoms are yellow in NADH and grey in protein (Dessen et al, 1995).
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b)
Dessen et al (1995) proposed that the disruption of the hydrogen bond network associated 
with co-factor binding is directly related to the subsequently acquired resistance of the 
mutant. They suggest protein / isoniazid binding is inhibited either by the reformation of a 
nucleotide inhibitor complex or upon conformational changes in the enzyme active site 
when NADH binds, which alters the substrate binding site.
Rozwarski and co-workers (1998) have elucidated the crystal structure of the activated form 
of isoniazid in complex with NADH and inhh.
Crystals were grown from an incubation mixture containing inhA, NADH, isoniazid and 
MnCl2 and resulted in the activated form of isoniazid associating with inhA bound NADH. 
The structure revealed an extended NADH molecule. The isonicotinic acyl group is 
attached through its carbonyl carbon to the carbon at position 4 of the nicotinamide ring of 
NADH. The carbon at position 4 of the nicotinamide ring of the isonicotinic acyl-NADH 
complex is tetrahedral, retaining one hydrogen. Figure 1.13.
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Figure L 13: Isonicotinic acyl-NADH superimposed onto the 2Fq-Fc electron density 
map contoured at la (C  ^  green, O = red, N  = blue and P ^magenta) 
(Rozwarski et al, 1998).
A comparison of the overall protein structures of the inhA / NADH and inhA / isonicotinic
acyl-NADH shows the structures to be almost identical. The only significant difference in
the protein is located in the position of the side chain of phenylalanine 149, Figure 1.14. In
the binding of isonicotinic acyl-NADH the bulky side chain is rotated ~ 90° to form n-n
interactions with the pyridine ring of the isonicotinic acyl group.
Figure 1.14: Superposition o f  the active sites o f  inhA with bound NADH (pink)
and with bound isonicotinic acyl-NADH (blue) (Rozwarski et al, 1998).
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Previous kinetic isotope experiments (Quemai*d, 1995) with inhA have demonstrated a 
preference for NADH binding prior to the acyi-ACP substrates which would result in the 
majority of the wild type enzyme being NADH bound, making it susceptible to isoniazid 
attack. Once isoniazid is bound, the enzyme is effectively inactivated and mycolic acid 
biosynthesis inhibited. Thus the vulnerable enzyme population resting with NADH bound is 
substantially reduced and enzyme that is actively turning over is resistant to isoniazid.
The existence of this complex (isonicotinic acyl NADH bound inhh) illustrates the crucial 
role NADH plays in the mechanism of action of isoniazid. Quite simply its presence is 
essential for isoniazid activity.
The predicted sequence of InhK shows strong sequence similarity with E. coll Enoyl 
Reductase (ENR) and the Brassica napus analogue which are known to catalyse the last 
reductive step of fatty acid biosynthesis (Baldock et al, 1996). NAD^ is an essential co­
factor in this reaction and is required for binding a known class of inhibitor of the reaction, 
the diazoborines (Baldock et al, 1998). In ENR the single mutation glycine 93 to serine 93 is 
responsible for inducing resistance to the diazoborines by conferring a reduced activity for 
NAD^, and consequently the inhibitor. Baldock and co-workers (1996) have determined the 
three-dimensional structure of native ENR and of two ENR / inhibitor complexes. The 
native ENR structure (2.1Â) was solved by multiple isomorphous replacement and used as a 
model in molecular replacement in order to solve the two complexed structures (2.2 and 
2.5Â). The native structure is tetrameric. Each monomer is composed of a 7 stranded 
parallel P-sheet flanked by 5 a  helices. An additional helix lies along the top of the P-sheet. 
The overall topology is again reminiscent of the Rossmann fold, as is expected with a
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NADH binding enzyme. Each monomer contains a loop of 10 disordered residues opposite 
the NADH binding site which become ordered on inhibitor binding.
Both diazoborines bind in a closely related manner. The bicyclic rings of the diazoborines
lie adjacent to the nicotinamide ring of NAD^ allowing the formation of extensive n stacking
interactions. The major difference is in the positioning of the respective tosyl and propyl
moieties. Figure 1.15. The tosyl moiety lies perpendicular to the bicyclic ring system and is
stabilised by a combination of interactions between nearby main and side chain atoms. The
propyl group however, folds back on the ring system in a manner not unlike a scorpion’s tail.
It also forms interactions with the main chain and side chains of nearby residues.
Figure 1.15: Adopted conformation o f  the diazoboranes in the two complexes in E. coli 
ENR diazoborane complexes (Baldock et al, 1998).
The most significant interaction comes between the boron atom of diazoborane and the 
2’ hydroxyl of nicotinamide. At a distance of 1.7Â it is comparable with a boron to oxygen 
covalent bond length (1.6Â). The boron atom is at the centre of a tetrahedral array, as is 
required of a boron atom forming four covalent bonds. Figure 1.16. The loss of biological 
activity upon replacement of the B-N group by C-C in diazoborines (Grassberger et al, 1984)
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is readily explained by this observation, that is the covalent bonding forming potential is 
removed. Boron has been observed to play a similar role in the inhibition of serine proteases 
by boronic acids where it also forms covalently bound tetrahedral adducts, resulting in 
chemical modification of the active site serine leading to enzyme inactivity (Zhong et al, 
1991).
Figure L6 : Schematic representation o f  the interactions made by the NAD^
thienodiazoborane with the enzyme and water molecules. Hydrogen bonds 
are dashed lines and Van der Waals interactions are hydrophobic arcs 
(Baldock et al, 1998).
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The analogies between the Baldock E. coli structures and the M. tuberculosis structures 
reported by Dessen and Rozwarski are clear. Both enzymes demonstrate a requirement for a 
dinucleotide co-factor, bound at a conserved ‘dinucleotide binding site’, described by 
Rossmann (1975). It is on the inhibition o f these enzymes however that the most significant 
similarities arise. Each enzyme is inhibited through the binding o f their respective inhibitors 
in a covalently bound tetrahedral adduct via the associated co-factor. That is, for enzyme 
inhibition prior cofactor binding is essential. Removal o f each co-factor induces the enzymes
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resistant to the inactivating drugs. A single point mutation is all that is required in each 
enzyme to bring this about.
Other reactive inhibitors involving NAD(P) have been described (Taillefumier et al, 1996) 
but none act with such potency. The differences in such structures originate from steric 
interactions preventing the formation of covalent bonds of the nature described by Baldock. 
Indeed, further studies on the ENR enzyme show that substitution of glycine 93 for amino 
acids with small side chains for example, serine, alanine, cysteine and valine, hardly affected 
the catalytic parameters of the enzyme, but still had the effect of inducing resistance to the 
drug. Substitutions with even larger amino acids for example, arginine, histidine, lysine and 
glutamine rendered the bacterial host completely resistant to the drug (de Boer et al, 1999). 
The findings of these studies involving the M. tuberculosis analogue enzyme ENR suggest 
the type of linkage that may be required not only in new anti-mycobacterial drugs but any 
inhibitor that involves NAD(P) as a co-factor. However, the underlying problem in the 
formation of these bonds is a steric one. If this can be overcome then a new class of 
antibacterial agents may be uncovered. In relation to the mycobacterial cell wall, these drugs 
would be targeted at inhibiting mycolic acid biosynthesis, overcoming the problems of 
MDR-strains of TB, particularly isoniazid resistant strains. However, given the potential 
toxicity of boron, such inhibitors will require boron replacement with an alternative atom. 
Although the structures described by Baldock and Rozwarski both involve the formation of 
bisubstrate analogues between a diazoborane and NAD+ or isoniazid and NADH 
respectively, the mechanism of drug action and resistance inferred are quite different. The 
isonicotinic acyl NADH / inhA structure provides a basis for the design of agents that inhibit 
inhA. Yet what remains unanswered, is if any drug designed to act in a mode similar to
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isoniazid will be efficacious against MDR-TB, including isoniazid resistant strains. InhA is 
undoubtedly a taiget for novel drug inteiwention, but one feels different modes of inhibition 
from that displayed by isoniazid will be required if novel anti-mycobacterial drugs are to be 
developed and to be efficient against MDR-TB strains, particularly isoniazid strains. The 
diazoboranes inhibit the E. coli analogous enzyme ENR, and should be assayed for activity 
in the inhA system. If effective they would provide a basis on which to design new anti- 
mycobacterial drugs. As mentioned previously, the toxicity of boron is another problem 
which still requires to be overcome.
1.9 Concluding Remarks
With more people estimated to die from TB in the forthcoming year than any other in living 
history, the urgency with which new anti-mycobacterial agents are required has never been 
greater. However, increased awareness of the TB problem, as a result of WHO intervention, 
has resulted in several co-ordinated research efforts world-wide aimed at tackling the 
problem. As a direct consequence of this a greater understanding of the mycobacterial cell 
wall has emerged. The basic and salient structural features are fully established and current 
research is now directed at dissecting the biosynthetic pathways involved in the assembly of 
these molecules. The cell wall structure of mycobacterium is unique and its biosynthesis 
reveals suitable targets for intervention, many of which are discussed in this and forthcoming 
chapters. One particularly appealing enzyme is UDP-galactopyranose mutase, which 
catalyses the formation of galactofuranose in the mAGP complex. This target, along with 
the others discussed may lead to new classes of drugs for the treatment of re-emerging 
mycobacterial disease.
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Chapter 2
Initiating a crystallographic study of UDP-galactopyranose mutase from
Escherichia coli.
59
2.1 Summary
Galactofuranose, the thennodynamically disfavoured form of galactose, is a key component 
of mycobacterial cell walls where the interconversion of UDP-galactopyranose and UDP- 
galactofuranose is catalysed by UDP-galactopyranose mutase. UDP-galactopyranose 
mutase, from Escherichia coli, has been crystallised in a form suitable for X-ray diffraction 
studies. Two crystal forms have been obtained. A single crystal of dimensions 0.4 x 0.2 x 
0.05mm was grown over one week from a solution of lOmg mf^ protein. The yellow crystal 
diffracted to 2.1 k  when fresh but decayed due to X-ray damage in less than 10 hours. The 
data were indexed in an orthorhombic space group (P222, P2|2|2i, P2i2i2 or P222|) with 
cell dimensions a = 56 Â, b = 94 A, c = 134Â, a = p  = y =90°. This crystal form has not 
been reproduced. However, crystals of both native and selenomethionine protein, grown 
over 5 days from a solution of 8 mg ml'* protein in hanging drops have been consistently 
reproducible. Ciystals grow as thin plates of dimensions 0.04 x 0.02 x -0.005mm and 
multiple rounds of seeding are required to obtain crystals (0.4 x 0.2 x -0.05mm) large 
enough for X-ray diffraction studies. Once at maximum size the ciystals diffract to beyond 
3.0Â on BM 14 at the European Synchrotron Radiation Facility (E.S.R.F.), France. Crystals 
are monoclinic, space group P2| and unit cell dimensions a = 71.12 Â b = 58.42 À c = 96.38 
Â, P = 96.38°. A 92% complete native data set, redundancy 2.5, Rmerge 5.0% has been 
collected at the E.S.R.F. to 2.9Â. The Matthew’s co-efficient is 2 . 3 5 Â equivalent to 47% 
solvent content for a dimer in the asymmetric unit. Data sets on potential derivatives and the 
selenomethionine variant protein have all been collected at the same source.
Ciystals of UDP-galactopyranose mutase are high in mosaic spread, the value of which 
varied from crystal to crystal but was always above l \  Even the largest crystals obtained by
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seeding diffracted weakly and the resolution observed varied considerably from crystal to 
crystal. In-house data collection, particularly with the selenomethionine crystals, has been 
limited by the weak diffraction and low resolution limit of the data. This prevented 
characterisation of the mosaic spread in-house. Only with the intense radiation available on 
BM14 has it been possible to fully characterise the mosaicity problem.
Crystals of UDP-galactopyranose mutase have also been obtained from a different organism, 
Klebsiella pneumonia. The crystals are currently too small for X-ray diffraction, however 
crystallisation conditions have yet to be fully optimised.
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2.2 Introduction
Mycobacterial Cell Wall
Galactofuranose, the thermodynamically unfavourable form of galactose is not commonly 
found in nature. It is however, found in various macromolecules including bacterial O 
antigens, fungal exopolysaccharides, glycoproteins and the ceil wall of mycobacteria 
(Stevenson et al, 1994; Latge et al, 1994; Nassau et al, 1996 and Moraes et al, 1987).
The recent structure determination of the O antigen of Escherichia coli K-12 together with 
the elucidation of the sequence of its ifb gene cluster (Stevenson et al, 1994) has allowed 
identification of the gene labelled orf6  that encodes for the enzyme UDP-galactopyranose 
mutase (mutase) (Nassau et al, 1996). The enzyme catalyses the ring interconversion of 
UDP-galactopyranose (UDP-Gal^,) and UDP-galactofuranose (UDP-Gal/), Figure 2.1.
Figure 2.1: Interconversion o f UDP-galactopyranose and UDP-galactofuranose
HO
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Galf is not found in humans and is structurally unique. It is therefore an appealing 
therapeutic target as inhibition of its biosynthesis would assist the development of new anti- 
mycobacterial drugs that are likely to be highly effective and non-toxic.
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UDP-galactopyranose Mutase from  E.coli.
E. coli mutase was the first enz>'me from any organism shown to catalyze the
interconversion of UDP-Gal^ and UDP-Gal/; though the enzyme has also been isolated firom
Klebsiella pneumoniae (Koplin et al, 1997) and M  tuberculosis (Weston et al, 1998).
Mutase from each source is known to incorporate flavin adenine dinucleotide (FAD). That
the enzyme incorporates FAD and possibly NAD(P) is not surprising as analysis of the
primary sequence identifies a consensus p-a-p (Rossmann fold) motif consistent vdth
nucleotide binding enzymes (Bellamacina, 1996). The Rossmann Fold, so called after it was
first identified by Michael Rossmann in 1975, is a conserved region among dinucleotide
binding proteins. In mutase the sequence is located close to the N terminal incorporating
amino acids 3 to 39. This sequence from E.coli mutase was used as the subject of a Basic
Logical Alignment Search Tool (BLAST) search at the Structural Classification of Proteins
(SCOP) server, (http://scop.mrc-lmb.cam.ac.uk/scop/) where its compared to the primary
sequences of proteins of known tertiary structure. The search identified several positive
matches where the sequence was located in other proteins, where either FAD or NAD(P)
was a bound co-factor. An example is shown in Figure 2,2.
Figure 2.2: Output from a BLAST search performed with SCOP. The sequences 
display 51% identity and 61% homology. The conserved amino acids 
are crucial in the binding o f  the associated dinucleotide.
YDYIIVGSGLFGAVCANBLKKLNKKVLVIEK Mutase
YDYII+GSG A E LN KV +1E+
YDYll 1GSGGAAFSSAIBAYALNAKVAMIER MLR.
M LR. is mercuric ion reductase from Bacillus sp. strain RC607, (Schiering, 1991) and is 
known to contain a FAD / NAD(P) binding domain.
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Subjecting the complete mutase sequence to a BLAST search reveals no other known protein 
with a greater sequence identity than 30%, other than alternative versions of mutase (date of 
search 14/07/99). Unsurprisingly, the region (80 amino acids) of glutathione reductase (EC 
i.6.4.2) from Haemophilus influenzae where this identity is found contains a nucleotide 
binding motif (Fleischmann, 1995).
UDP-galactopyranose Mutase from Klebsiella pneumoniae
Mutase is also encoded for by one of six genes recently isolated that are involved in the 
synthesis of D-galactan. D-galactan, [—>3)-P-D-Galj<“( 1—>3)-(X-D-Galjj-( 1—>], forms the 
backbone of the O - side chain polysaccharide in the lipopolysaccharide of K. pneumoniae. 
The enzyme shows approximately 40% sequence identity to the protein from E.coli. 
Analysis of the primary sequence identifies a PaP ADP binding domain at the N-terminus 
consistent with what is found in the E.coli enzyme (Koplin et al, 1997). As the protein also 
displays a distinct yellow colour it is anticipated this region would be involved in FAD 
binding. As in the case of the E.coli enzyme, enhanced activities are also observed when the 
protein from K. pneumonia is incubated with NADH or NADPH together with FAD (Koplin 
et al, 1997). As the reaction involved does not involve the net transfer of electrons, the 
mechanistic role of these cofactors is unknown. Our work with E.coli mutase demonstrates 
FAD incorporation and suggests the enzyme also requires NAD(P).
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2.3 Experimental
Overexpression ofE. coli BL21 (DE3) (pORF6).
All materials used were obtained from Sigma (Poole, UK) unless otherwise stated. Prior to 
all cultivation procedures, all containers, pipette tips and media were sterilised by 
autoclaving at 120°C for 30 minutes.
In a typical experiment five millilitres of Miller’s Luria Broth Base (LB) medium containing 
ampicillin (200|Ltg ml ') was inoculated with a single colony of BL21 (DE3)(pORF6) and 
incubated overnight at 37°C. This culture was used to inoculate 500ml of similarly treated 
LB medium and the resultant solution shaken at 200ipm, 37°C. The optical density was 
monitored until the Aeoo reached 0.6 whereupon IPTG was added to a final concentration of 
ImM. The incubation was continued for a further 3 hours under the same conditions. The 
cells were then harvested by centrifugation (lOOOOg, 4°C, 30 minutes) and frozen at -78°C 
until required.
Preparation o f Cell Extracts.
Frozen cell paste was thawed in ice-cold lysis buffer (50mM TRIS pH 7.6, ImM DTT, ImM 
PMSF) at a concentration of 0.5g wet cell paste for each mL buffer. Lysozyme (200pg ml*'), 
DNase (20pg ml*') and EDTA (2mM) were added and the solution left at room temperature 
for 30minutes before the cell contents were released by sonication (140kW, 20kHz) at 4°C 
for 6 X 30 seconds, resting on ice in between. Cell debris was pelleted by centrifugation 
(20000g, 4°C, 30 minutes). The cell extract was transferred to a clean tube and the contents 
assayed by the Bradford assay (Bradford, 1976) and SDS-PAGE.
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Overexpression of mutase in LB by this protocol typically yielded Img soluble protein for
every litre of media. The majority of the protein was insoluble and seen in the lysis
precipitate when viewed on denaturing gels. Alteration of the expression temperature and
the IPTG concentration to try and overcome this problem had little effect, Table 2.1.
Table 2.1: Different expression conditions fo r  overexpression o f UDP-galactopyranose 
mutase in LB and yield o f protein obtained.
Media Temperature
("C)
IPTG
(mM)
Yield
(mg L'^ )
LB 37 1 1.0
LB 37 0.4 0.9
LB 30 1 1.2
LB 30 0.4 1.3
LB 25 1 1.1
LB 25 0.4 1.1
As no assay was readily available to detect mutase’s activity purification from inclusion 
bodies was not considered as a means of purification. The harsh agents required to release 
the protein from inclusion bodies, that is guanidine HCl or urea, would denature the protein 
and on removal of these agents correct refolding of the protein could not be assessed. With 
this in mind alternative expression media were sought to improve the level of soluble protein 
expressed. A total of 5 different media were tried at both 30°C and 37°C and at 0.4 and 
ImM IPTG concentrations. Table 2.2. The media that resulted in the optimum amount of 
soluble protein was terrific broth (Maniatis, 1982). The yield of soluble protein increased to
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some S. lmgL'' by growing the cells to an optimum cell density at 37° and then on addition
of ImM IPTG lowering the temperature to 30®C and leaving the cells for a further 3 hours.
Table 2.2: Different media tried and yields o f  soluble protein obtained 
after purification.
Media 
Post Induction Temperature
IPTG(mM) 
0.4 1
30°C
IPTG(mM) 
0.4 1 
3TC
LB* + Sorbitol 1.1 1.3 1.2 1.3
LB + Betaine 1.0 1.2 1.1 1.1
LB + Sorbitol/Betaine 1.1 1 .2 0.9 1.0
M9'’ 1.1 1.3 1.1 1.1
Terrific Broth® 7.7 8.1 2.2 2.4
To 950 ml of deionized water add lOg bacto-tryptone, 5g bacto-yeast extract and lOg Na Cl. Adjust pH to 7.0 
To 750ml of deionized water add 2 0 0 ml 5 x M9 salts (see below), 2 ml IM MgS0 4 , 2 ml glycerol, 0 .1ml CaCh.
5 X M9SaIts: To 150ml of deionized water add 12.8g Na2HP0 4 .?H2 0 , 3g KHz PO4, 0,5g NaCl and Ig NH4CI. Make to 
2 0 0 ml after dissolution of solutes and sterilise separately.
 ^To 900ml of deionized water add 12g bacto-tryptone, 24g bacto-yeast extract and 4ml glycerol. Sterilised separately, to 
90ml of deionized water add 2.3 Ig KH2PO4,12.54g K2HPO4. Adjust the volume to 100ml after the salts have dissolved and 
add to the sterile media.
Preparation o f  Selenomethionine Variant UDP-galactopyranose Mutase.
As increasing numbers o f protein structures are being solved by Multi-wavelength 
Anomalous Dispersion (MAD) then different methods for the overexpression of seleno­
methionine substituted protein are becoming apparent. Three different routes are outlined in 
this thesis and each was evaluated in terms of the yield of soluble protein and convenience. 
One method of overexpressing selenomethionine protein involves using a cell line 
auxotrophic for methionine. The advantage o f this being that maximum selenium 
incorporation in the protein is more likely than the alternative (using a non-auxotrophic
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strain). However, unless the gene of interest is already in an auxotrophic cell line, some 
DNA manipulation will be required to make the cells producing the protein auxotrophic for 
methionine.
DNA Extraction and Transformation into the Methionine Auxotroph B834
Single colonies of E. coli BL21 (DE3) (pORF6 ) were selected from agar/ampicillin plates 
and used to inoculate 5ml LB/ampicillin (200|iig mi ') broth and incubated overnight at 37°C 
with shaking. 1.5ml of this culture was transferred to a sterile 1.5ml Eppendorf tube and 
microcentrifuged for 2 minutes at room temperature. Supernatant was discarded and the 
pellet resuspended in lOOjil 50mM glucose, lOmM EDTA, 4mg ml ' lysozyme, lOOjig ml"' 
Rnase A, 25mM TRIS pH 8 in sterile HiO. This solution was left at room temperature for 
10 minutes whereupon 200pl of fresh sterile SDS was added and the tube shaken thoroughly 
before being incubated on ice for a further 5 minutes. 150pl of ice cold 3M NaOAc pH 4.8 
was added and the solution mixed well and incubated at 4°C for a further 45 minutes. The 
samples were then centrifuged for 10 minutes before carefully transferring 400p,l of the 
supernatant into a clean sterile Eppendorf tube, taking care not to transfer any of the 
precipitate. 400pl of a 1:1 mixture of phenol and chloroform was added and the solution 
vortexed and centrifuged for 2  minutes before transferring the top aqueous phase to a clean 
tube. Ice cold ethanol was added with thorough mixing and the solution centrifuged again 
for 10 minutes. The supernatant was carefully drained by pipette and tube inversion. The 
DNA pellet was redissolved in 100p,l of O.IM NaOAc pH 6  and incubated at room 
temperature for 15 minutes. 200pl absolute ethanol was added and mixed well. This 
solution was centrifuged for 10 minutes. The supernatant was drained as before and the 
pellet air-dried for 45 minutes before re-suspending in 50p.l sterile HiO. The DNA was
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stored at 20°C until required. DNA content (when stained with ethidium bromide, which 
intercalates DNA) was quantified by running on an agarose gel against markers of known 
composition and comparing band intensity under UV light. Generally for a high copy 
number plasmid (Marie-France Giraud, personal communication) as used here, pET-1 la, 0.5 
- 2p,g DNA is sufficient for successful transformation with efficient electrocompetent cells. 
Aliquots (20pl) of B834 electrocompetent cells were thawed on ice before addition of Ijig 
and lOpg of mutase DNA, along with positive and negative controls. These suspensions 
were transferred to electroporation cuvettes and electroporated for 5 xlO'^ seconds at 2500 
volts. After electroporation 1ml of sterile LB medium was added and the cells left to recover 
at 37°C for 1 hour. The cells were then microcentrifuged for 2 minutes and 800pl of the 
supernatant removed. The cells were resuspended in the remaining media and streaked on 
LB agar/ampicillin plates and incubated overnight at 37°C.
Approximately twice as many colonies grew with the lp.g transformation compared to the 
10|ig transformation. The positive control yielded thousands of colonies indicating the cells 
were indeed highly competent and the negative control no colonies, confirming no 
contamination took place in the course of the experiment.
Overexpression and Purification ofB 834 (pORF6 ) Mutase in LeMaster Medium.
Single colonies of B834 (pORF6 ) were selected from an agaiVampicillin plate and used to
inoculate 2 x 5ml of LeMaster medium. Table 2.3, supplemented with 
Img L ' thiamine. This starter culture was incubated at 31°C overnight with agitation and 
used to inoculate 2 x 500ml of LeMaster medium. Incubation continued at 37°C, 200rpm 
before addition of ImM IPTG at an ODeoo of 0.6. The temperature was lowered to 30°C and
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the cells left shaking for a further 16 hours before being harvested by centrifugation (lOOOOg, 
4°C, 15 minutes).
Purification of seleno-methionine variant protein was performed in the same manner as the 
native with the only difference being an increased presence of DTT. 15mM DTT as opposed 
to ImM was used throughout purification to ensure there was no oxidation of 
selenomethionine. In all cases buffers were thoroughly degassed before use. Protein was 
eluted at the same position on the NaCl gradient (anion exchange) but the yield was 10 fold 
down on the native and the distinguishing yellow colour associated with FAD was absent. 
The increased concentration of DTT appeared to be stripping FAD from the protein. 
Subsequently the DTT concentration was dropped to 2mM and purification duly proceeded 
as the native. Protein quantity was assayed by Bradford and protein homogeneity by SDS- 
PAGE. Typical yield of protein was only an eighth of that obtained after expression in 
terrific broth at ImgL"'.
Overexpression o f B834 (pORF6) Mutase in Defined Medium.
A single colony of B834 (pORF6 ) was selected from an agar/ampicillin plate and used to 
inoculate 5ml of LB medium. This culture was incubated at 37°C overnight with agitation. 
The cells were harvested the following morning by centrifugation and the supernatant 
discarded. Cell pellets were resuspended and washed in 10ml of the defined medium, Table 
2.3, and again harvested by centrifugation. This process was repeated three times to 
minimise the carry over of methionine to the larger cultures. Cells washed in defined 
medium were used to inoculate 1000ml of similar media; incubation was continued at 37°C, 
200rpm. The OD^oo was monitored until it reached 0.6 AU when the temperature was
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lowered to 30°C and ImM EPTG added. Incubation was continued for a further 16 hours 
before the cells were harvested by centrifugation (lOOOOg, 4°C, 15 minutes).
Purification of the modified protein was as outlined previously for Le Masters medium. 
Protein quantity was assayed by Bradford and protein homogeneity by SDS-PAGE. 1.2mg 
of selenomethionine variant protein was obtained from 1 litre of media.
Overexpression o f BL21 (DE3) (pORF6) Mutase by Methionine Pathway Inhibition,
As an alternative to the methionine auxotroph one can produce selenomethionine protein by 
inhibiting methionine biosynthesis throughout overexpression. Some amino acids 
(isoleucine, lysine and threonine) are known to block methionine biosynthesis in E. coli 
when added to minimal media at a high enough concentration (Doublie, 1997). Under these 
conditions, selenomethionine is freely incorporated by the protein during overexpression.
A single colony of BL21 (DE3) (pORF6 ) was selected from an agar/ampicillin plate and 
used to inoculate 5ml of LB medium. This culture was incubated at 37°C overnight with 
agitation. The cells were harvested the following morning by centrifugation and the 
supernatant discarded. Cell pellets were resuspended in M9 minimal media. Table 2.4, 
before being added to 1000ml of fresh M9 media. Cells were grown to an OD of 0.6 at Aeoo- 
At this point the amino acids lysine, phenylalanine and threonine were added to a final 
concentration of lOOmg L '‘ and isoleucine, leucine and valine to 50mg L"'. 
Selenomethionine, 60mg L '\  was added at this stage. The media was left to shake at 37°C 
for 15 minutes before ImM IPTG was added and induction continued for 16 hours at 30°C. 
Purification was as outlined for Le Masters medium. Only 0.9mg of homogenous 
selenomethionine protein was obtained after purification.
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As the yield of protein obtained was essentially the same from each media, the methionine 
inhibition pathway was initially used to overexpress selenomethionine protein as it was the 
most convenient. However, characterisation of this protein by mass spectrometry suggested 
selenium incorporation was not complete and for this reason a switch was made to the 
methionine auxotroph route for expression of the selenomethionine protein. As the yield of 
soluble protein obtained from each media was essentially the same, the defined medium was 
chosen as it was the most convenient.
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Table 23: Composition o f Le Masters and defined media.
Le M asters 
M edia Substance^
D efin ed
M edia
0.5" Alanine 0.045
0.58“ Arginine 0.045
0.4“ Aspartic Acid 0.045
0.03“ Cystine 0.045
0.67" Glutamic Acid 0.045
0.33" Glutamine 0.045
0.54" Glycine 0.045
0.06" Histidine 0.045
0.23“ Valine 0.045
0.23" Isoleucine 0.045
0.23" Leucine 0.045
0.23" Threonine 0.045
0.42“ Lysine 0.045
0.13" Phenylalanine 0.045
0.1“ Proline 0.045
2.08" Serine 0.045
0.17" Tyrosine 0.045
0.05" Selenomethionine 0.1'*
0.5“ Adenine 0.5
0.67" Guanosine 0.5
0.17" Thymine 0.5
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Table 2.3 (cont): Composition o f Le Masters media and defined media.
0.5" Uracil 0.5
1.5" Succinic Acid
1.5" Sodium Acetate
0.75" Ammonium Chloride 1
2.16" Sodium Hydroxide
10.5" Di-Potassium Phospate ----
Sodium Chloride 0.5
Potassium di-Hydrogen Phosphate 3
---- Thiamine 0.002
10*’ Glucose 5
0.25*' Magnesium Hepta Sulphate 0.025
0.0042*' Iron Hepta Sulphate 0.004
8.4pl" Cone. Sulphuric Acid
“ Made up in 900ml of dHoO and autoclaved.
* Made up in 100ml of dHiO and 0.22jim filtered. Added to cool autoclaved portion of media (“). 
All amino acids are the L-enantiomer.
Added after the media has been 0.22pm filtered. “ Added at time of induction.
‘ All compounds mixed overnight at room temperature in 1000ml dHiO. 0.22pm filter sterilised.
Table 2.4: Composition o fM 9  Minimal media.
To 750ml sterile dHzO add: mL
5 X M9 Salts" 200
IM Magnesium Sulphate*' 2
20 %Glucose" 20
IM Calcium Chloride"’ 0 . 1
" Dissolve 64g NazHP0 4 .7 H2 0 , 15g KH2PO4, 2.5g NaCl and 5g NH4CI in dHiO and autoclave. 
Prepare MgS0 4  and CaCb separately, autoclave and add after diluting 5 x M9salts to 1L. 
Sterilised by 0.22pm filtration
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Purification o f Recombinant UDP-galactopyranose mutase
In planning the purification protocol, the objective is to obtain as maximum a level of purity 
as is efficiently possible. This is achieved by exploiting the different properties of the 
protein such that the number of steps required for sufficient purification is minimised. 
Techniques are evaluated for capacity, protein recovery, resolving power and cost 
effectiveness when deciding what methods to utilise and in what order they should be 
performed.
A concern in the early stages of purification is to reduce the working volume of sample; 
hence a high capacity technique is sought where sample concentration will be achieved. 
Typically, precipitation is the first step in a purification strategy as it is high capacity and 
almost all the protein is recovered; in addition the working volume of sample is greatly 
reduced. Although precipitation has these advantages the purification achieved can be low, 
hence subsequent steps place more emphasis on the resolving power of the technique. 
Separation based on charge, hydrophobicity, pi and affinity are more likely candidates at this 
stage as each have high resolving powers. A combination of two or more of these methods 
are often required together, exploiting different properties of the protein to achieve the 
desired state of homogeneity.
In designing the purification protocol for mutase all of the outlined factors were taken into 
consideration. The first step was ammonium sulphate fractionation. This removes fouling 
lipids and hydrophilic proteins from the sample.
The theoretically determined pi of mutase is 6,93. This is the point of no net charge of the 
protein. At pH values above this point the protein will become more positively charged and
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hence be suited to anion exchange chromatography. To determine the optimum pH for 
separation a series of separations were performed across the pH range 6 - 9 .  At pH levels 
below 7 the eluted protein was stripped of FAD. Above pH 7 the best resolution was 
obtained at pH 7.6. To compliment this separation a similar experiment was performed with 
hydrophobic interaction chromatography; again optimum separation was found to be at 
pH7.6. The purification protocol described here is equally applicable to protein expressed in 
either LB or terrific broth.
Ammonium Sulphate Fractionation and Anion Exchange Chromatography.
Cell extract was prepared as previously outlined and brought to 10% (NH4)2S0 4  saturation 
by the slow addition of 5.6g (NH4)2S0 4  per 100ml cell extract with gentle stirring at 4°C. 
This solution was centrifuged to remove precipitated contaminants and the supernatant 
transferred to a clean tube. Supernatant was dialysed 3 times against a 1000ml solution of 
50mM TRIS pH7.6, ImM DTT to remove ammonium sulphate before application to an 
anion exchange chromatography column. Dialysed protein was 0.02jO,m filtered (Acrodisk) 
and applied to a 7.84ml anion exchange column (Perseptive Biosystems, HQ) equilibrated in 
buffer A (50mM TRIS pH 7.6, ImM DTT) in lOOmg aliquots at 5ml m in '\ Protein was 
eluted was over 15 column volumes (CV’s) by application of a 0-500mM NaCl gradient. 
Figure 2.3. Protein elution was monitored on-line at 280 and 450nm. Mutase was easily 
identified by its distinct yellow colour, a function of the FAD co-factor. Appropriate A450 
peaks from subsequent runs were pooled and concentrated under nitrogen pressure in an 
Amicon ultrafiltration cell.
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Hydrophobic Interaction Chromatography.
Pooled fractions from the anion exchange column were brought to 40% NHj (8 0 4 )2  
saturation by the slow addition of 2.4g (NH4)2S0 4  per ml at 4°C with gentle stirring. Protein 
was again 0.02pm filtered before being applied at 5ml min'^ to a 7.84ml hydrophobic 
interaction chromatography column (Perseptive Biosystems, HP) equilibrated in buffer B 
(50mM TRIS, 40% (NH4)2 SO4 ImM DTT). Protein was eluted in a decreasing (NH4)2S0 4  
gradient (100-0%) over 15 CV’s, Figure 2.4. Appropriate A450 fractions were again 
combined and concentrated as before. Protein concentration was determined by the 
Bradford method (Bradford, 1976). Purity was assessed by SDS-PAGE, Figure 2.5, and lEF 
PAGE.
Figure 2.3: Anion exchange chromatography trace. The A 450 trace shadows the 
^280 helping to identify muta.se.
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Figure 2.4: Hydrophobic interaction chromatography trace. Again the A4S0 trace 
shadows the A280 identifying mutase.
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Figure 2.5: Silver stained SDS-PAGE displaying protein purity after subsequent 
purification steps.
Lane I: Molecular markers (kOa)
Lane 2: Crude UDP-galactopyranose mutase.
Lane 3: Post HQ UDP-galactopyranose mutase.
Lanes 4, 5 & 6 : Post HP UDP-galactopyranose mutase.
1 2 3 4 5 6
Lane Numbers
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N-Terminal Sequencing o f  Native Protein,
lOOjLig of purified protein was dialysed in H ]0 in preparation for N-terminal sequencing by 
Edman degradation (Stryer, 1988), 5 cycles were performed and the resulting sequence was 
unambiguous. The first 6 residues were found to be MYDYII, which exactly match the first 
6 residues found in the predicted sequence for E. coli mutase. Figure 2.6. The N-terminal 
sequencing revealed no heterogeneity.
Figure 2.6: Alignment displaying the sequence identity between mutase from
E. coli, M. tuberculosis and K. pneumonia. The shaded area represents 
the amino acids common to each enzyme. Sequence identity is 40%.
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Analysis o f Native Protein by Mass Spectrometry.
As isolated, three very closely related peaks are evident by mass spectrometry. Figure 2.7. 
The reasons for this are not exactly clear and several hypotheses may be made. Three peaks 
are visible in the molecular weight region predicted for mutase at 43082.1, 43813.9 and
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44596.6 Da. The theoretical molecular weight predicted for mutase is 42960 ± 8 Da 
(Nassau et al, 1996).
Figure 2.7: Analysis o f  native UDP-galactopyranose mutase by mass spectrometry.
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A gas phase reaction may occur after laser vaporisation in which FAD binds to the protein. 
This would create a molecule o f molecular weight 43789.5 Da, only 24.4 Da different from 
the observed middle peak from mass spectrometry. Similarly if NADP is also incorporated 
the theoretical peak would be at 44554.9, which again is only 41.1 Da away from the 
heaviest peak predicted from mass spectrometry. The peaks either side of the middle peak 
are 783 Da higher and 731 Da lower in predicted weight. As the molecular weight of NADP 
is 765Da, a scenario where NADP is and is not incorporated may be apparent. Table 2.5. It 
should be remembered that the enzyme from K. pneumonia has also been shown to 
incorporate NADP (Koplin et al, 1997), hence its presence here should not be surprising.
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Table 2.5 : A comparison o f  molecular weights as predicted theoretically and
by mass spectrometry.
Theoretical Native + FAD + NADP
Molecular
Weight
Molecular Weight 
by Mass Spec.
Molecular Weight. +
by Mass Spec 
(A m m ing FAD 
Incorporated, i.e. 43S13)
To try and clarify the uncertainty arising from this analysis the experiments will be repeated 
with different matrices.
Analysis o f Selenomethionine Variant Protein by Mass Spectrometry,
Analysis of selenomethionine substituted protein by mass spectrometry revealed the same 
breakdown pattern as the native protein. Three peaks were again evident in the region 
expected for mutase with no other peaks being observed. Figure 2.8. Although selenium 
incorporation is not complete at an average of 70-80%, it was thought to be of a high enough 
level to proceed with crystallisation. The shortfall in selenium incorporation is not 
surprising given that this sample originated from a "methionine inhibition’ overexpression 
experiment. A higher level of incorporation was anticipated from the protein produced 
using the auxotrophic expression system. Table 2.6 shows the predicted molecular weights 
from the native mass spectrometric analysis assuming 5, 6, and 7 methionines have been 
substituted in comparison to the experimentally found values.
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Table 2.6: A comparison o f  molecular weights calculated theoretically and found
experimentally by mass spectrometry fo r  selenomethionine protein..
Molecular Weight (Da) as Predicted by Native Mass Spec. *
5 6 7 methionine subs
44038 44083 44128
Molecular Weight
Predictions from Mass 43171 44059
Spectrometry.
Figure 2.8: Mass spectrometric analysis o f  seleno-methionine variant mutase
'1
«
20000 aôâo 40000 90000 60000 70000
Dynamic Light Scattering With Protein Expressed in LB.
For the successful ciystallisation of a macromolecule it is generally accepted that a 
monodisperse solution of protein is preferable (Ferre - D’Amare and Burley, 1996). Whilst 
common protein characterisation techniques, electrophoresis and chromatography, may 
detect contaminated protein solutions they do not reveal any aggregation that may be present 
within (http://www.protein-solutions com). There have been several extensive studies to 
assess the use of dynamic light scattering in determining the crystallisability of protein 
solutions, (Mikol et al, 1990; Zulauf and D’Arcy, 1992; and D’Arcy, 1994). The general
82
consensus arising is one of agreement in that monodisperse macromolecular solutions will 
crystallise, whereas aggregated solutions or polydisperse systems rarely yield ciystals. 
Dynamic light scattering (DLS) can be used quickly to analyse a protein solution for its 
monodispersity and subsequently its suitability for crystallisation. A simplified outline of the 
theory involved is presented below.
The translational diffusion coefficient of a macromolecule undergoing Brownian motion can 
be determined by exposing the solution to a wavelength of 780nm and collecting the light 
scattered from these molecules. The light is collected by a lens and transmitted through fiber 
optics to a photodetector where the photons are converted to electrical impulses. This data 
allows calculation of the hydrodynamic radius. As the technique is sensitive to aggregation 
an estimate of the sample polydispersity can calculated, as the intensity of light scattered is 
proportional to the square of the mass of the protein. If the polydispersity expressed as a 
percentage of the hydrodynamic radii is on average less than 30%, then the protein will likely 
crystallise (http://www.protein-solutions.com).
Purified mutase from LB was concentrated to lOmg ml'* under nitrogen pressure (Amicon) 
and dialysed 3 times against 20mM TRIS pH 7.6, 2mM DTT in preparation for analysis by 
dynamic light scattering. The instrumentation used for light scattering was the Dynapro 801 
(Protein Solutions). The optical cell was equilibrated by injecting a 0.02pm filtered solution 
of 20mM TRIS pH 7.6 until the photon count rate dropped below 10. On attempting to 
inject the protein through a 0.02pm filter the resistance felt was too great and the experiment 
aborted. That such resistance was encountered suggests the protein solution is highly 
aggregated and unsuited to crystallisation.
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Crystallisation o f UDP-galactopyranose Mutase From LB Broth.
Mutase from LB (and thereafter terrific broth) concentrated to lOmg ml'* was used for initial
crystallisation condotions. PEG 6K, PEG 6K/LiCl, (NH4)2S0 4 , MPD and NaCl grid screens
where precipitant concentrations are varied against pH were used to search for initial
crystallisation conditions. The hanging drop method was employed throughout all
crystallisation trials (Ducruix and Giege, 1992) where 2pl of protein is mixed with an equal
volume of precipitant on a siliconized glass cover slip. The cover slip was inverted and the
drop left to equilibrate against a known precipitant in a sealed environment. Each grid
screen was set-up at room temperature and left to equilibrate at a constant temperature of
20.5°C. After 4 days one yellow crystal of dimensions 0.4 x 0.2 x 0.1mm was grown from a
solution of lOmg ml’  ^ protein, 10% PEG 6K (w/v), HEPES pH 7.0, Figure 2.9. Table 2.7
charts the different crystallisation parameters tried to reproduce the crystallisation.
Table 2.7: Grid screens o f each listed precipitant were performed at room
temperature in a search for initial crystallisation conditions, 10% PEG 
6K (w/v), O.IM HEPES pH  7.0 was the only condition that resulted in a 
crystal.
Precipitant / 
Concentration
(w/v) / (v/v)
Buffer / pH 
O.IM
Protein 
Additive Concentration 
mg ml’^
Mixing® Crystals
Peg 6K ------ Yes
Peg 6K/LÎC1 4, 5, 6. No
(NH4)2S04 7, 8 & 9. 6 & 10 Yes No
MPD — No
NaCl — No
On addition o f an equal volume o f  mother liquor to the protein drop this solution can be mixed by drawing back on the pipette and 
redispensing the mixed solution.
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Figure 2.9: Yellow crystal o f  UDP-galactopyranose mutase from E.coli.
■M
Unfortunately this crystallisation could not be reproduced. Extensive efforts, utilising 
exactly the same stock solution as precipitant and a multitude of similar conditions. Table 
2.8, proved fruitless. Precisely why this crystallisation could not be reproduced is unclear. 
One reason would be the multitude of isoforms that exist when the protein is expressed in 
LB. Separating the protein by charge as opposed to mass disclosed several very closely 
related species not detectable by SDS-PAGE. Crystallisation of such species may prove 
problematic and difficult to reproduce, as indeed is discovered here. To assess if the 
problem of reproducibility lay in the method of overexpression protein was "re-expressed’ in 
the original media, LB. Unfortunately this did not resolve the problem. Batch variation is 
another possibility, however no subsequent batch characterised by conventional techniques 
(SDS-PAGE, lEF and DLS) disclosed any difference from the original sample with the
85
exception that subsequent batches were more homogenous. The failure to reproduce this
crystallisation resulted in having to re-screen for ‘initial’ crystallisation conditions.
Table 2.8: Different crystallisation parameters tried in attempts to reproduce 
the initial crystallisation o f UDP-galactopyranose mutase.
Precipitant 
Concentration 
(w/v) / (v/v)
Buffer / 
pH O.IM Additive
Protein 
Concentration 
mg ml*^ Mixing Crystals
PEG 6K  / 
5 -  30%
Citric Acid 
5.0-5.9 
MES 6.0 -  6.9 
HEPES 7.0-8.0
—
3.6,
8,10 & 12 Yes & No No
PEG 6K / LiCl 
5-30% HEPES 7.0-8.0 6, I0& 18 Yes & No No
PEG 200
MES 6 .0 - 6 .9  
HEPES 7.0-8.0 
TRIS 8.1 - 9 .0
No 6 &  12 Yes & No No
PEG 600
PEG 1000
PEG 3000
PEG 4000
PEG 8000
PEG 20 000
PEG MME 2K 
1 5 - 2 5 %
HEPES 7.0-8.0 No 4, 8, & 12 Yes NoPEG MME 5K 
1 5 - 2 5 %
PEG 6K HEPES 7.0
g*
Hampton 
Add I & Add II.
10 Yes and No No
“ Hampton Research Additive Kits I & II for Crystallisation. 
* Full Compilation listed in Appendix II
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Dynamic Light Scattering and Crystallisation o f Mutase From Terrific Broth.
The protein obtained after expression in terrific broth was more abundant and homogenous 
(a single lEF species) than that obtained from LB. With these factors in mind, together with 
the inability to reproduce the initial crystallisation results from LB, a screen for 
ciystailisation conditions from protein expressed in terrific broth was performed.
A protein sample and the Dynapro 801 were prepared as before for a dynamic light scattering 
experiment. On injection of the 0.02|am filtered protein the photon count rate was monitored 
until it reached a stable reading. Measurement then commenced and the results are displayed 
in Table 2.9.
Table 2.9: Dynamic light scattering results fo r  UDP-galactopyranose mutase.
The average polydispersity value as a function of the hydrodynamic 
radius is 15.6%.
# Ampl. Differ.
Coeff.
Radius
(nm)
Polyd.
(nm)
Est.MW
kDa
Temp.
C
Count
Rate
Base
Line
Poly
D%
1 0.871 530 3.7 -- 73 17.9 217 1.000
2 0.860 544 3.6 --- 67 17.4 213 0.999
3 0.873 534 3.7 -- 69 17.6 211 0.999
4 0.884 546 3.6 -- 66 17.4 206 1.000 --
5 0.874 538 3.6 0.601 68 17.7 204 0.999 16.6
6 0.876 543 3.6 68 17.6 200 1.000 --
7 0.873 547 3.6 68 17.1 198 1.000
8 0.873 534 3.6 -- 66 17.1 207 1.000 ---
9 0.868 526 3.7 --- 68 17.5 205 0.999 --
10 0.867 538 3.7 0.544 70 17.4 209 1.000 14.7
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The expression and purification had been refined such that the protein appeared considerably 
more suitable for crystallisation. The results from light scattering indicate the protein 
solution to be monodisperse and it was anticipated that any success in crystallisation now 
would be more reproducible. However, despite the improved route to crystallisation, the 
original crystallisation was still not reproducible. As a result commercially available 
screening kits from Hampton Research and an additional screen containing a further 119 
unique conditions® (John Mac Lean, personal communication) were screened for initial 
crystallisation conditions using the hanging drop method as previously outlined. The results 
are illustrated in Table 2.10.
Table 2.10: Screening for crystallisation conditions o f UDP-galactopyranose 
mutase with commercially available crystallisation kits.
Precipitant
Concentration
(w/v) / (v/v)
Buffer / pH 
O.IM Additive
Protein
Concentration
mg ml^
Mixing Crystals
Hampton
CSI®
No
6, 
12 & 
18
Yes
Hampton I 
#41
Hampton
c s n “ No
JMac® No
PEG 4K 20% 
Isopropanol 
12%
HEPES
7.5 8
Yes Yes
No No
Full Compilation listed in Appendix I.
The crystallisation of the enzyme was found to be readily reproducible using the conditions 
quoted in Table 2.10, although not in a form suited to analysis by x-ray diffraction. 
However, this is often the case with the first crystals obtained and optimisation of these 
parameters may yield crystals of higher quality. Increasing the PEG concentrations in 1% 
increments between 10% and 30%, (all other parameters as before), and similarly varying the 
isopropanol concentration between 5 and 20%, found the optimal conditions for crystal 
growth over a range of protein concentrations to be 20% PEG 4K and 12% isopropanol. The 
optimum protein concentration for crystal growth is 8mg m l'\ Table 2.11 lists these 
experiments.
Table 2.11: Initial optimisation o f primary hit with Hampton Screen 1, solution 
number 4L
Precipitant 
Concentration 
(w/v) / (v/v)
Buffer / 
pH O.IM Additive
Protein
Concentration
mg ml^
Mixing
Best
Crystals
PEG 4K 
10-30%  
Isopropanol 
10% 4, 6, 8,
20% 
PEG 4K
PEG 4K 
20% 
Isopropanol 
5 -2 0 %
HEPES 7.5 No 1 0&  12 Yes
12%
Isopropanoi
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The initial conditions that resulted in crystalline mutase were refined to 20% PEG 4K, 12% 
isopropanol, O.IM HEPES pH 7.6. These crystals were still not suitable for data collection 
and further experimentation with these parameters was required. Alternative buffers and 
alcohols were tried with a view to improving the quality of crystal obtained. Results are 
listed in Table 2.12.
Table 2.12: Buffer and alcohol optimisation in the crystallisation o f mutase.
Precipitant
Concentration
(w/v) / (v/v)
Buffer / pH 
O.IM 
7.0 -  8.0
Additive
10%
Protein
Concentration 
mg ml^
Crystals
Improved 
Crystals ?
Phosphate
PEG 4K 
20% 
Isopropanol 
12%
TRIS
Na Cacodylate
Imidazole
Na Acetate
MES
PEG 4K
20%
HEPES 7.6
No
Butanol
Ethanol
Methanol
Yes
No
No
No
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Although crystalline material was obtained with various other buffers and alcohols no 
variations produced better crystals and so optimisation continued.
Small molecule additives and detergents are known to interfere and alter the crystallisation 
characteristics of proteins (Cudney, 1994). Using the commercially available kits from 
Hampton Research hanging drops were set up with the optimal precipitant concentrations. 
Additives were used in a ten-fold dilution from the Hampton Kits. Along with the 
commercial screens known enzyme inhibitors (R. A. Field, unpublished results) were 
incubated with the protein at room temperature prior to crystallisation. It was anticipated 
that by ‘locking’ the enzyme with inhibitor the enzyme would be more susceptible to 
crystallisation. These crystals would have the added bonus in that if a structure were 
elucidated using them then the active site of the enzyme would be readily identifiable. 
Results are listed in Table 2.13.
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Table 2.13: Screening additives and detergents with UDP-galactopyranose mutase
Precipitant
Concentration
(w/v) /  (v/v)
20% PEG 4K 
12% 
Isopropanoi
O.IM 
Buffer 
pH 7.6
HEPES
Additive
Hampton 
A. S. I
Hampton
A .s .n
Detergent
Screen
2-F-GaI-l-P
i-Deoxygalf
Gal-a-o-methyl
Protein
Concentration
mg mi^
Improved
Crystals
Yes, 
Solution #2
No
No
No
No
No
Crystals were reproduced with various additives but only addition of L-cysteine at 0.01 M 
yielded crystals of better quality than those already available. However, there were many 
nucléation sites and crystals were very small, 0.04 x 0.02 x -0.002mm, though singular with 
growth appearing to originate from a small dark nucléation site. To improve crystal quality 
further and increase crystal size, it was evident that further optimisation was required. Table 
2.14. Trials with other reducing agents and screening of previously used commercial screens 
were performed both in the presence and absence of L-cysteine.
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Table 2.14: Optimisation o f reducing agent present in crystallisation.
Precipitant
Concentration
(w/v) / (v/v)
O.IM 
Buffer 
pH 7.6
Additive 
0.001 -  O.IM
Protein
Concentration
mg ml^
Mixing
Improved
Crystals
L-cysteine
Glutathione
PEG4K
20%
Isopropanoi
12%
DTT
HEPES
p-
Mercapto-
ethanol
Yes No
Hampton I
Hampton II
JMac
L-cysteine 
0.0 IM
4, 8, &10 Yes & No No
Again, although crystallisation was reproducible with both DTT and jJ-Mercaptoethanol 
these yielded smaller ciystals. Re-screening all the commercial kits in the presence of L- 
cysteine did not identify any new crystallisation conditions, though many conditions were 
discovered for the successful crystallisation of L-cysteine.
With optimisation avenues appearing to be at an end, and the crystals not at a size ideal for 
data collection, alternative methods of crystallisation using the optimised mother liquor as 
precipitant were explored.
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Free Interface Diffusion
In an effort to reduce the number of nucléation sites in crystallisation experiments thereby 
hopefully growing fewer but larger crystals, a ‘novel’ technique referred to as free interface 
diffusion was tried (Hampton Reseai'ch, 1995). This differs from the more conventional 
methods of crystallisation in that initially a high local concentration of protein and 
precipitant exists yielding many nucléation sites, followed by a rapid relaxation to more 
dilute concentrations suited for crystal growth from pre-existing nuclei (Salemme, 1985).
A thin walled quartz glass capillary of diameter 0.2mm was filled to slightly less than half 
volume before an equal volume of protein (containing L-cysteine) was pipetted on top of the 
mother liquor, being careful not to induce any mixing between the two layers. The capillary 
was sealed and incubated at 20.5°C horizontally. Over several weeks the protein and mother 
liquor slowly diffused together and yellow crystals of a relatively large (0.5 x 0.01 x 
0.01mm) feather like nature were observed. Unfortunately the crystals were of the same 
morphology as obtained prior to inclusion of L-cysteine and hence were of no use for data 
collection.
To reduce the rate of diffusion further a small layer of oil was placed between the mother 
liquor and protein before sealing the capillary. Three different oils (available from Hampton 
Research), which alter the rate of equilibration differently according to their composition 
were examined. Al’s, paraffin and silicon oil were pipetted on top of the mother liquor in 
the capillary in various amounts before addition of protein. Although the rate of ciystal 
growth altered, (paraffin, Al’s, silicon, diffusion becoming quicker) again no better crystals 
were observed in relation to the hanging drop experiment.
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MicroBatch Crystallisation Under Oil.
Crystallising macromolecules under oil allows one to control the rate of water diffusion 
through oil and hence the rate at which crystallisation occurs. If paraffin oil is used then no 
water diffusion is observed and all the reagents involved in the crystallisation remain at 
specific concentrations (Chayen et al, 1992); subsequently no concentration of the protein or 
the reagents can occur in the drop. However, by using silicon oil one can perform a 
microbatch experiment that allows for concentration of sample and reagents in the drop as 
diffusion of water is possible through the silicon oil (D’Arcy et al, 1996).
6|Li1 of 100% paraffin oil, or 6pl of a paraffin/silicon oil mix, was pipetted into the well of a 
72 well MicroBatch plate (Hampton Research). 2p.l of 8 mgml'^ protein was pipetted into 
the cone shaped depression in the MicroBatch plate followed by addition of an equal volume 
of mother liquor. Trials were set up with different ratios of paraffin to silicon oil to alter the 
rate of vapour diffusion obtained. The tray was covered to prevent dust contamination and 
incubated at 20.5°C. After 52 weeks and periodical checking no crystals were observed. 
This avenue of crystallisation was abandoned.
Seeding
A seed from a crystal too small to be of any use can be used as a template or a nucléation site 
onto which other ‘protein molecules’ can add themselves. Larger crystals with the same 
characteristics as the crystal from which the seed originated should then grow (E. Stura, 
personal communication). Two seeding techniques, streakseeding and macroseeding, were 
employed in combination with the hanging drop vapour diffusion method for all trials, (Stura 
and Wilson, 1992). Using a human hair to touch a crystal grown from the previously
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established conditions, a drop containing 2p,l protein, 0.5p.i L-cysteine and 2.5jil mother 
liquor was streaked with the hair after it had been used to dislodge seeds from a ciystal. 
Drops that had been prepared immediately prior to streaking did not yield any crystals but if 
drops were left to equilibrate for approximately 40 hours before streaking then a shower of 
single crystals resulted within 24 hours of streaking. The seeded crystals were of similar 
dimensions to those previously obtained but were now free from the polycrystalline 
nucléation sites. The crystals were still too small to be of use for structure determination but 
were used in macroseeding experiments.
Single crystals were washed in stabilising solutions of mother liquor 3 to 4 times before 
being introduced to freshly prepared protein drops, 2(il o f 4mg mi‘  ^ protein, 0.5pl of 0.0 IM 
L-cysteine and 2.5jil mother liquor. Each transfer of crystal was performed using a rayon 
loop of diameter just lai'ger than the largest dimension of the crystal. Allowing drops to 
equilibrate for any period of time before introducing crystals did not promote better growth. 
Typically, crystal growth would be complete after 2-5 days and the macroseeding process 
then repeated. To obtain crystals of sufficient size for data collection (0.5 x 0.3 x -0.06 
mm), Figure 2.10, seeding had to be repeated 3 to 4 times.
Using this protocol, protein solution was incubated with 2mM FAD both in the absence and 
presence of NAD(H)/NADP(H) prior to seeding to assess if larger crystals grew as a 
consequence of the protein being incubated along with co-factor. Table 2.15.
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Table 2.15: Incubation conditions and results from subsequent seeding 
experiments.
Precipitant
Concentration
(w/v) / (v/v)
O.IM 
Buffer 
pH 7.6
2 mM 
FAD 
+ 2 mM
Incubation
Temperatures
°c
Protein
Concentration
mg ml^
Improved 
Crystals ?
PEG 4K 20% 
Isopropanoi 
12% 
L-cysteine 
0.0 IM
HEPES
NAD 4 37
4, 8, 12
No Yes
NADH 4 37 No Yes
NADP 4 37 No Best
NADPH 4 37 No Yes
Crystals were routinely reproduced by this protocol using protein incubated prior to 
crystallisation at 37°C with FAD and NADP.
Crystallisation o f Selenomethionine Variant Mutase.
Selenomethionine protein crystallised using the same precipitating reagents and techniques 
used to crystallise the native enzyme. To ensure the likelihood of oxidation was kept to a 
minimum all buffers for crystallisation were thoroughly degassed before use. Furthermore, 
an argon atmosphere was established by attaching an inverted funnel through which argon 
gas was flowing. All crystallisation experiments involving selenomethionine protein were 
performed in this atmosphere.
Overall, crystal growth with selenomethionine protein was slower than the native; generally 
requiring an extra seeding step to get crystals suitable for X-ray diffraction. Even the crystal
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size was smaller than the typical size obtained with native protein. The maximum sizes of 
selenomethionine crystals was 0.3 x 0.15 x -0.03mm.
Figure 2.10: Crystals o f  UDF-galactopyranose mutase before and after seeding.
The dimensions before seeding are 0.08 x 0.04 x ^0.004mm and 
increase to 0.5 x 0.3 x M).06mm.
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Determination o f Cryo-protectant Conditions for the Precipitant used to Crystallise 
Mutase.
Data collection at room temperature is often hampered by the generation of free radicals 
within the crystal, which limits if not destroys the diffraction obtainable from the crystal. 
This was observed with the first mutase crystal grown which no longer diffracted after 6 
degrees of data collection in-house at room temperature. Data collection at cryogenic 
temperatures (~ lOOK) serves to reduce radiation damage suffered by macromolecular 
crystals. There are other benefits to data collection at low temperature including a reduction 
in background scatter, an effective resolution increase, reduction in thermal parameters and 
the capability to collect all data from one crystal before storage at cryogenic temperature for 
further use at a later stage (Rodgers, 1997). For data collection with very high intensity 
beams found at synchrotrons, it is almost essential that macromolecular crystals are suitably 
cryoprotected.
Good ciyoprotectants will neither crack nor increase the mosaic spread of the crystal and will 
form a ‘rigid glass’ around the crystal on exposure to cryogenic temperatures. Ice formation 
should be avoided, as this often degrades both the crystal and the data.
To the mother liquor used to grow crystals, glycerol was added in 2% increments until 
complete cryoprotection was obtained. This was judged by scooping up cryo-liquor with a 
rayon loop and positioning it in the centre of the cryostream (Oxford Cryosystems) at I lOK. 
If the cryo-liquor remains transparent then no ice has formed and the solution is suitable for 
cryoprotection. The integrity of any crystals in the cryoprotectant can only be assessed after 
exposure to X-rays and comparing the data to room temperature data. Ideally the two pieces 
of data should scale isomorphously. The minimum percentage of glycerol required for
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mutase precipitant was 12% but on occasion ice was observed at this percentage of glycerol. 
To guarantee complete cryo-protection all the time the concentration of glycerol was 
increased to 15%. MPD and PEG 400 were also assessed as potential ciyoprotectants and 
again 15% was the optimum percent of reagent required.
Native Data Collection.
Two crystal forms were obtained. The first crystal form, grown over one week from a 
solution of lOmg ml’' protein using 10%PEG 6K (w/w), O.IM HEPES pH 7.6 as precipitant, 
dimensions 0.4 x 0.2 x 0.1mm was mounted in a thin-walled glass capillary and sealed in the 
presence of mother liquor. All diffraction data were recorded at room temperature using the 
Enraf-Nonius/MacScience DIP2000 dual image plate. X-rays were generated (X=i.54Â) 
using an Enraf-Nonius FR591 rotating anode generator and focussed using the MacScience 
mirror system. An oscillation range of 1° was set, exposure time 30 minutes and the crystal 
to detector distance set at 150mm. The fresh crystal diffracted to 2.7Â. Radiation damage 
limited the number of degrees of data collected to 6. The data was indexed using DENZO 
(Otwinowski & Minor, 1996) in an orthorhombic space group (P222, P2|2i2;, P2i2i2 or 
P222|) with cell dimensions a=56Â b=94Â and c=134Â a=p=7^90®. As mentioned 
previously it has not been possible to reproduce this crystal form.
Crystals grown from the seeding procedure have been readily reproduced. Crystals are again 
yellow, diamond shaped flat plates of average dimensions 0.4 x 0.2 x -0.05mm. Using the 
in-house Nonius rotating anode and image plate system as before a crystal of dimensions 0.6 
X 0.3 X -0.05mm was equilibrated in a solution of mother liquor containing 15% glycerol 
and rapidly transferred to the cold nitrogen stream (IlOK). An oscillation range of 1° was
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employed, exposure time 50 minutes and crystal to detector distance 200mm. The crystal 
diffracted very weekly to 3.5Â throughout the 180° degrees of data collected. Data were 
processed using DENZO and SCALEPACK (Otwinowski & Minor, 1996) this time in a 
monoclinic space group P2 or P2iwith unit cell dimension a = 69.544Â, b = 57.126Â, c = 
97.555Â, a  = y =90, (3 = 96.44°. Analysis of systematic absences confirmed the space group 
as P2i. The data are 98.4% complete from 26Â to 3.5Â, Rmerge 18.6% and redundancy 1.7. 
The high Rmerge is a function of weak data and low resolution. Data collection and reduction 
statistics are shown in Table 2.16.
The mosaic spread was fixed to 0.5° for scaling, as it proved unstable in refinement. It 
should be noted that although this crystal diffracted to 3.5Â not all crystals of this size did. 
The diffracting power of these crystals varied from batch to batch. Some crystals only 
diffracted to very low resolution -10Â whilst others would diffract to nearer 3.5Â in-house. 
As the data was weak an accurate estimation of the mosaic spread was impossible to 
ascertain.
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Table 2.16: Quality o f the in-house native data set o f UDP-galactopyranose
mutase.
Resolution (A) No. Reflections % Complete R-Merge % Average
Redundancy
26.00-7.49 965 92.2 8.8 1.6
7.49-5.97 1014 98.7 13.2 1.6
5.97-5.22 979 99.4 15.4 1.6
5.22-4.74 998 99.2 14.7 1.6
4.74-4.41 994 99.3 15.7 1.7
4.41-4.15 988 99.1 18.4 1.7
4.15-3.94 983 99.2 22.2 1.7
3.94-3.77 981 99.0 27.0 1.7
3.77-3.62 984 99.4 31.0 1.7
3.62-3.50 989 99.3 36.9 1.7
25.00-3.50 9875 98.4 18.6 1.7
A higher resolution data set was collected on BM14 (À,=1.001Â) using the MAR345, image 
plate at the European Synchrotron Radiation Facility (E.S.R.F.), Grenoble, France. The 
MAR was set in the 18cm mode and the slits were set to 200pm x 200pm. Data collection 
proceeded as 145 non-overlapping images in steps of 1° at a ciystal to detector distance of 
242mm. Each exposure was for 120 seconds. For images 1 - 2 5  the beam cuiTent was 
138.9mA, ion chamber 1.1. The beam was refilled after image 25. Thereafter the current 
slowly decayed from 200mA ion chamber 11.3 to a current of 185.6mA and ion chamber 
10.4 at the end of data collection. Diffraction was visible to 2.8Â, though weak below 2.9Â, 
Figures 2.11 and 2.12. No significant crystal decay was observed. Data were processed 
using DENZO and SCALEPACK (Otwinowski & Minor, 1996) yielding 17660 unique 
reflections. The crystal was indexed in a monoclinic space group with unit cell dimensions a
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= 71.12Â, b = 58.42Â, c = 97.89Â, a  = y =90, P = 96.38. Analysis of diffraction data 
identified systematic absences consistent with space group P2|. The mosaic spread refined 
to 2.3° in SCALEPACK. Assuming a dimer of molecular mass 43kDa per monomer, the 
is 2.35Da '^  which falls in the allowed range for protein crystals (Matthews, 1968) and 
indicates a solvent content of 47%. The data are 92% complete from 15Â to 2.9Â, with an 
Rmerge 5.0% and redundancy 2.5. The average I over a  for the data is 16.6. Data collection 
and reduction statistics are shown in Table 2.17.
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Figure 2.11: Section o f  a 1° oscillation diffraction pattern from a crystal o f  
UDP-galactopyranose mutase taken at BM  14, E.S.R.F., Grenoble 
recorded with a MAR 345 image plate. The resolution at the edge o f  the 
photograph corresponds to 2.8À.
Figure 2.12: High resolution section o f  a 1° oscillation diffraction pattern o f  native 
mutase. Diffraction is visible to 2.8Â at the edge but weak beyond 3.0À.
9
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Table 2.17: Quality o f the native data set o f mutase collected on BM14 using the 
MAR345, at the E.S.R.F., Grenoble, France.
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
15-6.12 1489 82.0 2.6 2.89
6.12-4.91 1678 95.2 2.6 2.89
4.91-4.31 1676 94.5 3.1 2.89
4.31-3.92 1649 95.3 3.8 2.89
3.92-3.65 1654 95.7 4.7 2.89
3.65-3.43 1674 94.3 6.6 2.89
3.43-3.26 1562 90.9 11.4 2.89
3.26-3.12 1556 88.3 19.7 2.89
3.12-3.00 1495 86.0 24.0 2.89
3.00-2.90 1365 80.0 27.7 2.88
15-2.90 15798 90.2 5.0 2.89
Screening for Heavy Atom Derivatives.
As no homologous structure is known, phases have to be determined experimentally. To this 
end a search for isomorphous derivatives was undertaken in-house. The effectiveness of this 
seai'ch was limited by the variability of crystal quality from batch to batch and the effective 
resolution to which even the best crystals diffracted to in-house (-3.5Â). If encouraging 
results were obtained (as judged from data reduction and scaling with DENZO and 
SCALEPACK) in-house then the crystals were stored in liquid nitrogen for data collection at 
a later date using a synchrotron source. A summary of results obtained in-house is shown in 
Table 2.18.
Assessment of any potential derivative was primarily carried out in SCALEPACK as an 
indication of the usefulness of any crystal could be obtained after collection of only a few
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trames of data. Examination of the and Rmerge output in the last page of the SCALEPACK 
log file after scaling a few frames of ‘derivative’ data against a native data set gives an 
indication of how good a derivative may be. Crystals that scale closely with the native, that 
is x“~ 1, will not be useful derivatives, as there is little statistical difference between the data 
sets. If and R“«R, then this indicates a potential derivative as the differences
measured are much larger than the expected error. If is much larger than 10 then non­
isomorphism may be a problem, (Gewiith, 1996). Results that looked promising in 
SCALEPACK were later assessed in SCALEIT (CCP4, 1994).
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Table 2.18: Searching fo r isomorphous heavy atom derivatives.
S a l t
Concentration
(mM)
Length of 
Soak (Hrs)
%" R % R ^ %
Comments
KiPtCU 10 0.1 Crystal Dissolved
K zP tC L 5 1 No Diffraction
KiPtCU 2.5 6 3 19 21 2 min b/s^
KsPtCU 4 6 4 21 23 2 min b/s
KiPtCL 4 18 4 20 24 2 min b/s
K iP tC L 4 36 3 21 22 2 min b/s
K.PtClô 10 0.1 --- Crystal Dissolved
K.PtClô 5 6 --- --- --- No Diffraction
K .P tC le 2.5 6 2 19 21 2 min b/s
KsPtClô 3.3 6 4 16 16 2 min b/s
K.PtClô 3.3 20 7.5 23 25 2 min b/s
KsPtClô 3.5 13 3 13 15 4 min b/s
K.PtClô 3.6 20 8 20 21 2 min b/s
KzPtCla 3.6 13.5 5.4 18 21 2 min b/s
KsPtClô 3.6 24 4 19 20 3 min b/s
KoPtClô 3.7 12.5 3 20 24 3 min b/s
3.8 9 12 14 18 2 min b/s
K.PtCla 3.9 11 11 16 18 2 min b/s
PtCl2(NHj)2 4.0 13 3.8 18 21 2 min b/s
PtCbCNHOî 4.5 18.5 4.5 19 20 2 min b/s
HzPtCL 4.0 13 3 13 16 4 min b/s
107
Table 2.18(cont): Searching for isomorphous heavy atom derivatives.
S alt
Concentration
(mM)
Length of 
Soak (Hrs) R  % R^% Comments
Hg OAc 5 6 --- --- --- Ciystal Cracked 
No Diffraction
Hg OAc 2.5 1 --- --- --- Ciystal Cracked 
No Diffraction
Hg OAc 0.5 12 --- --- M o sa ic  Pattern
Hg OAc 0.25 1 --- --- M o sa ic  Pattern
Hg OAc 0.05 4 5 24 26 2 min b/s
Hg OAc 0.025 12 2 21 23 2 min b/s
ThimerosaP 5 0.1 Crystal Cracked 
No Diffraction
Thimerosal 2.5 1 Crystal Cracked 
No Diffraction
Thimerosal 0.5 6 Mosaic Pattern
Thimerosal 0.1 3 3 20 25 2 min b/s
Thimerosal 0.05 6 4 19 20 2 min b/s
Thimerosal 0.05 24 5 24 26 2 min b/s
Ur OAc 2.5 1 --- --- Crystal Dissolved
Ur OAc 0.06 18 4 18 20 2 min b/s
Ur OAc 0.02 18 4 21 23 2 min b/s
“ Backsoak 
Collected at the E.S.R.F.
Ethyl (2-mercaptobenzoate-S) mercury sodium salt
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Data Collection with Crystals Soaked in
A putative platinum derivative was identified after soaking a crystal for 9.5 hours in 3.8mM 
K^PtCU. The crystal was back soaked in ciyo-protectant for 2 minutes before being rapidly 
transferred to the cold nitrogen stream. 19° of data were collected at the E.S.R.F. to 3.0Â 
and processed and scaled using DENZO and SCALEPACK. The data refined to a %“ = 11.4 
against the native data set previously collected at the E.S.R.F., Table 2.19, which is 
indicative of a potential derivative (Gewirth, 1996). Time limitations at the synchrotron 
prevented the collecting of a more complete data set.
Table 2.19: Analysis o f and Rmerge from SCALEPACK after scaling three frames 
o f data collected from a ciystal soaked in 3.8mM K2PtCl6 against a 
native data set.
A R R^
25,00-8.31 29.5 0.164 0.244
8.31-6.64 12.8 0.128 0.183
6.64-5.81 16.4 0.151 0.191
5.81-5.28 10.9 0.135 0.165
5.28-4.91 10.9 0.135 0.173
4.91 -4.62 10.8 0.134 0.173
4.62-4.39 1.8 0.136 0.199
4.39 - 4.20 6.8 0.123 0.159
4.20 - 4.04 7.3 0.165 0.216
4.04 - 3.90 7.6 0.201 0.238
All Reflections 11.4 14.0 18.5
The above experiment was repeated on a return journey to the E.S.R.F. and this time a full 
data set recorded. Data were collected as 298 non-overlapping images at 0.5° oscillations on
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station ID14 EH3 using a MAR CCD with a crystal to detector distance of 148mm and X = 
0.926Â. Each exposure lasted 120 seconds. The data were reduced and scaled using 
MOSFLM (Leslie, 1993) and SCALA (Evans, 1993). Scaling of 10° of the data to native 
data in SCALEPACK for comparison purposes revealed a = 12, R = 8.3% and R  ^= 9.1%. 
The mosaic spread of the crystal refined to 2.0°. The data are 81.4% complete to 3.5Â, 
Rmerge 9.1% and redundancy 2.8, Table 2.20.
Using the programs SORTMTZ, TRUNCATE, CAD and SCALEIT as implemented in 
CCP4 (CCP4, 1994), the data (20 -  3.5Â) were converted into a format suitable for 
difference Patterson map calculation. Isomorphous difference maps were calculated and 
plotted using NPO (CCP4, 1994), and viewed at section y = Figure 2.13. Patterson sites 
were calculated by hand and refined in MLPHARE, (CCP4, 1994). None of the sites refined 
any better than a random x, y, z, coordinate and subsequently the positions of the heavy 
atoms could not be deduced from this data.
Figure 2.13: Isomorphous difference Patterson map, Pt derivative native.
All data collected at the E.S.R.F., Grenoble, France.
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Table 2.20: Quality o f the platinum data set collected at ID 14, EH3 using a 
MARCCD, at the E.S.R.F., Grenoble, France.
Resolution (A) No. Reflections % Complete R-Merge % Average
Redundancy
15-9.49 530 70.8 7.3 2.3
9.49-6.71 1300 77.8 6.1 2.8
6.71-5.48 1747 80.3 6.1 2.9
5.48-4.74 2136 82.4 7.3 2.9
4.74-4.24 2314 82.8 6.7 2.8
4.24-3.87 2630 83.7 6.9 2.8
3.87-3.59 2791 84.0 8.3 2.8
3.59-3.35 3017 84.1 9.9 2.9
3.35-3.26 3294 84.7 12.7 2.8
3.16-3.00 3345 85.2 12.7 2.9
15-3.00 23104 81.4 9.1 2.8
Two platinum salts, K^PtCL (Pt”) and KaPtCL (Pt* )^, were tested for their potential to bind 
isomorphously to mutase crystals. Early experiments suggested KiPtCl^ was binding with 
somewhat more affinity judging from the SCALEPACK output. Binding parameters were 
refined to 3.8mM KiPtClô for 9.5 hours, though soaking crystals in concentrations between 
3.5 and 4.0mM largely gave the same results when soaked for the same length of time. 
Promising as the early indications were, we were not able to locate heavy atom positions 
with data from these 'derivatives’. Instead of a limited number of platinums binding 
specifically, many appear to be binding, contributing to the noisy Patterson maps obtained. 
The high mosaic spread is also a compounding factor.
As an alternative to platinum, two mercury salts were assayed for their potential to form 
isomorphous derivatives. Unlike platinum, mercury is known to bind specifically to cysteine
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residues (mutase contains two cysteines) so a problem of low occupancy is less likely. Initial 
experiments that never destroyed the crystals when judged by eye gave highly mosaic 
diffraction patterns on exposure to X-rays. However, lowering the working concentration 
removed this problem and indeed yielded some promising results. Results from 
SCALEPACK suggest binding is taking place; that the crystals crack and become mosaic at 
higher concentrations support this notion. More experiments are required to optimise the 
soaking conditions. Likewise, soaking experiments with uranium acetate have yielded 
similar results. Unlike mercury, uranium does not bind to any specific amino acid, hence an 
outcome similar to the platinum experiments is more likely.
Data collection with crystals ‘soaked^ in Xenon
If protein crystals are pressurised with xenon gas under the appropriate conditions it is 
possible to observe xenon binding to the protein (Sauer, 1997). Xenon tends to bind weakly 
in hydrophobic pockets reducing the problem of non-isomorphism, a problem often 
encountered when heavy metals are used. Several derivatives can potentially be produced 
from one crystal as xenon often binds reversibly, allowing the same crystal to be used in 
heavy metal soaking experiments. Similarly, as the pressure at which binding is performed 
controls the number of xenon atoms that bind, multiple xenon derivatives can be had from 
the same crystal.
A crystal of dimensions 0.4 x 0.25 x -0.005mm was soaked in cryoprotectant and scooped 
up inside an appropriately sized rayon loop. The loop was attached to magnetic head and 
attached to the lid of the pressurisation chamber and sealed in a closed system. 200jil of 
mother liquor was present within the chamber to prevent the crystal from drying out. The
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system was flushed with xenon gas before pressurising to 80 psi. This pressure was 
maintained for 20 minutes before a controlled release of xenon pressure, and the crystal 
quickly mounted in the cryostream at 11 OK. The apparatus used in this experiment was 
designed and built in-house. A schematic representation of the apparatus is shown in Figure 
2.14 along with a cross section of the pressurisation chamber in Figure 2.15.
5° of data were recorded at 1 lOK using the Enraf-Nonius/MacScience DIP2000 dual image 
plate in-house. An oscillation range of 1° was fixed, exposure time 50 minutes and the 
crystal to detector distance set at 200mm. The crystal diffracted weekly to 3.7Â and the data 
were processed in DENZO and SCALEPACK. The x“ refined to 5 and the linear Rmerge 
26%, square Rmerge 33%.
Encouraging though these early results were, it should be noted they were not achieved at the 
first attempt. Crystals often showed no diffraction and some diffracted more weakly than 
normal. It was felt that more reproducible results were guaranteed by other techniques, 
namely heavy metal soaking and selenomethionine substitution.
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Figure 2.14: Aerial view o f  a schematic representation o f  the xenon pressure cell
and components.
N<mi ■ irium valve*;
Figure 2.15: Cross section o f  the xenon pressurisation chamber and lid.
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MAD at BM14
Mult]wavelength Anomalous Dispersion (MAD) was examined as opposed to MIR as an 
alternative route to structure solution. Experiments were conducted at the E.S.R.F. with 
crystals containing either the anomalous scattering atom platinum or selenium.
A crystal of dimensions 0.5 x 0.25 x -0,05mm was soaked in 3.8mM K2PtCl6 for 10 hours 
and back soaked in ciyo-protectant before being transferred to the cold nitrogen stream. An 
EXAFS scan detected the presence o f platinum within the crystal. Figure 2.16.
The first data set (ptel) was collected on the platinum white line at À, = 1.0714 A (E ^  
11.57KeV). Data were collected as 150 non-overlapping images using a MAR345 detector 
in 18cm mode, in steps o f  1° at a  crystal to detector distance o f  220mm. Data were 
processed using DENZO and SCALEPACK to 3.0 Â (Otwinowski & Minor, 1996) yielding 
15202 unique reflections. The crystal was indexed in a monoclinic space group with unit 
cell dimensions a = 68.84 b = 56.35 c = 97.42 Â, a  = y =90°, (3 = 96.62°. The data are 
90.4% complete and the Rmer  ^is 6.1%. Data quality for individual resolution bins is shown 
in Table 2.21a.
Figure 2.16: EXAFS scan o f  crystal soaked in K jP tC f for 10 hours and used in 
data collection.
ÎOOO
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A second data set (pte2) was collected at the point of inflexion of the platinum edge À, = 
1.0714Â (E = 11.57KeV). All other data collection parameters were consistent with ptel 
collection. Data were again processed using DENZO and SCALEPACK to 3.0Â
(Otwinowski & Minor, 1996) yielding 15202 unique reflections. The crystal was indexed in 
a monoclinic space group with unit cell dimensions a = 68.88Â, b = 56.41Â, c = 97.44Â, a  = 
y =90°, P = 96.60°. The data are 94.0% complete and the Rmerge is 5.3%. Data quality for 
individual resolution bins is shown in Table 2.21b.
The third data set (pte3) was collected on the high energy side of the platinum edge, X =
0.8855Â (E = 14.00KeV). All other data collection parameters were the same as ptel
collection. Data were again processed using DENZO and SCALEPACK to 3.0Â
(Otwinowski & Minor, 1996) yielding 15265 unique reflections. The crystal was indexed in
a monoclinic space group with unit cell dimensions a = 68.94Â, b = 56.46Â, c = 97.56Â, a  =
y =90°, p = 96.60°. The data are 92.8% complete and the Rmerge 5.6%, Table 2.21c. The
mosaic spread refined to 1.7° in SCALEPACK during scaling of each data set.
Tables 2.21: Quality of the MAD data sets denoted ptel, 2 & 3. Collected at the 
E S R F, Grenoble, France, 
a) Collected on the platinum edge
Resolution (k) No. Reflections % Complete R-Merge % Redundancy
30.00-7.36 1577 80.8 2.3 1.6
7.36-5.86 1713 87.3 3.9 1.6
5.86-5.12 1697 89.0 4.2 1.6
5.12-4.66 1753 89.1 4.0 1.6
4.66-4.32 1735 89.8 3.9 1.6
4.32-4.07 1776 90.8 4.4 1.6
4.07-3.87 1800 90.8 5.3 1.6
3.87-3.70 1745 91.3 6.6 1.6
3.70-3.56 1820 92.5 8.1 1.6
3.56-3.43 1828 92.7 9.8 1.6
3.43-3.33 1760 92.8 13.1 1.6
3.33-3.23 1839 93.3 16.2 1.6
3.23-3.15 1780 93.5 20.0 1.6
3.15-3.07 1804 91.3 23.3 1.6
3.07-3.00 1782 91.4 27.2 1.6
30.00-3.00 26409 90.4 6.1 1.6
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b) Collected on the point o f iiiflexion
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
30.00-7.36 1634 83.7 2.1 1.6
7.36-5.86 1812 92.4 3.3 1.6
5.86-5.12 1791 94.0 3.7 1.6
5.12-4.66 1849 94.0 3.2 1.6
4.66-4.32 1819 94.2 3.4 1.6
4.32-4.07 1860 95.1 4.0 1.6
4.07-3.87 1883 95.0 4.7 1.6
3.87-3.70 1819 95.1 6.0 1.6
3.70-3.56 1887 95.9 6.8 1.6
3.56-3.43 1880 95.4 8.0 1.6
3.43-3.33 1825 96.2 10.8 1.6
3.33-3.23 1885 95.6 13.2 1.6
3.23-3.15 1831 96.2 27.8 1.6
3.15-3.07 1845 93.4 21.3 1.5
3.07-3.00 1831 93.9 23.1 1.5
30.00-3.00 27451 94.0 5.3 1.6
c) Collected on the high energy side o f the platinum edge.
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
30.00-7.36 1608 82.4 2.3 1.5
7.36-5.86 1774 89.9 3.3 1.5
5.86-5.12 1770 92.1 3.9 1.5
5.12-4.66 1842 93.0 3.3 1.5
4.66-4.32 1801 93.4 3.8 1.5
4.32-4.07 1828 94.0 4.2 1.5
4.07-3.87 1901 93.6 5.1 1.5
3.87-3.70 1789 93.7 6.3 1.5
3.70-3.56 1888 95.6 7.5 1.6
3.56-3.43 1853 93.7 9.1 1.6
3.43-3.33 1799 95.6 11.2 1.6
3.33-3.23 1902 95.1 15.3 1.6
3.23-3.15 1810 94.9 18.0 1.6
3.15-3.07 1830 91.7 22.9 1.6
3.07-3.00 1817 93.3 25.1 1.6
30.00-3.00 27212 92.8 5.6 1.6
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Data Analysis
The scaled data were taken through SCALEPACK2MTZ, CAD and TRUNCATE as
implemented in CCP4 (CCP4, 1994) to convert it into a format suitable for difference
Patterson map calculation. Both anomalous and dispersive difference maps were calculated
and plotted using NPO (CCP4, 1994) and viewed at section y = Vz, Figures 2.17 and 2.18.
Heavy atom coordinates were deduced using RSPS and refined in both MLPHARE (CCP4,
1994) and SOLVE (Terwilliger and Berendzen, 1999). Occupancy levels refined to 0.4 at
best, consequently phases could not be extracted from this data. Rather than having few
high occupancy platinum sites it appears there are many sites with low occupancy. This
explains the promising results acquired with this data at the processing level from
SCALEPACK and the noisy Patterson maps generated.
Figure 2.17: Dispersive difference Patterson map, p te l — ptel. All data 
collected at the E.S.R.F., Grenoble, France.
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Figure 2.18: Anomalous difference Patterson map, native - ptel. All data 
collected at the E S R F, Grenoble, France
Q>
a
Data Collection with Selenomethionine Variant Protein Crystals.
An EXAFS scan. Figure 2.19, was performed on a selenomethionine variant protein crystal 
to confirm selenium presence, and a data set subsequently collected on ID 14, EH3, at the 
E.S.R.F. A single crystal of dimensions 0.4 x 0.25 x -0.03mm was used to record the entire 
data set in two sweeps of 25 seconds per 1°. A MARCCD was employed and the crystal to 
detector distance was set to 148mm. The data was reduced and scaled using MOSFLM 
(Leslie, 1993) and SCALA (Evans, 1993). The data were 94% complete (74% of the 
anomalous data, Ranom 6.8%), consisting of 12293 unique reflections to 3.0Â yielding Rmerge 
6.8% and redundancy 1.8 The mosaic spread refined to 1.5°. This was encouraging, as at 
this level the mosaic spread would probably have been manageable. Table 2.22 shows the 
data collection statistics for individual resolution bins.
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Figure 2.19: EXAFS scan o f  crystal grown in defined media supplemented with 
selenomethionine and subsequently used in data collection.
20Q0
Table 2.22: Quality o f  the Se-Met data collected on ID 14, EH3 using a MARCCD, 
at the E. S. R. F., Grenoble, France.
Resolution (Â) No. Reflections % Complete R-Merge % Average
Redundancy
15-9.49 666 87.9 4.9 1.7
9.49-6.71 1353 91.9 3.9 1.8
6.71-5.48 1745 93.3 6.3 1.8
5.48-4.74 2090 94.5 4.5 1.8
4.74-4.24 2341 94.6 4.7 1.9
4.24-3.87 2570 94.6 8.3 1.9
3.87-3.59 2776 94.5 5.8 1.8
3.59-3.35 2976 94.3 7.2 1.9
3.35-3.26 3229 94.5 13.6 1.9
3.16-3.00 3337 94.4 13.7 1.9
15-3.00 23084 94.4 6.8 1.8
Using the programs. SORTMTZ, TRUNCATE, CAD and SCALEIT as i
CCP4 (CCP4, 1994) the data (15 -  3.0Â) were converted into a format suitable for Patterson 
map calculation. The native data set collected to 3.0Â on a previous visit to Grenoble was
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used. Both anomalous and isomorphous difference maps were calculated and plotted using 
NPO (CCP4, 1994) and viewed at section y = V2. Selenium coordinates were deduced using 
RSPS (CCP4, 1994) and refined in MLPHARE (CCP4, 1994). Again Patterson maps were 
noisy with the highest observable peak at 4a. The positions of the seleniums could not be 
deduced from this data.
A second MAD experiment was attempted at a latter date also at Grenoble when the beam 
was operating at a reduced power level. Despite mounting in excess of 30 selenomethionine 
variant protein crystals not one diffracted to sufficient resolution together with a low enough 
mosaic spread. If smaller crystals were used, 0.1 x 0.05 x -0.005mm, then although the 
resolution was low and the diffraction weak, the observed mosaic spread was manageable
UDP-galactopyranose Mutase from Klebsiella pneumonia
Chris Whitfield, University of Guelph, donated approximately 20mgs of purified mutase 
from K. pneumonia. The protein was shipped in 50% glycerol and displayed an intense 
yellow similar to mutase from E. coll. The protein was dialysed for 3 x 40 minutes against 
50mM TRIS, 2mM DTT. pH 7.6 in preparation for dynamic light scattering and 
crystallisation.
2mL of 50mM TRIS, 2mM DTT, pH 7.6 was 0.02pm filtered and injected through the 
optical cell of the Dynapro 801 to remove dust and air particles before injecting protein 
sample. 500pl of K. pneumonia mutase was diluted to 6mg ml ', 0.02pm filtered and 
injected into the optical cell. The protein count rate was monitored until stabilising around 
690. At this point measurement commenced. The results are displayed in Table 2.23.
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Table 2.23: Dynamic light scattering results at room temperature for mutase from
K. pneumonia. The average polydispersity value as a function
o f the hydrodynamic radius is 27.7%.
# Ampl. Differ.
Coeff.
Radiu
s
(nm)
Polyd.
(nm)
Est.M
W
kDa
Temp.
C
Count
Rate
Base
Line
PolyD
%
1 0.815 351 6.1 1.777 236 20.7 629 1.000 29.1
2 0.814 337 6.3 2.222 253 20.2 673 1.000 35.2
3 0.807 352 6.1 1.718 236 20.7 690 1.001 28.1
4 0.802 352 6.1 1.710 233 20.5 692 1.000 28.0
5 0.793 350 6.0 1.759 231 20.2 694 1.000 29.3
6 0.783 345 6.2 1.733 245 20.7 701 1.000 27.9
7 0.779 343 6.2 1.807 246 20.6 699 1.000 29.1
8 0.776 355 6.0 1.748 230 20.4 695 1.001 29.1
9 0.789 352 6.1 1.390 236 20.6 692 1.002 22.8
10 0.807 349 6.1 1.145 232 20.7 692 0.009 18.7
As the sample was not monodisperse at room temperature this experiment was repeated at 
4°C to judge if crystallisation at a lower temperature may be more profitable. The sample 
was recovered by drawing back on the syringe and used for the experiment the following 
morning after the Dynapro 801 had been stored at 4°C overnight. As before, 500pl of K. 
pneumonia mutase was filtered and injected into the Dynapro 801. The protein count rate 
was monitored and on stabilisation measurement began. The results are illustrated in Table
2.24.
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Table 2.24: Dynamic light scattering results at 10°Cfor mutase from K. pneumonia. 
The average polydispersity value as a function o f the hydrodynamic 
radius is 47.1%.
# Ampl. Differ.
Coeff.
Radius
(nm)
Polyd.
(nm)
Est.M
W
kDa
Temp.
°C
Count
Rate
Base
Line
PolyD
%
1 0.775 223 7.2 3.459 353 10.3 574 1.035 48.0
2 0.785 236 6.7 3.335 300 9.9 541 1.010 49.7
3 0.768 215 7.3 3.882 361 9.4 589 1.026 53.1
4 0.730 194 8.1 4.542 474 9.6 648 1.053 56.1
5 0.792 231 6.8 3.277 309 9.6 552 1.014 48.1
6 0.733 228 6.9 3.398 314 9.4 571 1.018 49.2
7 0.782 243 6.5 2.552 274 9.6 541 1.010 39.2
8 0.790 243 6.4 2.534 270 9.4 533 1.005 39.5
9 0.784 247 6.4 2.505 262 9.6 534 1.005 39.1
10 0.767 242 6.5 3.234 278 9.7 534 1.008 49.7
A  simple comparison of the average polydispersity as a function of the hydrodynamic radii 
reveals that crystallisation would be best attempted at room temperature. Recalling that if 
crystallisation is likely, then this figure should be lower than 25%. At 27.7% ciystallisation 
is not guaranteed but appears more likely than at 4°C.
Analysis of the protein by SDS-PAGE revealed more than one band on the gel. Without 
further purification the protein solution was estimated to be around 85% homogenous. As 
any further purification at this stage would result in loss of valuable protein it was decided to 
pursue crystallisation with the protein in this condition.
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Crystallisation of UDP-galactopyranose Mutase from K. pneumonia
The sitting drop vapour diffusion method was employed throughout all crystallisation trials 
of K. pneumonia mutase. Initially, commercial crystallisation screens from Hampton 
Reseai'ch along with the JMac and PEG, PEG/LiCl, MPD, (NH4)2S0 4  and NaCl grid screens 
were used to screen for initial crystallisation conditions with protein at 12 and 6mg ml '. 
Crystallisation agent number 100 from JMac, 15% PEG 4K, 0.2M MgCl], O.IM HEPES pH
7.5 proved successful in crystallising this protein at 6mg ml '. Crystals grew from precipitate 
as large clusters of thin needles, dimensions 0.2 x 0.01 x 0.01mm. The crystals were not 
suitable for X-ray diffraction and optimisation of these conditions was required. To this end 
the pH was varied from 4 - 9  and similarly the PEG 4K concentration from 2 -2 1 % , Table
2.25.
Table 2.25: Different buffers and pH  values tried against 2 - 2 1 %  PEG 4K in
optimising the original crystals obtained o f mutase from K. pneumonia.
Buffer (O.IM) PH Crystals
Citric 4.0 No
MES 4.0 -  6.5 No
Sodium acetate 5.0 No
Sodium aitrate 5.6 No
Imidazole 7.0 Yes
Sodium acetate 7.0 Yes
HEPES 7 .0 -7 .5 Yes
MES 7.0 Yes
Sodium cacodylate 7.5 Yes
TRIS 7.5 -  9.5 Yes
Bicine 9.0 Yes
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At pH levels <7.0 the enzyme failed to crystallise under these conditions, however above pH 
7 the enzyme readily crystallised with a variety of buffers. The optimum parameters for 
crystallisation were refined to 20% PEG 4K, 0.2M MgCE, O.IM TRIS pH 8.5. In place of 
the large clusters of needles that were first obtained, single crystals were now evident. 
However, the yellow crystals are essentially still only two dimensional, the largest dimension 
being 0.4mm and the other two dimension being in the \im range.
A single crystal of approximately 0.3 x 0.01 x 0.01mm was mounted in a thin wailed glass 
capillary in the presence of the mother liquor and mounted on the in-house Enraf- 
Nonius/MacScience DIP2000 dual image plate using an Enraf-Nonius FR951 rotating anode 
generator. The crystal was exposed to X-rays for 50 minutes over 1° oscillation range. No 
diffraction was observed.
That a crystal of these dimensions does not show any diffraction is not unusual. The crystals 
are very small. One would prefer to increase the smallest dimensions by a minimum factor 
of 10 or 50 - 100 ideally. Free radical generation may destroy the diffraction capabilities 
almost immediately, thus making cryoprotection essential. The crystals grown thus far have 
been obtained after limited optimisation. However, there are many other parameters that 
remain to be optimised.
As the protein was not overexpressed and purified in-house it may be more beneficial to 
overexpress and purify the protein ourselves and try to and achieve a higher state of protein 
purity before embarking on crystallisation. Analysis by mass spectrometry should be 
performed where possible, to ensure any sample is of maximum purity before attempting 
crystallisation. This analysis was omitted in the initial characterisation of this protein.
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We have recently received the clone for UDP-galactopyranose mutase from K. pneumonia 
from Chris Whitfield and work on the overexpression and purification of the enzyme in- 
house is on-going.
2.4 Discussion and Conclusions
UDP-galactopyranose mutase has been overexpressed and purified to suitable homogeneity 
such that crystallisation of the protein is viable. Characterisation of the protein by 
electrophoresis and mass spectrometry has shown the protein to be greater than 95% 
homogenous, although three peaks aie evident by mass spectrometry suggesting some 
heterogeneity. Dynamic light scattering results are consistent with a dimer of molecular 
mass 86kDa and data from non-denaturing gels confirm this data.
The purified protein displays a yellow colour due to the associated co-factor, FAD. It is also 
postulated that other co-factors may be present, NAD(H) or NADP(H) and indeed 
preincubation of the protein with two cofactors (FAD + NAD or NADP) yields better quality 
crystals. The protein from K. pneumonia is known to require NADP for activity.
Two ciystal forms of UDP-galactopyranose mutase from E. coli have been grown in a form 
suitable for x-ray diffraction. One crystal form is orthorhombic and diffracted to 2.7Â in- 
house. This crystal has not been reproduced despite extensive efforts. The inability to 
reproduce this crystallisation is attributed to multiple isoforms of the protein being present 
when the protein is overexpressed in LB. In combination with the possibility of co-factors 
being partially stripped from the protein this makes the crystallisation process more 
serendipitous than one would desire. To try and overcome these problems several expression 
media were examined for yield of soluble protein produced. Terrific broth was chosen as the
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best suitable media. Protein yield was increased eight fold and the multiple isoforms evident 
from LB were removed.
An alternative monoclinic crystal form has been reproducibly grown in hanging drops from 
protein overexpressed in terrific broth. However, to obtain crystals of suitable size for X-ray 
diffraction multiple rounds of seeding are required. Suitable cryo-protection conditions have 
been developed allowing data collection at cryogenic temperatures. The crystals diffract 
beyond 3.0Â resolution when subject to synchrotron radiation and two native data sets have 
been collected with these crystals. A 98% complete data set to 3.5Â has been collected in- 
house together with a 92% complete set to 2.9Â at the E.S.R.F. In the search for 
isomorphous heavy atom derivatives, crystals soaked in KzPtCL looked promising Judging 
from the statistics from SCALEPACK and SCALEIT. Unfortunately, the data were not good 
enough to locate heavy atom positions and hence solve the Patterson. Several metals have 
however been eliminated as potential derivatives. Early attempts to bind mercury and 
uranium isomorphously are encouraging and these avenues should be pursued further. A 
MAD experiment was also performed utilising platinum’s ability to scatter X-rays 
anomalously. After the necessary data processing, heavy atom positions were located and 
refined to very low occupancy making phase determination impossible.
The protein has also been overexpressed in a minimal media (minus methionine) 
supplemented with seleno-methionine. Mass spectrometry confirms selenium incorporation 
at least 75% providing a route to structure solution through MAD. An 85% complete data 
set was collected using the selenomethionine variant ciystals again at the E.S.R.F. 
Unfortunately heavy atom positions were indeterminable form this data.
127
The underlying problem throughout this project has been the inherent low diffracting power 
of the ciystals obtained and the variability from batch to batch. The crystals are at best 
0.06mm in the third dimension and diffract to low resolution in-house. The knock on effect 
of this has resulted in data collected in-house being more difficult to process and hence draw 
conclusions from. Perhaps the most disappointing aspect of this was the inability to 
characterise the large mosaic spread that was evident when experimenting with the crystals at 
the synchrotron. The percentage of glycerol used in cryoprotection and the protocol 
employed were modified without any observable decrease in mosaic spread. When 
mounting the crystal on the goniometer head loops just slightly bigger than the crystal itself 
where routinely used so to keep the scatter observed from the solvent to a minimum. 
However, loops so small may be inadvertently inducing stress on the crystals that in turn 
increases the observed mosaic spread. Conversely if loops of larger diameter were used this 
stress would be minimised and the crystal would be held in the centre of the loop by surface 
tension.
In nature it is known that plants and insects protect vital proteins from extreme conditions by 
wrapping them in a protective sugar cocoon (Potera, 1998). The sugars either forms a glass 
armour or vitrifies preventing the proteins from being damaged, then on coming into contact 
with water the sugars melt and the proteins regain their activity. This process may be 
directly applicable to the cryoprotection of protein crystals in X-ray crystallography. 
Cryoprotecting the crystals in a mixture of precipitant, glycerol and for example trehalose 
may prevent any internal damage to the crystal and subsequently reduce the observed mosaic 
spread.
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Ultimately, if the orthorhombic crystal form can be reproduced then many problems may be 
solved simultaneously. This crystal diffracted to a higher resolution in-house (2.7Â), (grown 
without any optimisation of the crystallisation parameters), than any seeded crystals did at 
the synchrotron. Incorporating seleno-methionine into these crystals may provide a trouble 
free and quick route to structure solution. Alternatively, crystals from K. pneumonia have 
also been grown. Should optimisation of these conditions yield well diffracting crystals then 
structure solution via this route should be pursued. The E. coli structure could then be 
determined by molecular replacement using the native data set already collected at the 
E.S.R.F.
2.5 Future Work
The observed mosaic spread of the crystals will be assessed when the crystals are mounted in 
loops considerably larger than the crystals themselves. In addition, different sugars will be 
characterised as potential cryo-protection agents, again with a view to reducing the mosaic 
spread of the ciystals. Should either of these alterations reduce the mosaic spread such that it 
becomes manageable then a structure may yet be obtained from these crystals. Failing these 
measures alternative ciystallisation conditions for the E. coli enzyme may be required.
The K. pneumonia enzymes crystallisation conditions should be optimised further. These 
crystals may be of better quality than the E. coli variety and provide a quicker route to 
structure solution.
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Chapter 3
The l.SSA structure of succinylated concanavalin A bound to the
synthetic bivalent ligand (1 ,3-di(N-propyloxy-a-D-mannopyranosyl)- 
carbomyl 5-methylazido-benzene).
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3.1 Summary
The low affinity binding that typifies protein-carbohydrate interactions is a primary concern 
for those striving to develop small molecule inhibitors of such interactions. Nature appeal's 
to overcome this problem through multivalency, where many simultaneous binding events 
overcome weak individual binding events. Accordingly, synthetic polyvalent ligands should 
access this effect. In collaboration with Eric Toone, Duke University, we have undertaken a 
project to determine the molecular basis of such interactions.
Crystals of x-ray diffraction quality have been obtained of succinyl con A bound to a 
synthetic bivalent ligand and the three-dimensional structure determined to 1.85Â by 
molecular replacement. Initially, diffraction data were recorded from a single ci-ystal to 
2.65Â at room temperature and the structure refined to this resolution. Subsequently, higher 
resolution data were collected on a flash cooled crystal at the Synchrotron Radiation Source 
on station PX9.6 Daresbury. The final model, refined to 1.85Â has good geometry and a 
final R factor of 20.8% and a Rfree of 23.3%. The structure shows the protein crystallises as a 
tetramer cross linked to 4 other protein tetramers, creating infinite plains of tetrameric 
molecules. A dimer is observed in the asymmetric unit and the ligand spans two monomers.
Both mannose residues are recognised at the so called monosaccharide binding site. While 
both amides remain planar in each structure, in the low resolution structure they adopt 
alternative conformations in cis and trans, breaking the two-fold rotation symmetry of the
ligand. The interactions in the succinylated con A tetramer are considerably less than those
1
observed in native con A, however they are extensive enough in that one would identify the |
protein to function as a tetramer. This is the first crystal structure of a protein bound to a |
synthetic multivalent caibohydrate ligand and together with data from agglutination assays,
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titration micro-calorimetry and analytical ultracentrifugation has profound implications for 
the design of multivalent ligands.
The structure of a trivalent ligand bound to succinyl con A has also been determined. 
However, the third mannose residue is disordered and the resultant structure is identical to 
the bivalent ligand / succinyl con A complex.
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3.2 Introduction
Proteins which recognise carbohydrates are ubiquitous and their functions diverse, (Sharon 
and Lis, 1989). They recognise carbohydrates with varying degrees of specificity and bind 
them with varying degrees of affinity. The processes, which govern such interactions, are 
not well characterised but the advent of more advanced biophysical techniques has made an 
understanding of such processes attainable.
Lectins comprise a vaiied family of sugar binding proteins and are found in all types of 
organism binding carbohydrates reversibly and with exquisite specificity (Goldstein and 
Portez, 1986). Plant lectins in particular are of intense interest as they are more tractable to 
characterisation by a broad range of biophysical techniques unlike their mammalian 
counterparts.
Concanavalin A (con A) is the most extensively studied member of the plant lectin family. 
The con A monomer consists of 237 amino acids and exists as a dimer in the pH range 5.0 -  
5.6, while at higher pH tetramerisation is more common until at pH 7 tetramers are the 
predominant species (Goldstein and Poretz, 1986). Succinylation provides a form of the 
protein that is thought to be dimeric at all pH values (Gunther et al, 1973).
Con A was first isolated and crystallised from the Jack Bean in 1919 (Sumner, 1919). 
However, it was not until 1975 that the native X-ray structure was determined (Reeke, et al, 
1975) and it was a further 14 years before the first con A carbohydrate complex (con A / a-o- 
mannopyranoside) was obtained (Derewenda et al, 1989). The delay in obtaining a 
complexed structure underlined the problems in obtaining suitable crystals of such 
complexes. A higher resolution study of this complex followed in 1994 (Naismith et al,
133
1994), allowing an extensive description of the monosaccharide binding site. The sugar is 
anchored to the protein by several direct hydrogen bonds, polar contacts and Van der Waals 
interactions burying 75% of the sugars accessible surface area. There are very limited main 
chain conformational changes upon carbohydrate binding to con A. Consequently, in 
relation to other carbohydrate binding proteins, more of the carbohydrate is exposed to the 
solvent and the full binding potential of the sugar is not realised (Quiocho, 1993).
In the years following this structure a plethora of new structures emerged revealing the 
specifics of the oligosaccharide binding site. Oligosaccharide binding is centered on a 
trimannoside core found in all TV-linked glyeans. Figure 3.1 (Rini, 1995). In 1996 Naismith 
and Field elucidated the crystal structure of con A bound to the trimannose highlighted in 
Figure 3.1 (Naismith & Field, 1996). The structure reveals the trisaccharide core sitting in 
an extended con A binding site with specific H-bonding between all three sugars and the 
protein. They also identified a structurally conserved water. The same water is present in 
the native structure and was proposed to be part of the binding site. Figure 3.2 (Naismith and 
Field, 1996).
Figure 3.1: Bianlenrmry N-linked glycan. The trimannoside core is shaded.
Gaip 1 -4GlcN Acp 1 -p fa n c t l^
!
Gaipi-4GlcNAcpi-:
When an oligosaccharide is specifically recognised, it exhibits an increased affinity for 
binding over the cognate monosaccharide. This is most likely directly related to the
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increased number of interactions possible between individual sugar rings and the extended 
binding site. The role water molecules play in this recognition is controversial. Originally it 
was proposed that water molecules are recruited to tfie binding site to mediate and stabilise 
interactions between the sugars and protein enhancing overall specificity. However, 
Naismith and Field’s structure (1996) suggests only conserved waters already bound to the 
protein are significant in recognition.
Figure 3.2: Schematic representation o f  the hydrogen bonds betvi^een the sugar and 
the protein fo r  the 2.0À crystal structure o f  the trimannoside con A 
complex. The structurally conserved water is also displayed (Naismith
ThfIS
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Ligand Multivalency
As therapeutic agents, carbohydrates are poor candidates. Oligosaccharides are too polar for 
satisfactory uptake and monosaccharides bind too weakly to be of value. However, it 
appears that in nature many carbohydrate binding proteins function as oligomeric species. 
This suggests that a possible solution to this conundrum may lie in the use of polyvalent 
ligands where multiple simultaneous binding events may overcome weak individual 
interactions. Several groups have pursued this, synthesising multivalent ligands and then 
assessing their affinity for carbohydrate binding proteins, reporting quite spectacular results. 
Enhanced affinities ranging from 10 to 10^  over the appropriate monovalent ligand have 
apparently been observed (Page et al, 1996; Quesenberry et al, 1997; Ashton et al, 1997; 
Zanini and Roy, 1997; Sigal et al, 1996).
Several stmctures exist of lectins bound with naturally occurring multivalent saccharides, 
occuiTing as cross-linked monomers / dimers, forming linear arrays of protein -  carbohydrate 
molecules (Bourne et al, 1994; Wright and Hester, 1996).
Bourne describes oligosaccharide bound structures of the bovine heart muscle lectin 
Galectin-1 bound with an octasaccharide and an asparaginyi-nonasaccharide (Bourne et al, 
1994). Both oligosaccharides are biantennary and contain LacNAc at the non-reducing end. 
For each complex three crystal forms are obtained as a result of different low energy 
oligosaccharide conformations in solution. The structures reveal infinite chains of lectin 
dimers cross linked trough the LacNAc units of the oligosaccharides, Figure 3.3.
It appears that the formation of such lattices is dependant on the valence of one of the 
reactants being at least two, allowing cross-linking in two or three dimensions. 
Bhattacharyya and co-workers (1987), who characterised solutions containing a single lectin
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in the presence of two oligosaccharides, have provided evidence for this. They discovered 
that only homogenous precipitates are formed and that heterogeneous complexes existed 
only in solution, that is they failed to precipitate. From this they concluded that each 
oligosaccharide formed a unique homogenous cross-linked lattice with the lectin and they 
were able to view these lattices by electron microscopy, revealing distinct patterns 
characteristic for the particular lectin carbohydrate complex (Bhattacharyya et al, 1987; 
Gupta et al, 1994).
Figure 3.3: Section o f  the infinite chains found in the crystal structure o f  bovine heart 
galectin-l octasaccharide complex (Bourne et al, 1994).
Energetics o f Protein  -  Carbohydrate Interactions
The principal method for assessing protein -  carbohydrate interactions until recently has 
been the inhibition of hemagglutination or oligosaccharide precipitation. The protocol 
involves measuring the ability of a synthetic ligand to inhibit aggregation of a polyvalent 
ligand. Whilst this technique offers the advantage of simplicity, results can be dominated by 
kinetic factors making the thermodynamic contributions undeterminable. The aggregates
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formed are ordered but not crystalline and structural data at the molecular level of the protein
-  ligand interaction is lacking. The advent of isothermal titration microcalorimetry allows 
the direct measurement of thermodynamic data. In this technique a soluble protein is titrated 
with aliquots of a soluble ligand. The heat evolved during ligand addition is deconvoluted to 
yield a binding constant K, which is related to the free energy of binding, AG --R T  Inif. In 
addition, binding enthalpies are measured directly and this allows the entropy of binding to 
be calculated via AG ~ AH - TAS\ Specific recognition of an oligosaccharide is indicated in 
a more negative free energy of binding compared to the cognate monosaccharide. Almost all 
carbohydrate interactions are entropically unfavourable in water (Chervenak et al, 1992; 
Mandai et al, 1994). Calorimetric analysis showed that a considerable proportion of the 
observed enthalpy increases arose from solvent reorganisation, that is a transfer of molecules 
between the bulk of the solvent and the solvation shell of the protein and the ligand 
(Chervenak and Toone 1994). This enthalpy -  entropy trade off is a general feature of lectin 
carbohydrate binding (Grunwald and Steel, 1995). The binding of larger specific ligands has 
more favourable enthalpy terms but this is compensated for to some extent by an 
unfavourable entropie term. This is interpreted in terms of changes in the rotational degrees 
of freedom as torsion angles are frozen, and in terms of solvent reorganisation upon binding 
(Toone, 1994).
The ^Cluster Glycoside Effect^
As well as being important recognition molecules in cell wall synthesis, the onset of a variety 
of viral, parasitic, mycoplasmal and pathogenic infections may also be triggered by a protein
-  carbohydrate interaction (Dwek, 1996). The prevalence of these interactions has led to
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intense research towards the development of carbohydrate based therapeutics (Lowe and 
Ward, 1997). Such species would provide a non-cytotoxic range of therapeutics applicable 
to a wide range of human diseases by interfering with the biological recognition process. 
However, the ubiquity of carbohydrates presents an immense challenge in the rational design 
of therapeutics, as the physical basis of protein -  carbohydrate interactions is still poorly 
understood. In addition, the weak interaction energies associated with protein -  
carbohydrate interactions has delayed progress, typical binding constants ranging from 
millimolai' to micromolar range (Mandai et al, 1994). An understanding of the recognition 
processes that govern such reactions is necessary. Recent years have seen significant 
progress made towards this through the combination of X-ray crystallography and isothermal 
micro-calorimetry.
Carbohydrate binding proteins (and carbohydrates) virtually always exist as oligomeric 
structures in vivo, suggesting nature overcomes the problem of weak carbohydrate / lectin 
binding through multivalency. That is, the use of polyvalent ligands can overcome the weak 
character of each individual interaction through simultaneous binding events. Hence, 
chemists have designed and synthesised polyvalent ligands, on the assumption that they 
would have high enough affinities to be useful therapeutic agents, bearing in mind 
monosaccharides bind too weakly, and oligosaccharides are too polar to be of general use. 
Several groups have pursued the goal of tight binding through the synthesis of a series of 
ligands of valencies ranging 2 through 20 for binding to lectins. Quite spectacular results 
have been observed with apparent binding affinities increasing from 10“ to 10  ^ over the 
cognate monosaccharide (Page et al 1996; Sigal et al, 1996; Ashton et al, 1997 and Zanini
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and Roy, 1997). This striking enhancement in binding has led to the general acceptance of 
what is termed ‘the cluster glycoside effect’ (Meunier & Roy, 1996).
Despite the apparent success of the cluster glycoside effect, a molecular interpretation of the 
phenomenon has been difficult to ascertain. Typically they are explained by way of entropie 
gains, either an effective concentration argument or a chelate effect. More often than not 
the linker region between recognition epitopes is too short to bridge two binding sites on the 
one molecule. Hence, the apparent increase in affinity is a result of two separate molecules 
being bridged. Figure 3.4a, and not when a multivalent ligand binds at one molecule. Figure 
3.4b, (a true chelate effect). Cluster glycoside effects have been observed for monovalent 
lectins (Miller et al, 1992).
Figures 3.4 a & b: Cartoon representation o f  a multivalent ligand (white) binding with 
a) Two lectins (orange) and b) One bivalent lectin (orange).
a) b)
Equation 1 relates the binding free energy for a bivalent ligand to a bivalent receptor, to the 
analogous monovalent binding free energies.
Equation 1: The binding free energy related to the analogous monovalent binding free  
energy where AGm represents the binding free energy o f  the component 
o f monovalent ligands and AGi is an interaction energy (Jencks, 1981).
AG = 2AG m + AG I
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Assuming the linker domain is of sufficient length and flexibility that allows the recognition 
domains of the lectin to be in their most favourable orientation for binding, then enthalpy 
contributions to AG°i will be small and entropie effects will dominate AG°j. The tethering of 
two binding sites will reduce the overall translational and rotational entropy of binding (AS  ^
i ) .  During the complete binding of a bivalent lectin by monovalent ligands, three molecules 
are converted to one; during the corresponding binding of a bivalent ligand only two 
particles are converted to one. That is, the binding of a bivalent receptor proceeds with 
entropie savings equivalent to the translational and rotational entropy of one monovalent 
ligand. This is known in chemistry as the chelate effect and current estimates as to the 
translational and rotational energy barrier to biomolecular complex formation range from 2.5 
to 15 kcal mol'' at room temperature (Mandai and Brewer, 1992). Countering this effect, the 
introduction of a flexible linker domain introduces an entropie penalty relative to 
monovalent binding, as conformational degrees of freedom in the linker domain are ‘frozen’ 
out in binding. The magnitudes of these effects are difficult to ascertain, though current 
estimates are around 0.5kcal mol"' per bond frozen during binding (Weis et al, 1996). As the 
distance between recognition domains on most polyvalent lectins is between 20Â and 70Â, it 
then seems unlikely that a chelate effect will be beneficial to reversible binding free energies, 
Table 3.1.
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Table 3.1: Estimation o f the entropy penalty (relative to monovalent) in bimolecular 
complex formation.
Distance Between 
Recognition Domains (Â) Number of C-C Bonds
Entropy Penalty 
(kcal Mol"')
20 8 4
50 20 10
70 28 14
In collaboration with Eric Toone (Duke University, North Carolina, USA) a program 
designed to explicitly separate the thermodynamic contribution of polyvalent ligand binding 
to their apparent affinities measured by assays has been undertaken. In this chapter the 
crystal structure of succinylated con A complexed with the synthetic bivalent ligand (1) and 
trivalent ligand (2) Figures 3.5 and 3.8 are reported. Both ligands are designed as mimics of 
biological sugars. Titration microcalorimetric binding studies of ligand (1) with con A 
reveal a binding constant of 1.9 x lO'^  mol ', a binding enthalpy of -5.9 kcal mol ' and a free 
energy of binding equivalent to -24 kJ mol"'. These are comparable with those of a  - d  -  
mannopyranoside, binding constant 7.6 x 10  ^mol"', a binding enthalpy o f-6.8 kcal mol"' and 
free energy of binding equal to -22 kJ mol"' (Chervenak & Toone, 1994). This work 
represents the first structural characterisation of a synthetic multivalent monosaccharide 
analogue complexed to a protein.
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3.3 Experimental.
Crystallisation and Data Collection o f the Bivalent Ligand 1 Complexed with Succinyl con 
A.
Succinylated con A was purchased from Sigma (Poole, United Kingdom). The bivalent 
ligand (1, 3-di (N-propyloxy-a-D-mannopyranosyl)-carbomyl 5-methlazido-benzene) was 
synthesised by our collaborator Eric Toone, Figure 3.5.
Figure 3.5: The bivalent ligand l,3-di(N-propyloxy-a-mannopyranosyl)-carbomyl 5- 
methylazido-benzene.
OH OH OH
OH
OH
Crystallisation trials were performed using the sitting-drop vapour diffusion method 
(Ducmix and Giege, 1992). A solution of succinylated con A (1.2mM) / ligand (18mM) was 
prepared in 20 mM TRIS pH 7.0, lOOmM NaCl, ImM CaC^ and ImM MnCla. Co-crystals 
of the succinyl con A-bivalent ligand complex were obtained after an initial screen 
consisting of 10, 15, 20 and 25% PEG 6K at pH units 4.0, 5.0, 6.0, 7.0, 8.0 and 9.0. Small 
crystals (0.1 x 0.2 x 0.2mm) were initially obtained with a PEG concentration of 20%, pH 
5.0, Optimisation of both the PEG and ligand concentration followed along with pH 
(Moothoo and Naismith, 1998a). Crystals of dimensions 1.0 x 0.8 x 0.6mm were obtained 
with the conditions outlined above but with a ligand concentration of 5mM. Crystal growth 
was complete within 14 days. In total 12 crystals were mounted in thin walled glass
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capillaries and their diffraction limits tested by exposure to X-rays. The resolution limit
varied markedly from 3.5Â to 2.65Â. Larger crystals did not improve the resolution.
All diffraction data were collected at 293.5 K from a single crystal (0.6 x 0.5 x 0.3mm) 
which diffracted to 2.65Â. Data was recorded on the Nonius/MacScience DIP2000 dual 
image plate and X-rays generated using an Enraf-Nonius FR951 rotating anode generator and 
focused using the MacScience mirror system, through a 0.5mm collimator. Data were 
collected as 92 non-overlapping images, 25 minute 1 oscillations with a crystal to detector 
distance of 140mm. The programs DENZO and SCALEPACK (Otwinowski, 1996) were 
used to index and merge the data. The crystal was indexed in a centered orthorhombic space 
group with unit cell dimensions a = 99.1Â, b = 127.4Â, c = 118.9Â. Analysis of diffraction 
data identified systematic absences consistent with space group C222|. A dimer in the 
asymmetric unit gives rise to a (Matthew’s, 1968) of 3.8A^ Da'* indicating a solvent 
content over 65%. Data quality is summarised in Table 3.2. Davina Moothoo is 
acknowledged for practical assistance relating to the crystallisation and data collection 
reported here.
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Table 3.2, Quality o f the data for the 2.65A model o f succinyl con A bound to a
synthetic bivalent ligand.
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
26.00-5.69 2143 93.6 4.0 2.6
5.69-4.53 2206 99.6 4.5 3.0
4.53-3.96 2177 99.8 5.4 3.0
3.96-3.59 2171 99.8 6.5 3.0
3.59-3.34 2138 99.5 8.0 3.0
3.34-3.14 2151 99.2 10.3 3.0
3.14-2.98 2124 99.2 12.1 3.0
2.98-2.85 2112 99.1 15.6 3.0
2.85- 2.74 2074 96.7 19.2 3.0
2.74- 2.65 1886 87.6 20.7 2.9
26.00-2.65 21182 97.4 7.2 2.9
High Resolution Data Collection
Data were also collected from a larger cryoprotected (15% glycerol) crystal, 0.8 x 0.6 x 
0.4mm, at a later date at the Daresbury Synchrotron Radiation Light Source on Station 9.6 
using a ADSC quantum 4 CCD at a crystal to detector distance of 210mm. The wavelength 
was set to 0.87Â. The temperature for data collection was held at lOOK. Data was recorded 
as 140 non-overlapping 2 minute 1° oscillations. The crystal had a mosaic spread of 0.45% 
MOSFLM (Leslie, 1993) and SCALA (Evans, 1993) were used to index and merge the data. 
Data quality is summarised in Table 3.3.
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Table 3.3. Quality o f the data fo r the 1.85A model o f succinyl con A bound to a
synthetic bivalent ligand.
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
25.0- 5.85 5254 87.1 7.5 3.0
5 .85-4 .14 3306 94.0 7.1 3.3
4 .14-3 .38 4335 96.0 7.5 3.4
3 .38-2 .92 5133 96.7 7.9 3.4
2.92 -  2.62 5805 96.9 8.6 3.4
2.62 -  2.39 6458 97.7 9.7 3.3
2.39-2.21 7035 98.2 11.4 3.3
2.07 -  2.07 7527 98.0 13.8 3.3
2.07-1 .95 7992 97.9 18.4 3.1
1.95-1.85 5734 67.1 30.9 2.4
25.0 -1 .8 5 55058 92.5 8.2 3.2
Structure Solution
The structure was elucidated using the moleculai' replacement package as implemented in 
CCP4 (Collaborative Computational Project Number 4, 1994) program AMoRe (Navaza, 
1994). The conventional con A dimer (monomer A and monomer B) from the trimannoside 
complex of conA (PDB code ICVN) was used as a seai'ch model with all metals, waters and 
sugar atoms removed and remaining atoms set to full occupancy. A cross-rotation function 
gave only one solution a  = 0.01, p = 66.59, y = 313.91 with a correlation coefficient of 0.28, 
12 standard deviations above noise for the 10 - 4Â data. The translational search produced a 
final solution x = 0.1339, y = 0.2521, z = 0.2987, correlation coefficient of 0.84, 33 standard 
deviations above noise, R-factor 38%. A translational search in C222 gave no solution. At 
this point the space group was definitively assigned as C222,. The asymmetric unit was
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redefined such that one monomer of the con A dimer (monomer A) was linked via the ligand
to another monomer (monomer C). Monomer C was generated by applying the symmetry
transformation (V2 - jc, /4 -y', z + Vi) to monomer B, Figure 3.6
Figure 3.6: The conventional dimer o f  con A is formed by monomer A and
monomer B, the ligand crosslinks monomer A to monomer C. The 
cross linking ligand is shown as a straight line between the two 
sugar binding sites.
Refinement.
The solution was imported into CNS (Brunger et al, 1998) and refinement carried out using 
the free R-factor (R as a guide. This was calculated on 10% of the data before any 
refinement had taken place and was subsequently excluded from all further refinement. Non 
-  crystallographic restraints were applied to thermal and positional parameters throughout 
refinement. The initial free R factor was 38%. Rigid body refinement of monomers reduced 
this to 30%. Restrained refinement of positional and thermal parameters further reduced the 
Rfree to 25%. At this stage 2Fo - Fg and F,, - Fg maps were calculated and clear density was 
visible for metal ions (2Mn^‘^  and 2Ca^^ and the ligand. The ligand geometry was defined 
using the Engh and Huber compendium of bond distances (Engh & Huber, 1991) and was 
included in the model for further refinement. Alternating cycles of automated refinement.
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NCS restrained thermal and positional, with manual intervention using O proceeded 
smoothly. No cut-offs were applied to the data except the 10% of data removed to monitor 
refinement. Overall anisotropic thermal parameters and bulk solvent corrections were 
applied to the data using standard CNS protocols (Brunger, 1998) for refinement. Electron 
density maps were calculated in CNS and converted for viewing in O (Jones et al, 1991) with 
MAPMAN (Kleywegt, unpublished program).
Water molecules were added to the model in batches providing they satisfied the following
criteria: (1) They corresponded to a peak > 3.5a in the Fq - Fc map, (2) they made hydrogen
bonds with reasonable stereo chemistry, (3) they reappeared in at least l a  in subsequently
calculated 2Fo -  Fc maps and (4) a drop in Rfree was observed. The progress of refinement is
summarised in Table 3.4. The quality of the final 2.65Â model is shown in Table 3.5.
Table 3.4. Progress o f refinement for the 2.65Â bivalent ligand -  succinyl con A 
model.
Refinement R factor /  Rfree
Starting 34% 38%
CNS : Rigid body fitting of monomers (30 cycles)
O : Ligand, metal ions (2Mn^^ and 2Ca '^^) added and 
Waters added.
26% 30%
CNS : Thermal (30 cycles) 
Positional (60 cycles)
O : More water molecules added
22% 25%
CNS : Thermal (40 cycles) 
Positional (70 cycles) 
O : More waters added.
18% 21%
CNS : Thermal (40 cycles) 
Positional (40 cycles)
17% 20%
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Table 3.5: Quality o f the final model o f the 2.65A succinyl con A  -  bivalent
ligand complex.
Data Collection
Unique reflections 21182
Completeness of data(%) (26.00 -  2.65À / 2.75 -  2.65Â) 96.4/98.3
Rmerge (I) (%) (26.00 -  2.65À / 2.75 -  2.65À) 7.2 / 20.7
Average data redundancy (26.00 -  2.65À / Z75 -  2.65À) 2.5 / 2.2
% of data > 1 a (26.00 -  2.65Â / 2.75 -  2.65Â) 94/83
Refinement
Resolution range (A) 26.00 - 2.65À
Rfree (% ) 20.0%
R factor (%) 17.6%
Bond r.m.s. deviation (Â)^ 0.008
Angle r.m.s. deviation C f 1.70
B-factor bounded atoms r.m.s deviation(A")^ 1.75
Ramachandran core/additional (%Ÿ 86.7/12.8
Protein mean B-factor (Â^)(all) 28.9
“ r.m.s. deviation from Engh & Huber ideal values (Engh & Huber, 1991).
 ^Core and additionally allowed regions as defined by PROCHECK (Laskowski et al, 1993).
B-factor deviation for bonded atoms
High Resolution Data
The refined 2.65Â ligand -  succinyl con A complex co-ordinates were used as a model 
against which to refine the 1.85Â data. When the resolution is extended, it is important that 
if the Rfree Is to remain free, the indices that form the free-R set in the lower resolution data 
set (2.65Â) remain in the free-i? set of the new high resolution set (1.85Â). This is 
accomplished by correct use of UNIQUEFY procedures in CCP4. Refinement proceeded 
using the same protocol used for the 2.65Â stmcture, rigid body followed by alternating
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thermal and positional refinement incorporating manual intervention using O. The trend 
throughout refinement, lowering R^ee, validates the refinement protocol.
3.4 Analysis of the 1.85Â Final Model
The final model contains a dimer of 546 residues, 2 Ca^^ ions and 2 Mn^^ ions, 330 water 
molecules and 160 sugar atoms. The quality of the data for the final model to 1.85Â is 
summarised in Table 3.6 and the Ramachandran plot (Ramakrishnan and Ramachandran, 
1965), calculated using PROCHECK (Laskowski et al, 1993) for the final model is shown in 
Figure 3,7. Glycine residues (not restricted to any particular region of the plot) are 
represented by a A and non-glycine residues by a ■. The darker the shaded region, the 
more favourable is the (p, v|/ combination. No residues lie outside the additionally allowed 
regions. Regions are labelled as follows; A = core alpha, a = allowed alpha, ~a = generous 
alpha, B = core beta, b = allowed beta, ~b = generous beta, L = core left handed alpha, 1 = 
allowed left handed alpha, ~1 = generous left handed alpha, p = allowed epsilon, ~p = 
generous epsilon.
Figure 3,7; Ramachandran plot fo r  the L85Â succinyl con A -  ligand model.
op*»-135-
80 T 35 6 45
Phi (degrees)
Î35 ife
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Table 3.6: Quality o f the final model o f the 1.85A succinyl con A  -  bivalent
ligand complex.
Data Collection
Unique reflections 55473
Completeness of data(%) (25.00 -  1.85Â / 1.95 - 1.85 A) 92.5/67.1
Rmerge (D (%) (25.()0 -  1.85À / 1.95 - 1.85 A) 8.2/30.9
Average data redundancy (25.00 -  1.85A /1.95 - 1.85 A) 3.2/2 .4
Refinement
Resolution range (A) 26 .00- 1.85À
23.32%
R factor (%) 20.72%
Bond r.m.s. deviation (Â)“ 0.01
Angle r.m.s. deviation (^ )* 1.79
B-factor bounded atoms r.m.s deviation(A")^ L42
Ramachandran core/additional {% f 86.5/13.3
Protein mean B-factor (À")^ (all) 34.6
 ^r.m.s. deviation from Engh & Huber ideal values (Engh & Huber, 1991).
Core and additionally allowed regions as defined by PROCHECK (Laskowski et at,  1993). 
B-factor deviation for bonded atoms.
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Structure Solution of Succinyl con A Bound to a Trivalent Ligand.
Crystals were also obtained of succinyl con A incubated with the bivalent ligand 2, Figure 
3.8.
Figure 3.8: The trivalent ligand crystallised with succinyl con A. H,
OH OH
OH
NH
(2)
The same strategy for obtaining the initial crystals and then optimisation was followed as 
outlined for the bivalent complex. The best crystals grew after equilibration with a solution 
composed of succinylated con A (l,2mM) / ligand (18mM) prepared in 20 mM TRIS pH 7.0, 
lOOmM NaCl, ImM CaCl2 and ImM MnCl2 and equilibrated against O.IM Citric acid 
pH4.0, 18%PEG 6K. The crystals were pyramidal and the maximum size to which they 
grew was small relative to other con A carbohydrate crystals at 0.2 x 0.2 x 0.2mm.
The same protocol for data collection and structure solution was followed as outlined for the 
bivalent ligand 1. The crystals diffracted in-house to 3.0Â. Indexing with DENZO 
(Otwinowski, 1996) indicated that the cell dimensions for the complex were almost identical 
to those for succinyl con A / bivalent ligand 1, Table 3.7.
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Table 3.7: A comparison o f the unit cell and space group found for the succinyl con
A bivalent ligand complex and succinyl con A crystallised with the trivalent 
ligand.
Succinyl con A / Bivalent Ligand Succinyl con A / Trivalent Ligand
a = 99.1 À a = 99.4À
b =  127.4À b = 127.2Â
c =  118.9Â c =  118.7Â
a  = |3 = y = 90 a  = p = y = 90
C222, C222,
A data set to 3.0Â was collected on the trivalent succinyl con A complex. Molecular 
replacement and refinement proceeded in a manner identical to that for the bivalent complex. 
Clear electron density was evident at the monosaccharide binding sites for mannose residues, 
however no density was evident for the third sugar. It was concluded that this part of the 
ligand was disordered. To ensure no handling eirors took place and that the bivalent ligand 
had not been crystallised and solved twice, the experiments (crystallisation and data 
collection) with the trivalent ligand were repeated. The initial results were reproduced. In 
addition, our collaborator confirmed by mass spectrometry that no degradation of the ligand 
had taken place.
Crystallisation ofTetra and Hexa Valent Ligands with Succinyl Con A
In addition to the bivalent (1) and trivalent ligand (2) two other con A multivalent ligand 
complexes were crystallised. Neither complex, as yet, has been characterised by x-rays.
The same crystallisation strategy as adopted for the other ligands was employed here. The 
tetravalent ligand. Figure 3,9, crystallised when prepared in a solution of 1.2mM succinyl 
con A / 9mM sugar after equilibration against 12 % PEG6K, O.IM citric acid pH 5. 
Similarly the hexavalent ligand. Figure 3.9, crystallised when prepared in a solution of
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1.2mM succinyl con A / 6mM sugar after equilibration against 8 % PEG6K, 0. IM citric acid 
pH 5.
Figure 3.9: The tetravalent and hexavalent ligands ciystallised with succinyl con A.
%
Dynamic Light Scattering
Con A is reported to exist predominately as a dimeric species in solution at pH 5, whereas at 
neutral pH, the dimers dimerise, yielding a tetrameric species (Goldstein & Poretz, 1986). It 
has been reported that succinylation of the protein provides a dimer that remains dimeric at 
all pH levels (Gunther et a f  1973). At neutral pH tetrameric con A visibly precipitates from 
solution upon addition of ligand 1. However, if  succinyl con A is used in place of native con 
A no precipitation is observed.
To further explore the range of species present fonned between the bivalent ligand and 
succinyl con A, mixed solutions were examined by dynamic light scattering. Solutions were 
prepared at 5mg ml‘  ^ in 20mM TRIS pH 7, lOmM NaCl, ImM MnCl], ImM CaCl2. 
Tetrameric con A was also analysed for comparison purposes. All solutions were 0.1pm 
filtered immediately prior to analysis and the results are shown in Tables 3.8, 3.9 & 3.10. 
This experiment was repeated with the other ligands discussed in this chapter (tri, tetra and 
hexavalent) yielding essentially identical results to those obtained with the succinyl con A 
bivalent ligand complex.
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Table 3.8: Analysis o f native con A by dynamic light scattering. The average
polydispersity value as a function o f the hydrodynamic radius is 19%.
# Ampl. Differ.Coeff.
Radius
(nm)
Polyd.
(nm)
Est.MW
kDa
Temp.
°C
Count
Rate
Base
Line
%Radius 
/ PolyD
1 0.833 578 4.46 1.1 108 2T9 432 1.000 24
2 0.846 581 4.45 0.4 108 27.8 432 1.000 9
3 &838 562 4.60 1.4 117 27.9 452 1.007 30
4 0.842 541 4.79 1.5 129 2T8 457 1.009 31
5 0.846 569 4 j3 0.3 112 2%9 442 0.009 6
6 0.846 575 4.50 1.3 111 27.8 439 1.000 28
7 0.850 592 4.36 1.0 103 2T8 438 1.001 23
8 0.844 563 4.60 0.6 116 27.9 441 1.000 13
9 0.844 575 4.50 0.7 111 27.9 438 1.000 15
10 0.840 572 4J2 0.8 112 2T8 442 1,000 17
Table 3.9. Analysis o f succinyl con A by dynamic light scattering. The average
polydispersity value as a function o f the hydrodynamic radius Ü ^2%.
Ampl. Differ. Radius Polyd. Est.MW Temp. Count Base %Radius
Coeff.
(nm)
(nm) kDa Rate Line /  PolyD
1 0.810 489 4.3 1.6 100 21.2 280 1.005 39
2 0.800 432 4.8 2.9 135 21.5 243 1.027 55
3 0.802 479 4.4 1.7 106 21.4 330 1.004 39
4 &809 485 4.3 1.7 104 21.0 347 1.005 39
5 0.813 482 4.3 1.7 104 21.3 335 1.006 39
6 0.809 486 4.3 1.7 104 21.5 331 1.005 41
7 0.729 477 4.3 1.7 104 21.5 315 1.006 40
8 0.801 487 4.4 1.7 110 21.4 312 1.005 39
9 0.820 458 4.3 2.2 121 21.4 315 1.007 51
10 0.824 453 4.4 2.0 117 21.4 316 1.007 45
Table 3.10: Analysis o f succinyl con A/bivalent ligand by dynamic light scattering.
The average polydispersity Value as a function o f the hydrodynamic 
radius is 96%.
# Ampl. D iffer.Coeff.
Radius
(nm)
Polyd.
(nm)
Est.MW
kDa
Temp.
°C
Count
Rate
Base
Line
%Radius 
/ PolyD
1 0.713 75 29.0 2T8 10200 21.2 280 1.090 95
2 0.725 107 20.6 19.8 4446 21.5 243 1.071 96
3 0.714 78 2T9 2&8 9306 21.4 330 1.080 96
4 0.725 76 28.5 27.4 9795 21.0 347 1.094 96
5 0.729 84 26.1 25.1 7905 21.3 335 1.087 96
6 0.725 85 25J 24.7 7618 21.5 33 1.074 96
7 0.729 93 23J 2Z7 6237 21.5 315 1.074 95
8 0J35 91 2A2 212 6570 21.4 312 1.066 95
9 0.736 88 24.7 23.7 6942 2L4 315 1.064 96
10 0.735 89 2A8 216 6950 21.4 327 1.063 95
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3.5 Discussion
The crystal stmcture of succinylated con A bound to the synthetic polyvalent ligand 1 has 
been determined to 1.85Â. The overall structure of the protein is essentially unchanged from 
previous con A complexes (Naismith et al, 1994; Naismith and Field, 1996; Moothoo and 
Naismith, 1998b)
Sugar Binding
Clear electron density is visible for the entire ligand in both the low and high resolution 
structures. However, at 2.65Â the carbonyl groups adopt different positions with respect to 
the aromatic ring. Figure 3.10. While both amides remain planar, one is orientated in a cis- 
conformation and the other in a trans-confonrntion. The ligand breaks its 2 fold rotation 
axis of symmetry, Figure 3.5, and each half of the ligand is chemically distinct in the 
structure. At high resolution both amides are in the trans orientation. The flexible portion of 
the ligand adopts a mainly extended conformation and separates the sugars by over 13Â, 
Figure 3.11. Both mannose residues are bound at the monosaccharide binding site of con A. 
The interactions between the ligand and the protein are shown in Table 3.11. The ligand is 
anchored to the protein by a combination of hydrogen bonds and Van der Waals interactions. 
The mannose residue dominates the contacts and the ligand and makes a few additional 
interactions with the protein. The orientation of the mannose residue within the binding site 
is little changed from that described previously for other con A carbohydrate complexes 
(Naismith and Field, 1996; Moothoo and Naismith, 1998b). The portion of the ligand 
outside the binding site occludes significantly more surface area than the simple 
monosaccharide, Table 3.11. Each mannose appears to be acting independently of the other 
in binding to the monosaccharide site. Modelling shows that maintaining the ligands strict
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two fold rotation axis allows the protein to cross-link but such an array has no protein 
protein contacts and would appear unlikely to form crystals. Whether such a symmetrical 
arrangement exists in solution is unknown. The protein protein interaction between the 
linked monomers is small, burying only 318Â^ of polar and 313Â^ of apolar surface. Both 
values are commonly associated with crystal contacts. Hence, it appears that protein protein 
contacts are relatively unimportant in controlling the aggregation of con A by this ligand but 
may influence the conformation of the ligand.
Table 3.11: The interaction between one protein monomer and the ligand. The values
for the mannose are shown in parenthesis. The mannose values are comparable 
to that observed in the ManOMe con A complex (Naismith et al,1994).
Van der Waals Contacts (<4.0Â) 48 (44)
Hydrogen Bonds and Polar Contacts 11 (10)
Polar Buried Surface Area 280 (216)
Apolar Buried Surface Area 237(125)
Figure 3,10: Fq - Fc map contoured at 3.2<t  with the refined ligand at 2.65A. The
phases fo r  the map were calculated from the model at 25% which did
not include the ligand, metals or water molecules.
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Figure 3.11: The ligand binds two monomers o f  succinyl con A effectively cross linking 
them.
Tetramer Organisation
Dimérisation of the dimers occludes 4300Â^ of surface area. The buried surface area is 
considerably less than that found in native con A (5200Â^) (Deacon et al, 1997; Reeke et al, 
1975) and in the mannose con A complex (4800Â^) (Naismith et al, 1994). There are 120 
protein protein contacts less than 4.0Â between two dimers, compared to 260 for the native 
and 160 for the mannose complex. Although this tetramer is less tightly packed than the 
other two, one would still identify the protein to be a functional tetramer. The results 
observed from light scattering lend credence to this. Analysis of succinyl con A suggests a 
molecular weight o f around 110 kDa, which is almost the exact weight of the predicted 
tetramer. The observation that succinylated con A forms into apparently normal tetramers
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also requires caution when assuming that succinylated protein exists ‘exclusively’ in dimeric 
form.
Supranwlecular Structure
The estimated molecular weight of the bivalent complex from light scattering ranges from 
4456 kDa to 10200 kDa. That the profile is so broad suggests a range of multimeric species. 
Similar results were obtained when either the tri, tetra or hexavalent ligand was used in 
place of the bivalent ligand.
This phenomenon is supported in the crystal structure, as each tetramer is cross-linked to
four other tetramers by the bivalent ligand. The interplay of crystal symmetry is complex
and results in the formation of an infinite sheet of cross-linked tetramers. Figure 3.12. Two
sheets pass through the unit cell and are related by a two-fold rotation axis.
Figure 3.12: The infinite sheet o f  succinyl con A tetramers found in the crystal. Each 
tetramer is bound to four other tetramers.
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As the addition of ligand i to con A at neutral pH results in a precipitated solution then the 
structure reported here may reflect a more ordered array of this precipitate. (At pH 5 
succinyl con A does not precipitate ligand 1). Correlation of this suggests the combination 
of protein and ligand valency is crucial in determining whether aggregate formation is 
energetically favourable. Where dimeric con A requires ligands with a valency of 3 or more 
to induce aggregation, tetrameric con A forms aggregates with the bivalent ligand. 
Apparently, aggregates only form under conditions where one dimer is linked to more than 
two other dimers. This crystal structure shows one dimer linked to two other dimers, the 
light scattering experiments similarly suggest a tetramer.
The results caution against an interpretation of solution behaviour based on observations 
from single techniques (aggregation states of con A are based on ultra-centrifugation 
experiments from the 1970’s). Our results on the nature of succinylated con A suggest a 
much more dynamic environment than those based on the assumption that the solutions are 
composed of a single species. Combining results from light scattering and crystallography 
suggest a very complex equilibrium exists in solution between tetrameric and dimeric con A 
even after succinylation. Precipitation is a kinetically controlled process and caution as to 
how it is inteipreted must be exercised. On the basis of these results it seems more likely 
that the ligands promote infinite aiTays, however the rate of aggregate formation is highly 
dependent on the rates of exchange between dimers and tetramers. This rate of exchange is 
probably altered by pH and succinylation (hence the observed polydispersity of succinyl con 
A). Other lectin / carbohydrate complexes are known to exist as similar infinite arrays but as 
yet such aggregates have not been observed in solution.
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Trivalent Complex
The trivalent ligand con A complex crystallised in the same space group as the bivalent 
complex with almost identical cell dimensions. The structure was solved to 3.0Â, however 
on visualisation no density was observed for the third mannose residue as all the 
monosaccharide binding sites were occupied. It appears likely that as a result of this the 
third sugar is disordered.
Data from calorimetric titration experiments show all ligands exhibit a 1:1 carbohydrate: 
binding site stoichiometry with the exception of the trivalent ligand 2 (binding stoichiometry 
0.8) used here in crystallisation studies (Eric Toone, personal communication). However, 
the findings from this crystal structure raise the possibility that the soluble aggregates formed 
in solution pack in a similar fashion to the insoluble aggregates observed by X-ray 
diffraction. Theoretically, the binding of two carbohydrates by a trivalent ligand gives a 
binding stoichiometry of 0.67, that in practise it is 0.8 suggests that the aggregates are likely 
of lower order than the crystal foim. However, the low stoichiometry is more likely as a 
result of some form of local order in aggregate formation that inhibits binding of the third 
saccharide of a trivalent ligand, even in solution.
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3.6 Conclusions
Despite evidence to the contrary succinyl con A crystallises as native con A; in a tetrameric 
form. The bivalent ligand 1 infinitely cross-links monomers resulting in an infinite array of 
cross-linked tetramers. The sugars are bound at the monosaccharide binding site through a 
combination of hydrogen bonds and van der Waals interactions. The linking region of the 
ligand makes few additional contacts with the protein. Although the interactions holding the 
tetramer together are not as extensive as found in other con A complexes, by a standard set 
of crystallographic criteria one would still identify the protein to function as a tetramer. It 
appears that the energy barrier between dimers and tetramers is small enough that crystal 
packing forces are sufficient to drive formation of the tetramer (if dimers do exist in 
solution).
The results here also call into question the validity of the binding constants of multivalent 
ligands obtained by agglutination assays. This structure reveals the protein carbohydrate 
interactions observed with polyvalent ligands are essentially identical to those involved in 
the binding of a-methyl mannose. Assuming other multivalent ligands bind similarly then 
the enhanced binding efficiencies observed by assay are more likely kinetic in origin and 
result from aggregate formation and or protein precipitation. Such effects may or may not be 
relevant to the design of therapeutically useful saccharides. The conclusions of this work 
raise serious questions regarding the validity of the techniques and conclusions hence drawn 
from previous studies probing protein carbohydrate interactions.
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3.7 Future Work
As this is the first structure lectin / multivalent ligand structure to be characterised in this 
manner, confoimation of the results by characterisation of similar solutions would be 
valuable.
In addition throughout the work described in this chapter it has been assumed that the linker 
region between binding epitopes has been too short to span separate recognition domains on 
one molecule. Knowledge as to whether a true effect (increase in binding avidity) would be 
noticed if the linker region was of the sufficient length to permit multiple binding to one 
lectin is lacking. A crystal structure with such a ligand would identify such an entity, which 
would be useful in assessing true binding affinities where macroscopic aggregation prevails.
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Chapter 4
The 2.7Â structure of concanavalin A complexed with the branched
pentasaccharide
a-M an-(l->6)-[a-M an-(l->3)-a-M an(l”^6)]»[a“Man-(l-->3)]-Man.
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4.1 Summary
The structure of concanavalin A bound to the high order oligosaccharide a-M an-(1^6)-[a- 
Man-(l-^3)-a-M an(l-^6)]-[a-M an-(l-»3)]-M an has been determined and refined at 2.1 k .  
Crystals of the complex are of dimensions a=81.73Â, b=66.12A, c=108.66Â, (3=97.69° and 
grow in space group P2i. One tetramer is present in the asymmetric unit and each monomer 
binds one pentasaccharide molecule along with one manganese and calcium ion. In each 
subunit electron density exists for 4 of the 5 sugar residues in a well-ordered binding site and 
for the 5*^  sugar in 2 of the subunits. The pentasaccharide binds at the extended binding site 
of concanavalin A via the trimannose moiety of the molecule, stabilising the oligosaccharide 
through a combination of hydrogen bonding and Van der Waals interactions. Neither of the 
4'^ or 5**^ sugar residues are specifically recognised. The pentamannose ligand does not 
crosslink to another concanavalin A, subunit as the 4^ '^  and sugars adopt a conformation in 
which the sugar residue binds to the protein through a bridging water.
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4.2 Introduction
Oligosaccharide chains of glycoproteins have been implicated as receptors in a variety of 
cellular recognition processes (Rini, 1995). They are found as sophisticated arrays on cell 
surfaces and are recognised with varying degrees of specificity by, among others, enzymes 
involved in cell wall synthesis. The asparagine linked or N-linked oligosaccharides form 
one class of these oligosaccharides which themselves can be further divided into three 
classes (Kornfeld and Kornfeld, 1985) and include the ‘high maimoses’. N-linked high 
mannoses are branched chains of multivalent oligosaccharides of the type in Figure 4.1. The 
binding of multivalent lectins to N-linked high mannoses on the surfaces of cells can lead to 
the cross-linking and aggregation of certain glycolipids, which in turn is associated with a 
variety of biological responses including the molecular sorting o f glycoproteins in the 
secretory pathways o f cell (Chung et al, 1989) and the signal transduction mechanism of 
certain glycoprotein horaiones (Sairam, et al 1989).
Figure 4.1: The high order mannoses discussed in this chapter and the Man5 used in 
this study. The mannoses o f  Man5 are labelled 1 - 5  fo r  reference.
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Higher order oligosaccharides binding to protein falls into one of two categories. They aie 
either highly water mediated where the rearrangement of the water structure in and around 
the binding site mediates binding (Bourne et al, 1994). Or, interaction is through an 
extended carbohydrate binding site on the surface of the protein (Naismith and Field, 1996; 
Moothoo and Naismith, 1998b; Moothoo et al, 1999). The concanavalin A (con A) studies 
have employed high affinity oligosaccharides and provided a rationale for the high affinity 
displayed by con A for the trimannoside.
As the majority of the high mannose oligosaccharides precipitate tetrameric con A 
(suggesting cross-linking is apparent) the thermodynamic experiments to elucidate the 
binding affinities have primarily been performed with dimeric con A (succinyl conA) in 
titration microcaiorimetry experiments (Mandai et al, 1994). The thermodynamic 
parameters for the binding of the pentamannose (Man5) used in this study. Figure 4.1, with 
succinyl con A are given in Table 4.1, along with those for the corresponding binding of the 
trimannoside. Figure 4.1, and higher order oligosaccharides (Man 7, 8 & 9), Figure 4.1, for 
comparison. The values reported for Man5 are consistent with a 1:1 binding stoichiometry 
where one mole of saccharide is bound per mole of lectin, whilst the higher order saccharides 
have binding ratios of around 0.92 suggesting some cross-linking. It should be noted that 
although the affinity displayed by succinyl con A for the ‘higher’ order oligosaccharides Man 
7, 8 & 9 is essentially the same as that of the trimannose (and Man5), these giycopeptides 
have been reported to have nearly 7-fold higher affinities for tetrameric con A relative to the 
trimannose (Mandai & Brewer, 1993). However, these results are based on the same 
hemaglutination assays discussed in Chapter 3. The results are dominated by kinetic effects 
making the thermodynamic parameters indeterminable. That these oligosaccharides
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apparently display greater affinities for tetrameric con A may be because the molecules are 
themselves of sufficient size that they have the ability to span two subunits and cross-link 
adjacent domains.
Table 4.1: Thermodynamic data fo r  succinyl con A binding to a variety o f high order 
oligosaccharides (Mandai et al, 1994).
-AH° 
kcal mol^
-TAS° 
kcal mol'^
-AG° Ka(M-')
Trimannoside 14.3 (±0.1) 6.5 7.8 (±0.1) 5.3 (±0.22)xl0"
Man5 14.5 (±0.1) 6.6 7.9 (±0.1) 6.6 (±0.40)xl0°
Man7&8 13.6 (±0.2) 5.6 8.0 (±0.1) 7.7 (±0.12)xl0°
Man9 17.1 (±0.4) 9.0 8.1 (±0.1) 8.9 (±0.14)xl0^
As the results from the microcaiorimetry suggest Man5 is recognised by con A with the same 
affinity as the trimannose, it is proposed the pentasaccharide will bind to con A via the 
trimannosyl moiety located on the a  (1,6) arm of the molecule (sugars 1, 2, and 3). The 
thermodynamic parameters for the binding of Man5 to acetyl con A, Table 4.2, are in 
somewhat contrast to these results and demonstrate a binding stoichiometry approaching 0.5. 
This suggests a binding ratio of 1:2 for ligand to lectin, which would be consistent with 
crosslinking of con A monomers. The binding of both the a  (1,6) arm (trimannosyl moiety) 
and the a  (1,3) arm leads to a greater enthalpy change per mole of bound saccharide than that 
observed for the trimannose alone, and explains the greater AH° observed here relative to 
succinyl con A. The Man9 oligosaccharides display similar binding properties with acetyl- 
con A as the Man5. only demonstrating an even greater tendency for crosslinking relative to 
the analogous Man9 - succinyl con A experiment (Mandai et al, 1994).
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Table 4.2: Thermodynamic data fo r  the pentamannose binding to acetyl-con A 
(Mandai et al, 1994).
-AH° 
kcal mol^
-TAS° 
kcal mol^
-AG°
Man5 18.4 10.8 7.6 3.51(±0.27)xl0°
A  similar enthalpy difference is reported by Ambrosino and co-workers (1987) who, using 
titration microcaiorimetry, suggest the enthalpy of binding of Man5 to dimeric 
con A is -18.8 kcal mol ', along with a binding stoichiometry of 0.5, implying the saccharide 
has the ability to bind two con A monomers.
The structure of the bulb lectin Galanthus nivalis agglutinin (GNA), complexed with Man5 
has previously been solved to 2.0Â (Wright and Hester, 1996). Monomers of the GNA each 
contain three binding sites as a result of the 3-fold internal repeats that constitute the 
molecule. In the structure with Man5 two unique modes of binding are observed. At CRDl 
(conserved recognition domain 1), the highest affinity monosaccharide binding site, Man5 
crosslinks GNA dimers creating a pore like super structure. Figure 4.2. However, only 3 of 
the mannose residues (essentially the trimannose) are resolved in the structure and neither 
sugars 4 or 5 are visualised.
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Figure 4.2: Pore-like assembly created by cross-linking o f  GNA dimers 
(Wright and Hester, 1996).
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From the structural studies on the bivalent ligand discussed in Chapter 3, it is possible the 
Man5 ligand may crosslink con A subunits, though some of the microcalorimetric results 
suggest otherwise. A three dimensional structure will clear up this ambiguity and answer 
other questions. If the ligand does not crosslink subunits, then why not? Does specific 
recognition of the 4^  ^and S*'' sugars preclude crosslinking? And if so, then why is the sugar 
recognised with the same affinity as the trimannose?
In order to delineate the interactions involved in the binding of Man5 with con A, the three 
dimensional structure of con A complexed with this ligand has been elucidated and are 
discussed in this chapter.
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4.3 Experimental 
Crystallisation and Data Collection
Co - ciystals of the con A -  Man5 complex were initially obtained from a screen consisting 
off 10, 15, 20 and 25 % PEG 6K, pH 4, 5, 6, 7, 8 and 9. Optimisation of pH and PEG 
concentration followed (Moothoo and Naismith, 1998a). The largest crystals grew from a 
5pi solution containing 0.6mM con A (Sigma, Poole, UK), 18mM a-Man-(l->6)-[a-Man- 
(1^3)-a-M an(l->6)]-[a-M an-(1^3)]-M an (Dextra Laboratories, Reading, UK), ImM 
MnCL, ImM CaCL, 20mM TRIS pH 7.0 and O.IM NaCl mixed with 5pi of a reservoir 
containing 12% PEG 6K pH 5.0 in a sitting drop tray (Douglas Instruments) after 24 hours 
equilibration. Crystals grew as thin diamonds in dimensions ranging from 0.2 x 0.15 x 
0.05mm^ to 1.0 x 0.8 x O.lmm^.
To allow data collection at cryogenic temperatures, crystals were allowed to equilibrate in 
precipitant solution poisoned with 15% glycerol for 30 seconds immediately prior to data 
collection. All data were collected from a single cryo-protected crystal at 1 lOK using the 
Enraf-Nonius/MacScience DIP2000 dual image plate. Data collection proceeded as 129 
non-overlapping 20 minute 1° oscillations with a crystal to detector distance of 160mm. The 
data were indexed and processed with DENZO and SCALEPACK (Otwinowski, 1996) in a 
primitive monoclinic spacegroup. Systematic absences were consistent with a 2, screw axis 
and the space group was assigned P2i with unit cell dimensions a=81.73A, b=66.12Â, 
c=108.66Â, (3=97.69°. The asymmetric unit contains one tetramer; Matthews number 
2.9IDa approximately 57.39% solvent. The quality of the data is shown in Table 4.3.
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Table 4.3. Quality o f the data for the 2.7A model o f the con A pentasaccharide
complex.
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
25.00 -  5.80 2666 81.0 8.8 1.5
5.80-4.61 2725 84.8 10.5 1.9
4 .61-4 .03 2744 85.6 11.7 1.9
4.03 -  3.66 2722 85.7 13.7 1.9
3.66 -  3.40 2716 85.7 16.7 1.9
3.40-3 .20 2727 85.9 21.3 1.9
3.20 -  3.04 2678 84.9 27.6 1.8
3.04-2.91 2660 84.0 34.0 1.8
2 .91-2 .80 2674 84.5 47.1 1.7
2 .80-2 .70 2587 82.4 52.1 1.7
25.00 -  2.70 26899 84.4 15.3 1.8
Structure Solution
The structure was determined using the molecular replacement package AMoRe (Navaza, 
1994) as implemented in CCP4 (Collaborative Computational Project Number 4). The 
trimannoside con A complex tetramer (PDB Accession Number ICVN) (Naismith and Field, 
1996) was used as a search model. All metals, waters and sugar atoms were removed and the 
remaining atoms set to full occupancy. A cross rotational function gave one solution a  = 
89.02, (3 = 84.82, y = 293.09, 19 standard deviations above noise. The translational search 
found one tetramer, solution x = 0.2727, z = 0.2411, yielding a correlation coefficient of 0.73 
and an R-factor of 33.7%. Y is arbitrary in this space group.
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Refinement
The solution was imported into CNS (Brunger et al, 1998) and refinement carried out using 
the free R-factor (Rfree) as a guide. Rfree was calculated on 5% of the data, which was 
excluded from all refinement calculations, providing an unbiased assessment of the progress 
being made. Non -  crystallographic restraints were applied to thermal and positional 
parameters throughout refinement. The initial model for refinement included structurally 
conserved metals and waters consistent with other con A crystal structures; total 8 metals and 
16 waters. A cis peptide was restrained between residues 207 and 208. The R and free R 
factors from the raw molecular replacement solution were 33.7 and 34.4% respectively. 
Rigid body refinement of the whole tetramer reduced these both to 30.5%. Further rigid 
body refinement of the individual monomers saw the R and R^ee fall a further 0.3 and 0.1 % 
respectively. At this stage 2Fo - Fc and Fq - Fc maps were calculated. Clear density was 
visible for the three sugar residues at the trimannose binding site and a fourth sugar a(l-6) 
linked to the reducing mannose. These residues were included in the model for further 
refinement. The ligand geometry was defined using the Engh and Huber compendium of 
bond distances (Engh & Huber, 1991). Alternating cycles of refinement, NCS restrained 
positional and thermal parameters, followed with manual intervention using O, reducing the 
Rfree to 27.9%. Water molecules were added to the model providing they satisfied four 
criteria: (1) They coiTesponded to a peak > 4.0a in the Fq - Fc map, (2) they reappeared in at 
least l a  in subsequently calculated 2Fo -  Fc maps (3) they made hydrogen bonds with 
reasonable stereo-chemistry and (4) a drop in Rfree was observed. No cut-offs were applied 
to the data except the 5% of data removed to monitor refinement. Overall anisotropic 
thermal parameters and bulk solvent corrections were applied to the data using standai*d CNS
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protocols (Brunger et al, 1998) for refinement. Electron density maps were calculated in 
CNS and converted for viewing in O (Jones et al, 1991) with MAPMAN (Kleywegt, 
unpublished program). The high R factor and Rfree are a function of the low quality data used 
in this study. To obtain better statistics, crystals of higher quality yielding better data will be 
required. However, as this model was able to answer the questions posed in the literature 
regarding this ligand, the data were judged of sufficient quality for the time being. The 
progress of refinement is summarised in Table 4.4.
Table 4.4. Progress o f refinement fo r  the 2.7A model o f the con -  Man5 complex.
Refinement R factor /  Rfree
Starting 33.7% 34.4%
CNS : Rigid body fitting of tetramer (30 cycles) 30.5% 30.5%
Rigid body fitting of individual monomers 30.2% 30.4%
O : Four sugar residues of the ligand added.
CNS : Theraial parameter (30 cycles)
Positional (60 cycles) 25.1% 28.4%
O I Water molecules added
CNS : Thermal parameter (40 cycles) 24.4% 27.9%
This final model contains a tetramer of 948 protein atoms (4 subunits of 237 amino acids), 4 
Ca“^  ions and 4 Mn"^ ions, 118 water molecules and 280 sugar atoms. The quality of the 
data for the final model to 2.7Â is summarised in Table 4.5 and the Ramachandran plot 
(Ramakrishnan and Ramachandran, 1965), calculated using PROCHECK (Laskowski et al, 
1993) is shown in Figure 4.3. Glycine residues (not restricted to any particular region of the 
plot) are represented by a A and non-glycine residues by a ■ . The darker the shaded region, 
the more favourable is the cp, \j/ combination. No residues lie outside the additionally
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allowed regions. Regions are labelled as follows: A = core alpha, a = allowed alpha, ~a = 
generous alpha, B = core beta, b = allowed beta -b  = generous beta, L = core left handed 
alpha, 1 = allowed left handed alpha, ~1 = generous left handed alpha, p = allowed epsilon, 
~p = generous epsilon.
Figure 4.3: Ramachandran plot fo r  the 2.7A con A -  ligand model.
-135-
è  45 %  i l s  18
Phi (degrees)
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Table 4.5: Quality o f the final model fo r the 2.7k  model o f the con 
complex.
A pentasaccharide
Data Collection
Unique reflections 26890
Completeness of data(%) (25.00 -  2.1k  / 2.8 -  2.1 A) 84.4/82.4
R m erge(I) (%) (25.00- 2 .7 À /2 .8 -2 .7À ) 15.3/52.1
Average data redundancy (25.00 -  2.7A / 2.8 -  2.7A) 1.8/ 1.7
% of data > ia  (25.00- 2 .7 Â /2 8 -2 .7À ) 78.4/52.7
Reftnement
Resolution range (Â) 25 .0 -2 .70
Rfree (% ) 229
R factor (%) 24.4
Bond r.m.s. deviation^ 0.008Â
Angle r.m.s. deviation^ 1.61°
B-factor bounded atoms r.m.s deviation'" 1.55À-
Average NCS r.m.s. difference 0.1
Ramachandran core/additional {%Ÿ 81.2/18.8
Protein mean B-factor (all) 28.8À-
‘ r.m.s. deviation from Engh & Huber ideal values (Engh & Huber, 1991).
Core and additionally allowed regions as defined by PROCHECK (Laskowski et al, 1993). 
B-factor deviation for bonded atoms
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4.4 Discussion
Overall structure of the protein in con A  -  ManS complex
In the model of the con A - Man5 complex described here, con A exists as a tetramer where 
each monomer consists of a sandwich of two p sheets. The overall fold of the protein is 
identical to the native structure (Deacon et a i  1997). The 2Fo-Fc map is unbroken for the 
backbone of the structure at la , excluding the commonly found disordered residues at 118- 
123, 161-163 and 203-205. The unit cell is almost identical to that of the trimannose con A 
complex (Naismith and Field, 1996). A comparison of the pentamannose structure reported 
here with the trimannose model shows an average root mean square deviation for all 
atoms of 0.22Â.
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Structure o f the bound pentamannose in the con A — ManS complex.
The pentamannose con A complex displays clear difference density for 4 of the 5 sugar
residues in each monomer. For the 5^  ^sugar, the terminal a (l,3 ) mannose of the branch,
convincing density exists in 2 of the 4 subunits. Figure 4.4. Higher quality data may result in
all five sugar residues being visualised. In contrast, the previously reported pentamannose -
GNA complex (Wright and Hester, 1996), only the trimannose was evident and the branched
sugar residues were disordered. GNA binds the trimannose more weakly than succinyl con
A, Ka = 3.0 X lO^M'* compared to 3.4 x lO^M'^ for succinyl con A trimannose binding
(Chervenak and Toone, 1995). The lack of order in the 4^  ^ and 5‘^  sugar residues o f the
ligand reflects the non-specific interactions evident in the GNA Man5 complex.
Figure 4.4: Difference density 2Fq-Fc map (green) contoured at la . The blue
density is from an Fo ~Fc map contoured at I a  and corresponds to the 
position o f  the the sugar residue.
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Conformation o f  bound pentamannose
Recognition of the pentamannose is essentially at the extended trimannose binding site first 
described by Naismith and Field (1996), utilising the trimannose moiety present in the 
ligand. The remaining sugars branch away from the reducing mannose and arc back towards 
the protein in a manner not unlike a scorpions tail. Figure 4.5. If the (p and i|/ angles are as 
defined in Figure 4.6, then the orientation of the 4^^^ and 5^ '^ mannose residues in the 
crystallographic model is in agreement with previous solution NMR data which predicted a 
\\f = 60° rotation of the a  (1,6) linkage (Wooten et al, 1990).
Figure 4.5: Stereo view o f  the branched sugars arcing back towards the protein making 
a stabilising H-bond with the main chain via a bridging water molecule.
The mannose residues are labelled 1 -5 .
Man-5
Man-3
Man-4 Man-4
Man-2Man-2
Tyr-100Tyr-100
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Figure 4.6: The a  (1,6) linkage between mannose residues 2 and 4 in Man5. The 
inter sugar glycosidic torsion angles are defined as (p = Cj Cg Cjx 
and y/ = Q  Og C O5.
Specific protein  -  carbohydrate contacts
Only the recognised ‘trimannose’ of the pentamannose makes direct contact with the 
protein. It does so through a combination of hydrogen bonds and Van der Waals 
interactions. Tables 4.4 and 4.5.
As the pentamannose is anchored to the protein through the trimannose moiety of the 
molecule at the extended trimannose binding site it is not surprising to find the interactions 
between the saccharide and con A are primarily those discussed by Naismith and Field 
(1996).
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Table 4.6: Hydrogen bonding and polar contacts less than 3.5Â between the con A 
and the pentamannose.
Sugar Protein Distance A
I, 3 terminal mannose (3)
0-3 Thr-15 OGl 2.91
0-3 Thr-15 N 2J3
0-3 Pro-13 0 278
0-4 Thr-15 OGl 2.51
0-4 Asp-16 N 2.96
0-4
reducing mannose (2)
Asp-16 ODl 3.07
0-2 OW 2 J5
0-4 Tr-12 OH 246
1,6 terminal mannose (I)
0-3 Arg-228 N 2.93
0-4 Asn-14 ND2 3 J ^
0-4 Asp-208 0D2 2.47
0-5 Leu-99 N 2.84
0-6 Tyr-100 0 3.14
0-6 Tyr-100 N 2 J9
0-6 Leu-99 N 3.01
1,3 Branched Mannose (5)
0-4 OW 2.70
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Table 4.7: Van der Waals contacts less than 4.0A
Sugar Residue
1, 3 terminal Mannose (3) Tyr-12, Pro-13, Asn-14, Thr-15, Asp-16
Reducing Mannose (2) Tyr-12, Asp-16, Leu-99, Arg-228
1, 6 Teiminal Mannose (1) Tyr-12, Asn-14. Gly-98, Leu-99, Tyr-100
Asp-208, Gly-227, Arg-228
1, 6 Branch Mannose (4) Leu-99
1, 3 Branched Mannose (5) Tyr-100
The oc (1,6) Mannose oc (1,3) Mannose branch (sugars 4 and 5)
As noted above neither of the 4^ '^  or mannose residues form any direct interaction with the 
protein. Only one water molecule acts to stabilise these sugars through hydrogen bonding. 
04  of the terminal sugar in the branch makes contact with the protein (Tyr-100 OH) via a 
bridging water molecule. Figure 4.5. The non-displacement of the trimannose core from the 
extended binding site coupled with the non-specific recognition of the 4^  ^ and 5^*^ sugar 
residues reflects the similar affinity displayed by con A for the trimannose and the 
pentamannose discussed in this chapter. The additional interactions observed with mannoses 
4 and 5 of the ligand help stabilise the overall ligand conformation. In addition, as the 
pentamannose is recognised by con A as the ‘trimannose’ then any crosslinking bridge could 
only involve the 4'*’ and 5'*^  sugars of the oligosaccharide, that is a maximum of around 11 C 
- C bond lengths. Molecular modelling has shown that this is too short to allow the tethering
182
of two recognition domains on separate con A molecules and cross-linking would be 
prevented by steric interactions.
4.5 Conclusions
It is clear from this structure that the recognition of higher order oligosaccharides to con A is 
via the trimannoside moiety of the molecules. That this pentamannose does not crosslink 
con A is probably an accumulation of factors. Firstly, before any aggregation could take 
place the trimannose core would have to be displaced from the binding site. The rate of 
aggregation would then be controlled by the rate at which the trimannose re-bound. That is, 
aggregation would be kinetically controlled between a trade off of the displacement the core 
and subsequent aggregation of subunits, against the re-binding of the trimannose core and the 
complex existing as a single entity. In addition, the size of the non-specifically recognised 
branch of the ligand (4''^  and 5'  ^ sugars) appears to be too short to allow the tethering of 
adjacent con A subunits and would incur severe steric penalties in the absence of the 
displacement of the trimannose core. As sugars 4 and 5 of the ligand adopt a conformation 
which allows only non-specific interactions with the protein reflects the almost identical 
thermodynamic properties of this ligand to those displayed by the trimannose and highlights 
errors in the literature where it was anticipated this oligosaccharide would crosslink con A 
monomers.
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4.6 Future Work
The first improvements to this model should involve the collection of better data, this will 
ultimately require better crystals of the complex. To probe the binding of these higher order 
oligosaccharides further still, a three-dimensional model of a larger branched oligosaccharide 
would be desirable. Either of the Man 7, 8 or 9 oligosaccharides discussed in the 
introduction of this chapter which apparently display upto 7-fold greater affinities for con A 
would appear more likely to crosslink this lectin.
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Chapter 5
Initiating A Crystallographic Study of 3-Methylaspartate Ammonia Lyase
Ï
185 I
5.1 Summary
Methyiaspartate ammonia lyase (MAL) from Clostridium tetanomorphum has been 
overexpressed and purified in two different cell lines. Initially the enzyme was expressed in 
the constitutive strain pSG4 which required some 16 hours incubation. By a process of 
anion exchange and hydrophobic interaction chromatography the enzyme was purified to 
95% homogeneity, judged by SDS and lEF PAGE. Attempts to purify the enzyme further 
have been unsatisfactory, however dynamic light scattering experiments confirmed the 
enzyme to be monodisperse. Purification yields less than 1 mgL'* culture. Small crystals 
(0.1 X 0.1 X 0.1mm) have been obtained in hanging drops when the enzyme is equilibrated 
against (NH4)i SO4. The crystals only diffract to 6Â and attempts to acquire an accurate unit 
cell were hampered by this.
MAE has also been overexpressed in two high efficiency constructs. Overexpression in 
pET16b BL21 (DE3) yields some 8.1 mgL‘‘. As the enzyme expressed from this system 
contains 6 consecutive histidine residues at the N-terminus it can be purified to near 100% 
homogeneity via nickel chelation and anion exchange chromatography. However, light 
scattering experiments showed the enzyme to be polydisperse and subsequently 
crystallisation of the enzyme failed. Attempts to selectively cleave the tag proved 
unsatisfactory.
Similarly, overexpression in pETl la BL21 (DE3) yields 7.1 mgL'^ culture after purification. 
Despite these results this enzyme also failed to crystallise. Sequencing of the clone revealed 
a mutation relative to the constitutive strain, resulting in a C-terminai extension. It appears 
this extension is not conducive to crystallisation.
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5.2 Introduction
It is common that specialty chemicals synthesised by pharmaceutical companies require long 
and complex synthetic pathways. On an industrial scale these processes often become highly 
expensive, generate pollution and result in low yields. This problem is particularly acute for 
bioactive compounds which are often only active in one enantiomeric form, and in the worst 
case scenario the wrong enantiomer may have unwanted side effects, for example 
Thalidomide.
Enzymes, by their nature, are highly stereo and regio selective and are often extremely 
efficient catalysts. As enzymes work in water they do not require organic solvents or 
elevated temperatures, eliminating the expensive and pollutive disposal measures which 
organic waste requires. If it were possible to harness the ‘natural skills’ of biochemical 
enzymes within industrial processes this would go some way to alleviating the problems of 
pollution and expense. Essentially, biotransformations hold out the promise of new efficient 
and highly selective synthetic routes.
One example where x-ray crystallography has aided the development of a new series of 
enzymes is in the work described by Withers (1999) on glycosidases. The determination of 
the three-dimensional structures of several glycosyl-enzyme complexes has identified the 
amino acids directly involved in catalysis. As a result a new class of enzymes have been 
developed where glycosidic bonds are selectively synthesised but not hydrolysed allowing 
the controlled synthesis of oligosaccharides upto 5 sugars in length with yields upto 90% in 
individual steps.
a , p - unsaturated amino acid residues play important roles in many biochemical reactions 
allowing additional new functionality to be added whilst retaining stereo control of the
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reaction. Conventional methods of achieving this reaction are difficult and expensive on a 
commercial scale.
Methyiaspartate ammonia lyase
MAL occurs in the obligate anaerobe Clostridium tetanomorphum, where it functions in the 
main metabolic pathway for glutamate (Barker et al, 1958). The enzyme catalyses the regio 
and stereoselective addition, and the reverse elimination, of ammonia from (2S, 3S)-3- 
methylaspartic acid yielding mesaconic acid which is further processed to glutamic acid 
Figure 5.1. The enzyme is a member of the ammonia lyase family of proteins, for which no 
X-ray structure currently exists. The Clostridial enzyme is a 91 000 Da homodimer of 413 
amino acids where both monovalent and divalent cations are required for optimal enzyme 
activity; potassium and magnesium having been shown to be most effective (Goda et al, 
1992). The enzyme can process various analogues of the natural substrate including the L- 
erythro~(2S, 3R)- diastereoisomer of methylaspartic acid (Barker et al, 1958; Archer and 
Gani, 1993) as well as (2S)-aspartic acid and a number of three 3-alkyl homologues (Winkler 
and Williams, 1967). In addition the enzyme is capable of providing access to various 3- 
substituted aspartic acids by direct amination of the substituted fumaric acids, and has been 
shown to tolerate some non-ammonia N-nucleophiies (Akhtar et al, 1987). The enzymes 
ability to accommodate different substrates and ammonia surrogates reveals its potential use 
in the synthesis of homo chiral a-substituted P-amino acids.
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Figure 5.1: The methylaspartase reaction.
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In the other ammoma-lyase enzymes a dehydroalanine residue has been implicated in the 
mechanistics of the processes involved and has been suggested to perform a similar function 
for methylaspartase (Goda et al, 1992). The source of the dehydroalanine in both 
phenylalanine and histidine ammonia lyases is the serine residue o f the catalytic triad Ser- 
Gly-Asp. This sequence is common to both histidine and phenylalanine ammonia lyases 
and is not surprisingly also found in the sequence of MAL (Goda et al, 1992). The 
mechanism by which methylaspartase operates has been probed in recent years by Gani and
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co-workers (Goda et al, 1992; Botting and Gani. 1992; Pollard et al, 1998). Most recently 
they postulate that each true substrate forms a covalent adduct with the enzyme through the 
amination of a dehydroalanine residue (Goda et al, 1992). Substrates are N-protonated and 
the alkylammonium groups are deprotonated internally in a closed solvent-excluded pocket 
after a K"*" ion has bound (Botting and Gani. 1992). The enzyme-substrate complex is 
subsequently deaminated in two elimination processes (Goda et al, 1992). (2S, 3S)-3-
methylaspartic acid, the natural substrate for the enzyme, is eliminated in a concerted process 
(Botting et al, 1989) as is (2S)-aspartic acid. However, the h-erythro-{2S, 3R)- 
diastereoisomer of methylaspartic acid appears to be eliminated via a carbocationic 
mechanism, suggesting that a change in stereo chemistry at C-3 induces a change in 
mechanism (Pollard et al, 1998).
The ultimate aim of this research is to redesign the active site of methylaspartase and 
determine a structural basis for the mechanism of the reaction. This will be achieved 
through a combination of site directed mutagenesis, molecular modelling and structure 
determination. Mutants of the enzyme and subsequent crystal structures of the mutant 
protein along with protein-inhibitor complexes would permit characterisation of the enzyme 
mechanism, which may be unprecedented in biology.
Assay
The enzyme was assayed according to the method of Barker (Barker, 1958) where one unit 
of enzyme is defined as the amount that catalyses the formation of Ipmol of mesaconic acid 
at pH 9.0 and 30°C. This is determined by the increase in OD240 in the presence of 4mM 
(2S,3S)-3-methylaspartic acid, 50mM TRIS-HCl, lOmM KCl, and ImM MgCl2.
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5.3 Experimental
Constitutive Expression System
All materials used were purchased from Sigma (Poole, UK) unless otherwise stated. Prior to 
all cultivation procedures, all containers, pipette tips and media were sterilised by 
autoclaving at 120 C for 30 minutes.
Overexpression o f E. coli pSG4
A single colony of E. coli pSG4 was selected from an ampicillin (200p,gmL‘ )^ agar plate and 
used to inoculate 5 niL of LB media in the presence of 200jLigmL ‘ ampicillin. This culture 
was incubated at 37°C, 90rpm and the A^ oo monitored until it reached 0.6. At this point the 
cultures were used to inoculate 500ml of similarly treated media. This culture was incubated 
for a further 16 hours at 37 C, 90rpm, The cells were harvested by centrifugation (lOOOOg, 
4°C, 30 minutes) and frozen at -78 C until required.
Preparation o f Cell Extracts and Ammonium Sulphate Fractionation
Frozen cell paste was thawed in ice-cold lysis buffer (50mM TRIS pH 7.6, ImM DTT, ImM
PMSF) at a concentration of 0.5g wet cell paste per mL buffer and the cell contents released 
by sonication (140kW, 20kHz) at 4°C for 6 x 30 seconds. Cell debris was pelleted by 
centrifugation (20000g, 4°C, 30 minutes) and the resulting supernatant brought to 40% 
(NH4)2S0 4  saturation by the slow addition of 24.2g (NH4)2S0 4  per lOOmL"' at 4 C. This 
solution was left to stir for 30 minutes at 4°C. After centrifugation (20000g, 4°C, 10 
minutes) the supernatant was brought to 80% (NH4)2S0 4  saturation by slow addition of a 
further aliquot of (NH4)2S0 4 . This solution was left to stir for a further 30 minutes at 4 C
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before centrifugation (20000g, 4°C, 10 minutes). The pellet obtained contained the target 
enzyme, MAL, with assays confirming -90 % enzyme recovery. The resultant pellet was 
resuspended in lysis buffer and dialysed for 3 x 40 minutes against 20mM TRIS, pH 7.5.
Purification and Characterisation o f MAL
lOOmg of total protein were 0.02jim filtered before being applied to an anion exchange 
chromatography column (Perseptive Biosystems, HQ) pre-equilibrated in buffer A (20mM 
TRIS, pH 7.5). Elution was over an increasing gradient from 0 to 500mM NaCl in buffer A. 
Initially all peaks were collected and assayed for activity after which only the active peak 
was pooled and concentrated by ultrafiltration. Dialysis (3 x 40minutes) against 50mM KPi, 
40% (NH4)2S0 4 , pH8.5 followed before application to a hydrophobic interaction 
chromatography column (Perseptive Biosystems, HP). 50mg of total protein was applied to 
the column pre-equilibrated with 50mM KPi, 40% (NH4)2S0 4 , pH8.5. Elution was achieved 
over a decreasing (NH4)2S0 4  gradient (40 to 0%). Again all peaks were initially pooled to 
identify the active fraction, after which only the methylaspartase peak was collected. 
Enzyme was concentrated by ultrafiltration ahead of dialysis (3 x 40 minutes, 20mM TRIS, 
lOmM KCl, ImM MgCL, ImM DTT) in preparation for crystallisation. Analysing enzyme 
purity by both SDS and lEF PAGE showed the enzyme to be greater than 90% homogenous. 
Dynamic light scattering experiments revealed a slightly polydisperse solution. Table 5.1. 
The average polydispersity value as a function of the hydrodynamic radius was 23%. 
Knowing that for successful crystallisation monodisperse solutions are desired, attempts 
were made to further purify the enzyme. Throughout purification enzyme activity was
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monitored spectrophotometricaily and concentration by the Bradford method (Bradford, 
1976), Table 5.2.
Table 5.1: Dynamic light scattering results fo r constitutively expressed MAL. The 
average polydispersity value as a function o f the hydrodynamic radius
# Ampl. Differ.
Coeff.
Radius
(nm)
Polyd.
(nm)
Est.MW
kOA
Temp. Count
Rate
Base
Line
%
Radius / 
PolyD
1 0.713 621 3.6 0.975 66 20.2 180 1.003 27
2 0.725 608 3.6 1.048 62 20.5 183 1.002 29
3 0.714 615 3.6 1.069 65 20.4 177 1.002 29
4 0.725 621 3.6 0.834 68 20.0 183 1.001 23
5 0.729 605 3.7 0.816 66 20.3 183 1.001 22
6 0.725 614 3.6 0.968 64 20.5 184 1.000 26
7 0.729 601 3.6 1.063 62 20.5 179 1.002 29
8 0.735 605 3.6 0.826 65 20.4 180 1.001 23
9 0.736 615 3.6 0.822 69 20.4 181 1.000 22
Table 5.2. Yield o f constitutively expressed protein obtained after subsequent 
purification steps.
Vol
(mL)
Protein
(mg)
Total 
Activity (U)
Specific
Activity
(U/mg)
Yield
(%)
Crude Extract 24 201 2500 12.4 100
(NH4)2S04 3 97 2180 22.5 87
Post HQ 3 10 1440 144 60
Post HP 1 1 870 290 35
It was previously noted that at pH values below 7 no enzyme activity is recorded. This 
eliminated cation exchange chromatography as an additional purification method. Size 
exclusion chromatography appeared the only viable alternative. Three different gel
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permeation columns (Sephadex G -  150, Superose 7 and Sepharose 75) were tried in order to 
achieve some form of improvement in enzyme purity, however analysing protein purity 
afterwards by electrophoresis and light scattering displayed no obvious enhancement. The 
yield of protein obtained from this expression system (~ Img L '‘) was not conducive for 
crystallisation studies. An overexpression system, where a higher percentage of the soluble 
protein expressed was the target protein, would likely result in a higher yield of more pure 
enzyme.
Crystallisation o f Constitutively Expressed MAL
In spite of a less than ideal level of enzyme homogeneity, crystallisation of the enzyme 
employing the sparse matrix approach utilising the vapour diffusion methodology was 
attempted (Ducruix and Giege, 1992). Commercially available Crystal Screen Kits I and II 
from Hampton Research were used for initial screens along with (NH4)2$0 4 , NaCl, PEG, 
PEG / LiCl and MPD grid screens. After 6 weeks incubation at 20.5°C small crystals of 
dimensions 0.1 x 0.1 x 0.1mm were observed with 1.8M (NH4)2$0 4 , O.IM HEPES pH 7, 
Table 5.3.
A small crystal was mounted in a thin walled glass capillary and sealed in the presence of the 
precipitating agent. X-rays were generated using a FR-951 rotating anode (Enraf Nonius) 
with copper target and focussed with the MacScience mirror system. With operating 
parameters at 50kV, 100mA, % ~ 1.54Â, \ oscillation, exposure time 60 minutes and a 
crystal to detector distance of 150mm, data were observable to 6 Â as recorded on the DIP 
2000 image plate. The unit cell could not be determined with any certainty from this data, 
though preliminary analysis suggested it to be rhombohedral.
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Table 5.3: Initial screens performed in crystallisation o f MAL.
Precipitant pH
Protein 
Concentration 
mg mi^
Mixing Crystals
PEG 6K
4 - 9 10 Yes
No
PEG 6K/LÎC1 No
(NH4)2S04 Yes
MPD No
Na Cl No
Hampton CS I No
Hampton CS II No
The cloning of MAL into a pET vector offers many advantages from the previous expression 
system. Overexpression of the enzyme, in a pET vector, is controlled by the addition of the 
artificial inducer isopropyl-p-D-thiogalactopyranoside (IPTG). However, the host must 
contain a chromosomal copy of the gene for T7 RNA polymerase. Such hosts are lysogens 
of bacteriophages DE3 which carry the lacUV5 promoter and the gene for T7 RNA 
polymerase (Studier and Moffat, 1986). Once the lysogen is formed, the only promoter 
known to direct transcription of the T7 polymerase is lac UV5, which is inducible with 
IPTG. Consequently, addition of IPTG to a growing culture of the lysogen induces T7 RNA 
polymerase, and the target DNA is transcribed in the plasmid. As T7 RNA polymerase is 
very selective, almost all the cells energies are tuned to target gene expression. As a result of 
this as much as 50% of the total cell protein may be the desired product. In addition, a poly­
histidine tag (6 consecutive histidines at the N-terminus of the protein, HIStag) was included 
in this expression system. This allows near 100% purification of the enzyme to be achieved 
in one step utilising the tags specific affinity for nickel (Janknecht et al, 1991).
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Over expression ofE. coli pET16b BL21 (DE3) MAL
A single colony of E. coli pET16b BL21 (DE3) containing the poly his-tagged gene for MAL 
was selected from an ampicillin (200pgmL'^) agar plate and used to inoculate 5 mL of LB 
media in the presence of 200|igmL'^ ampicillin. This culture was incubated at 31°C, 150rpm 
and grown to an optimum cell density (ODgoo 0.6) before the addition of ImM IPTG. 
Incubation continued for a further 3 hours under the same conditions. The cells were 
subsequently harvested by centrifugation (lOOOOg, 4°C, 30 minutes) and frozen at -78°C 
until required.
Preparation o f Cell Extracts
Frozen cell paste was thawed in ice-cold lysis buffer (50mM KPi, pH 8.0, ImM DTT, ImM 
PMSF) at a concentration of 0.5g wet cell paste per mL buffer before the cell contents were 
released by sonication (140kW, 20kHz) at 4 C for 6 x 30 seconds, resting on ice in between. 
Cell debris was pelleted by centrifugation (20000g, 4°C, 30 minutes).
Purification o f MAL by Ni Chelation and Anion Exchange Chromatography.
The cell extract was 0.02pm filtered before being loaded to a Ni-NTA Superflow affinity 
column (Qiagen) previously equilibrated in lysis buffer poisoned with 50mM imidazole. 
Column washing continued with equilibration buffer until the OD280 of column wash 
matched that of the equilibration buffer. MAL was eluted in an increasing lysis buffer / 
imidazole gradient (50 to 500mM). All active fractions were pooled and concentrated by 
ultrafiltration before dialysis against 20mM TRIS, pH 7.5. 50mg total protein were 0.02pm 
filtered before being applied to an anion exchange chromatography column (Perseptive 
Biosystems, HQ) pre-equilibrated in 20mM TRIS, pH 7.5. Elution was over an increasing
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salt gradient from 0 to 500mM NaCl. Active peaks were pooled and concentrated by 
ultrafiltration to around 10 mg ml'^ and dialysed against 20mM TRIS pH7.5, lOmM KCl, 
ImM MgCL, ImM DTT, ImM EDTA in preparation for crystallisation. Throughout 
purification enzyme activity was monitored spectrophotometricaily and content by the 
Bradford assay. Table 5.4.
Characterisation o f E. coli pETl6b BL21 (DE3) MAL.
Dynamic light scattering experiments were performed on uncleaved enzyme at a range of 
concentrations (2 -  15 mg ml ') and results were indicative of a polydisperse suspension. 
Table 5.5. The average polydispersity value as a function of the hydrodynamic radius was 
greater than 35 % in all instances. However, the protein did migrate as a single band on SDS 
- PAGE, Figure 5.2.
Cleavage o f the HIStag by Factor Xa
In an effort to selectively cleave the HIStag tail. Factor Xa was added to aliquots of enzyme 
at concentrations of 0.6, 1.2 and 1.6 units/mg total protein and incubated at room 
temperature for 6, 12 and 18 hours. A specific cleavage site had been inserted in the gene for 
this purpose. However, cleavage was not specific. Visualisation of the products on SDS 
gels revealed many products after incubation of the enzyme with Factor Xa, Figure 5.3.
Crystallisation ofE. coli pET16b BL2I (DE3) MAL
Crystallisation trials were undertaken employing the sparse matrix approach utilising the 
vapour diffusion methodology. Commercially available Crystal Screen Kits I and H from
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Hampton Research were used for initial screens along with (NH4)2 SO4. NaCl, PEG, PEG / 
LiCl and MPD grid screens.
After 52 weeks incubation at 20.5°C with periodic viewing no ciystalline material was 
observed.
With the failure of the HIStag variant of the enzyme to crystallise, together with the inability 
to selectively cleave the tag, it was concluded a non-tagged version of the enzyme was 
required.
Table 5.4. Yield ofE. coli pET16b BL21 (DE3) MAL protein
Vol
(mL)
Protein
(mg)
Total 
Activity (U)
Specific
Activity
(U/mg)
Yield
(%)
Crude Extract 30 412.5 12840 29 100
(NH4)2S04 16 54.0 10656 197 83
Post HQ 20 40.5 7792 192 60
Post HP 2 8.1 4675 192 36
Table 5.5: Dynamic light scattering results fo r  E. coli pET16b BL21 (DE3) MAL. The
average polydispersity value as a function o f the hydrodynamic radius
Ü 45 %.
# Ampl. Differ. Radius Polyd. Est.MW Temp. Count Base %  RadiusCoeff. (nm) (nm) kDA °C Rate Line /  PolyD
1 0.853 184 12.5 4.895 1331 23.2 438 1.006 41
2 0.858 193 12.6 4.952 1368 23.5 423 1.006 39
3 0.848 180 12.8 6.341 1423 23.4 421 1.006 49
4 0.849 180 12.9 5.044 1430 23.5 420 1.005 39
5 0.843 181 13.0 6.398 1455 23.9 434 1.008 49
6 0.85 175 13.2 6.515 1521 23.5 432 1.006 49
7 0.850 179 13.0 5.094 1465 23.5 421 1.005 49
8 0.851 180 12.9 6.259 1445 23.4 414 1.005 39
9 0.865 181 12.9 4.787 1419 23.4 413 1.008 39
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Figure 5.2: Silver stained gel displaying MAL.
Lane I: Molecular markers (kDa)
Lane2: Post (NH4)2 SO4 fractionation.
Lane2: Post anion exchange chromatography.
Lane4 & 5: Post hydrophobic interaction chromatography.
Figure 5.3: Silver stained gel displaying attempts to cleave the HIStag 
by factor Xa.
Lane I & 11: Untreated homogenous MAL.
Lane2: 60 minutes incubation 0.6 units factor Xa.
Lane3: 120 minutes incubation 0.6 units factor Xa.
Lane4: 30 minutes incubation 1.2 units factor Xa.
Lane5: 60 minutes incubation 1.2 units factor Xa.
Lane6 : 120 minutes incubation 1.2 units factor Xa.
Lane? : 30 minutes incubation 1.6 units factor Xa.
LaneS: 60 minutes incubation 1.6 units factor Xa.
Lane9: 120 minutes incubation 1.6 units factor Xa.
Lane 10: Overnight incubation 1.2 units factor Xa
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Cloning of MAL in pET 11a
Tracey Neal performed the cloning of the new construct in David Gani’s laboratory. 
Expression o f Recombinant MAL in E, coli p e tlla  BL21 (DE3)
5 mL of terrific broth medium containing ampicillin was inoculated with a single colony and 
incubated overnight at 37°C. This culture was used to inoculate 500ml of similarly treated 
terrific broth and the resulting solution was shaken at 150rpm at 37 C until an Aôoo value of 
0.6 -  0.8 was reached. Protein production was induced by the addition of IPTG to a final 
concentration of ImM and incubation continued for 3 hours. Cells were harvested by 
centrifugation (lOOOOg, 4°C, 30 minutes) and stored at -78 C until required.
Preparation o f Cell Extracts
Cells from cultures of p e tlla  BL21 (DE3) were resuspended in ice-cold lysis buffer (50mM 
KPi, pH 8.0, ImM DTT, ImM PMSF) at a concentration of 0,5g of cells per mL buffer. 
Suspended cells were sonicated on ice for 6 x 30 seconds with a cooling period of 30 
seconds in between. Cell debris was pelleted by centrifugation (20000g, 4°C, 30 minutes) 
and the cell supernatant transferred to a clean tube and used in cell-free assays.
Purification o f Recombinant E. coli p E T lla  BL21 (DE3) MAL.
Crude extract was brought to 20 % (NH4)2S0 4  concentration by the slow addition of 10.7g 
(NH4)2S0 4  per 100 ml of extract. Precipitated protein was pelleted by centrifugation 
(20000g, 4°C, 30 minutes) and the supernatant transfeixed to a clean tube. (NH4)2S0 4  was
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removed by dialysis against buffer A (20mM TRIS, pH 7.5, 2mM DTT) in preparation for 
anion exchange chromatography.
A 7.84ml anion exchange column (Perseptive Biosystems, HQ) was equilibrated in buffer A 
and lOOmg’s of total protein was applied at a flow rate of 5ml min '. After column washing 
(3 column volumes of buffer A), protein was eluted with a gradient of 0 to 500mM NaCl in 
buffer A. Protein was detected on-line at 280nm and fractions were assayed for biological 
activity. Active fractions were pooled from successive runs and concentrated by 
ultrafiltration.
Protein from anion exchange was dialysed for three changes against buffer B (50mM KPi, 
40% (NH4)2S0 4 , pH8.5) before application to a hydrophobic interaction chromatography 
column (Perseptive Biosystems, HP) pre-equilibrated in buffer B. After washing the column 
in 3 volumes of buffer B protein was eluted by application of a 40 - 0% (NH4)2S0 4  gradient 
over 15 column volumes. Again protein was detected on-line at 280nm and active fractions 
detected by assay. Protein content was measured by Bradford, Table 5.6, and analysed by 
SDS-PAGE.
Table 5.6. Yield of E. coli p E T lla  BL21 (DE3) MAE protein obtained after 
subsequent purification steps.
Vol (mL) Protein
(mg)
Total 
Activity (U)
Specific
Activity
(U/mg)
Yield
(%)
Crude Extract 160 3888 49040 12.6 100
(NH4)2S04 19 548 43510 79.4 89
Post HQ 18 117 31000 265 63
Post HP 18 71 23606 332.5 48
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Characterisation of Recombinant E. coli pETlla BL21 (DE3) MAL.
Dynamic light scattering experiments were performed on purified enzyme. The average 
polydispersity value as a function of the hydrodynamic radius was 39%.
Crystallisation of Recombinant E. coli p E T lla  BL21 (DE3) MAL.
(NH4)2S0 4  was removed by dialysis against buffer A in preparation for crystallisation.
As before the crystal screens from Hampton Research were used to screen for initial 
crystallisation conditions along with the following grid screens; PEG 6K, PEG 6K / LiCl, 
(NH4)2S0 4 , MPD and NaCI. All experiments were performed as hanging drops at a range of 
protein concentrations. Table 5.7.
Table 5.7: Screens performed in crystallisation o f E. coli p E T lla  BL21 
(DE3) MAL
Precipitant pH
Protein 
Concentration 
mg mi’^
Mixing Crystals
PEG 6K
4 - 9 5, 10& 15 Yes
No
PEG 6K /L i Cl No
(NH4)2S04 No
MPD No
NaCl No
Hampton CS I No
Hampton CS II No
As with the previous high efficiency expression strain of the enzyme no crystals were 
apparent after several weeks’ incubation at 20.5 C. As the enzyme was still biologically 
active, the failure to reproduce the initial crystallisation from the constitutive strain with a 
cleaner more active enzyme was puzzling.
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Sequence Characterisation
Automated sequencing of pE T lla  BL21 (DE3) MAL was performed using dye deoxy 
methodology and one mutation was uncovered at the C-terminus of the protein. The ‘true’ 
TAA stop codon had mutated to TAT, encoding a tyrosine residue, which allowed for a 
further 6 amino acids to be transcribed, before another TAA stop codon was encountered. 
The extension included two glycine and one cysteine residue.
5.4 Results and Discussion
MAL has been overexpressed and purified from E. coli pSG4. However, levels of protein 
obtained (Img mT^) are so low that a crystallographic study of the enzyme would be 
extremely time consuming. Despite this limiting factor, small crystals of the enzyme have 
been grown after equilibration against (NH4)2SÜ4 and X-ray data have been recorded in- 
house to 6 Â. Given that the crystals were only 0. Imm^ and suffered from radiation damage, 
the low resolution diffraction obtained is not surprising.
To try and increase the yield of soluble protein obtained per preparation, the enzyme was 
overexpressed in a high efficiency vector; E. coli pET16b BL21 (DE3). Using this vector 
system the enzyme was expressed under the control of a T7 lac promoter allowing enzyme 
production to be initiated by the addition an artificial inducer, IPTG. Subsequently, a larger 
quantity of soluble protein should be obtained. An additional feature of this clone is the 
presence of an extra 6 consecutive histidine residues at the N terminus which can be 
selectively cleaved by the enzyme Factor Xa. With the HIStag, purification is simplified by 
the inclusion of an affinity chromatography step utilising the ability of nickel to selectively 
bind the tag. Approximately 10 times more soluble protein was produced with this system
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and the modified enzyme showed activity on a par with the native (constitutive enzyme). 
However, although the method of expression and the purification protocol employed resulted 
in increased amounts of pure enzyme, results from dynamic light scattering were not 
promising for crystallisation. The initial intention was to cleave the tag before 
crystallisation, but as it did not interfere with enzyme activity attempts to crystallise the 
tagged enzyme seemed justified. Crystallisation trials employing over 300 different 
conditions at various protein concentrations and temperatures failed to grow crystals. These 
results were not unexpected given the dynamic light scattering results. Repeating these 
crystallisations after cleavage of the tag was the next logical step but the inability to 
selectively cleave the tag made this impossible. Factor Xa cleaves after the sequence EEGR. 
Inspecting the primary sequence of MAL, the sequence lEGP is identified starting at residue 
271. It seems likely that this sequence may be acting as a pseudo cleavage site, which could 
result in the multiple products discovered in practice. Alternatively, small amounts of 
contaminating thrombin activity are known to be present (Boehringer Mannheim, 1993) in 
Factor Xa, so cleavage at very exposed thrombin sites cannot be dismissed.
Several experiments were performed with the intention of introducing order into the tag, as it 
was believed the flexible nature of 6 histidines located at the N terminus might be inhibiting 
crystallisation. As dynamic light scattering suggested extremely high molecular weights it 
was presumed extensive cross-linking was taking place. To try and circumvent this problem 
EDTA (to complex any metals) and detergent (to further solubilise the solution) were added. 
Neither additive offered a solution with the dynamic light scattering results remaining 
unchanged.
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As an alternative approach to introduce order to the tag the addition of chelating agents was 
examined. However, the addition of either one of the transition metals nickel and zinc at 
ImM induced immediate precipitation. It had been hoped the metals would serve to chelate 
the tag internally and possibly limit its movement, yet as the solutions precipitated, this 
suggests that with two free coordination sites (Ni and Zn the metals were actually 
promoting more extensive cross-linking. It appeared the tag designed to aid in purification 
of the enzyme created more problems than it solved and ultimately prevented crystallisation. 
For this reason the enzyme was recloned in a tag free high efficiency vector pE T lla  before 
overexpression and purification. Again crystallisation proved fruitless. Sequencing of the 
enzyme revealed the C-teiminal extension, including two glycine residues and a cysteine. 
Giving the nature of the alternation relative to the native enzyme the failure to re-crystallise 
the enzyme is not surprising.
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5.5 Conclusions and Future Work
It is apparent that no variant of the enzyme presented here is favourable to work with given 
the ultimate aim of the project. The constitutive strain does not express sufficient quantities 
of enzyme that would allow a comprehensive search for crystallisation conditions. Whereas, 
although the pET strains overexpress large amounts of soluble protein, the protein has failed 
to crystallise for a variety of reasons.
It is clear that for this project to succeed, the enzyme will have to be cloned into an 
expression system that allows large amounts of enzyme to be expressed, but is lacking in any 
additional tags. There are several commercially available expression systems that will 
facilitate this process and work is ongoing within David Gani’s laboratory to rectify this 
situation.
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Chapter 6
Initiating a Crystallographic Study of a-D-Glucose-1-Phosphate 
Thymidylyltransferase and TDP-Glucose 4,6-dehydratase
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6.1 Summary
RmlA from Streptococcus suis has been overexpressed and purified to homogeneity suitable 
for crystallisation. The enzyme migrates as a single band at 30kDa on denaturing gels and 
has an average polydispersity of 30.5%. The enzyme has been crystallised from both PEG / 
LiCl and (NH4)2S0 4 . Cunently only crystals from PEG / LiCl have been characterised. The 
crystals (0.1 x 0.1 x 0.1mm) diffract to around 8Â in-house and 3.5Â at the synchrotron 
radiation source, Daresbury. Further optimisation of the crystallisation parameters is 
required.
A seleno-methionine variant of RmlB from Salmonella enterica has also been 
overexpressed, purified and crystallised in a form suitable for x-ray data collection. The 
enzyme migrates as a single band at 44kDa on denaturing gels and crystallises after 14 days 
equilibration against O.IM MES pH 6.3, 1.5M LiS0 4 , 2mM DTT. A partially complete data 
set (85%) has been collected in-house to 3.1Â.
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6.2 Introduction
L -  rhamnose (L -  rha), like galactofuranose (chapter 2), is a key component of the cell wall 
of many pathogenic bacteria including mycobacteria (McNeil et al, 1990). As in the case of 
gal/, its presence is essential for cell wall integrity being the linker between the inner 
peptidogiycan layer and arabinogaiactan Figure 1.6. From this it is clear that the inhibition 
of L -  rha biosynthesis would prove lethal to mycobacterial cells. As with gal/, rhamnose is 
neither synthesised nor utilised by mammalians thus it becomes an appealing target for the 
generation of new therapeutic agents. Similarly, as L- Rha biosynthesis is conserved across 
species (Ma et al, 1997) any new treatments would have a wide spectrum of activity.
The biosynthesis of dTDP - L - rhamnose from a  - d  -  glucose-l-phosphate is catalysed by 
four enzymes Figure 6.1, (Tsukioka et al, 1997), termed RmlA, RmlB, RmlC and RmlD in a 
variety of both gram negative and positive bacteria including mycobacteria (Tsukioka et al, 
1997; Ma et al, 1997; Brazeau et al, 1996). As a result, inhibition of any one of the four 
enzymes could prove effective in the inhibiting L -  rha biosynthesis. The work described 
here involves the first two enzymes of the pathway, RmlA from Streptococcus Suis type II 
{S. suis n) and RmlB from Salmonella enterica {S. enterica).
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Figure 6.1: Anabolism o f  dTDP-L-rhamnose from  a-D-glucose-l-phosphate
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Glucose-l-Phosphate Thymidylyltransferase from Streptococcus suis Type II: RmlA 
S. Slits II is a gram positive, haemolytic and facultative anaerobic pathogen. Presently 35 
capsular serotypes of S. Suis exist with type H being the most commonly found in cases of 
disease and meningitis (Gottschalk et al, 1995). It is primarily a porcine pathogen where 
infection costs run to $300 million per annum in the United States (Staats et al, 1997). 
Human infection is rare but not unknown; slaughterhouse workers and butchers being the 
most at risk from infection (Tayaro et al, 1996). Ineffective vaccines and antimicrobials as a 
result of increased resistance by S. suis II has made the treatment of the disease difficult. 
This highlights the urgency with which the development of new drugs are sought. However, 
in designing inhibitors particular care will have to be exercised primarily to ensure that drugs 
are highly selective for RmlA and do not disrupt the similar reaction catalysed by glucose-l- 
phosphate uridylyltransferase where uridine 5'-phosphoryl is transfeired from UDP-glucose 
to galactose-1-phosphate. This enzyme is essential in human metabolism.
RmlA catalyses the first step of the rhamnose pathway, the addition of dTDP and a -D - 
glucose-l-phosphate, Figure 6.1. The enzyme has been isolated from S. suis II and cloned 
in pET 21 for overexpression. Its molecular weight is 32 kDa and the pi is 4.7. At UVigo 1 
AU corresponds to 1.23mg m l'\ The primary sequence contains 10 methionines. As the 
enzyme is homologous between pathogens the solution of one three-dimensional structure by 
de novo methods will simplify the solution of subsequent structures, Figure 6.2.
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Figure 6.2: Sequence Alignment o f  RmlA from (l)E. coli (2) S. suis II and (2) S. enterica
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dTDP- D  -glucose-4, 6-dehydratase from  Salmonella enterica: RmlB
The genera Salmonella comes under the classification umbrella of enterobacteriaceae, 
implying a gram negative, aerobic and facultative anaerobic bacteria. It is the causative 
agent in many diseases including infections of the intestinal tract, the urinary tract 
septicemia and meningitis (Elliot et al, 1996).
Analysing the primary sequence of RmlB identifies 3 methionine residues, however unlike 
RmlA, RmlB will not require de novo phase acquisition as the structure of a 38% 
homologous protein UDP-galactose-4-epimerase (UDPGE) already exists. UDPGE 
catalyses inter conversion of UDP-galactose and UDP-glucose in normal galactose 
metabolism and the three dimensional structure has been elucidated to 1.8Â by Thoden & 
Holden (1998). The protein folds in two distinct motifs; an N-terminal or nucleotide binding 
domain consisting of a 7 stranded p sheet flanked by a  helices. The smaller C-terminal 
domain consists of 3 p sheets and 2 a  helices. The active site is wedged between the two 
domains. It is postulated the conversion proceeds through a 4'-ketopyranose intermediate 
where NAD^ plays a crucial functional role in the mechanism, as shown in Figure 6.3.
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Figure 6.3: Postulated mechanism fo r the interconversion o f  UDP-galactose and 
UDP-glucose flhoden and Holden, 1998)
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The key features of the mechanism include removal of the 4' hydroxyl by a catalytic base 
(Ser 124 and Tyr 149), the transfer of a hydride from C4 to NAD^ and the rotation of the 
resulting 4’-ketopyranose in the active site which allows return of the hydride from NADH 
to the opposite face of the sugar. As the catalytic triad reported to be essential for UDPGE 
activity, Ser 124, Tyr 149 and Lys 153, is also present in RmlB, a similar mechanism of 
enzymatic action seems likely. The sequence alignment in Figure 6.4 illustrates the 
conserved amino acid regions from the epimerase discussed here, RmlB from S. enterica 
and RmlB from Salmonella typhimurium.
RmlB (TDP-D-glucose 4, 6-dehydratase) catalyses the conversion of dTDP-o-glucose to 
dTDP-6-deoxy-D-xylo-4-hexulose, Figure 6.1, and has been cloned from S. enterica ready 
for overexpression. The enzyme has a molecular weight of 42kDa and the point of no net
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charge is 5.7. At UV280 1 AU corresponds to 0.62mg ml' . Enzyme activity drops to below 
10% when the protein is assayed in the absence of NAD^. Thoden and Holden 
(unpublished, 1998) have also solved the structure of E. coli RmlB (PDB Accession Number 
IBXK).
The overexpression, purification and crystallisation of native RmlB from S. enterica had 
previously been optimised by a colleague. Dr. Marie-France Giraud. Only work on the 
selenomethionine variant enzyme is discussed in this chapter. At the time of the work 
described in this chapter, the epimerase structure had not been reported, and consequently it 
was thought phases would have to have calculated ah initio. For this reason the experiments 
reported here were performed with a view to solving the three dimensional structure by 
MAD techniques.
Figure 6.4: Alignment report o f  (I) UDP-galacto.se-4-epimerase and lànlB 
(2) S. typhimurium and (3) S. suis II
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6.3 Experimental
Overexpression of Recombinant RmlA form Streptococcus suis
Ail materials used were obtained from Sigma (Poole. UK) unless otherwise stated. Prior 
to all cultivation procedures, all containers, pipette tips and media were sterilised by 
autoclaving at 120°C for 30 minutes. Dr. Andrew Allan, University of Cambridge 
generously supplied the clone for RmlA.
In a typical experiment 5 milliliters of LB containing kanamycin (SOpg ml'*) was 
inoculated with a single colony of BL21 (DE3) cells containing the gene for RmlA and 
incubated overnight at 37°C. This culture was used to inoculate 500ml of similarly 
treated LB medium and the resultant solution shaken at 200rpm, 37 C. The optical 
density was monitored until the Aôoo reached 0.6 where upon IPTG was added to a final 
concentration of ImM. The incubation was continued for a further 3 hours under the 
same conditions. The cells were then harvested by centrifugation (lOOOOg, 4°C, 30 
minutes) and frozen at -78 C until required.
Preparation of Cell Extracts.
Frozen cell paste was thawed in ice-cold lysis buffer (50mM TRIS pH 7.6, ImM DTT, 
ImM PMSF) at a concentration of 0.5g wet cell paste for each mL buffer. Lysozyme 
(200pg m l'’), DNase (20pg ml'^) and EDTA (2mM) were added and the solution left at 
room temperature for 30 minutes before the cell contents were released by sonication 
( 140kW, 20kHz) at 4 C for 6 x 30 seconds, resting on ice in between. Cell debris was 
pelleted by centrifugation (20000g, 4°C, 30 minutes). The cell extract was transfeired to 
a clean tube and the contents assayed by the Bradford assay (Bradford, 1976) and SDS- 
PAGE.
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Ammonium Sulphate Fractionation and Anion Exchange Chromatography 
Cell extract was brought to 10% (NH4)2S0 4  saturation by the slow addition o f 5.6g 
(NH4)2S0 4  per lOOml'^ cell extract with gentle stirring at 4*^ C. Precipitated contaminants 
were pelleted by centrifugation and the supernatant dialysed 3 times against a 1000ml 
solution of 50mM TRIS pH7.5, ImM DTT to remove ammonium sulphate before 
application to an anion exchange chromatography column. Dialysed protein was 0,02pm 
filtered and applied to a 7.84ml anion exchange column (Perseptive Biosystems, HQ) 
equilibrated in buffer A (50mM TRIS pH 7.6, ImM DTT) in lOOmg aliquots at 5ml min"\ 
The optimum pH for separation was detennined experimentally through application of a pH 
multi-method. Small amounts o f protein were applied to the column and eluted at pH levels 
differing in 0.5 units over the pH range 6-9. Eluent was collected over 15 column volumes 
(CV’s) by applying a 0-500mM NaCl gradient. Protein elution was monitored on-line at 
280nm. The required fraction was identified after analysis by SDS -  PAGE and appropriate 
peaks from subsequent runs were pooled and concentrated under nitrogen pressure in an 
Amicon ultrafiltration cell.
Hydrophobic Interaction Chromatography.
Pooled fractions from the anion exchange column were brought to 35% (NH4)2S0 4  
saturation by dialysis overnight against a solution of 20mM TRIS, 35% (NH4)2 SO4 and 
ImM DTT. The protein solution was 0.02pm filtered again before application at 5ml min'^ 
to a 7.84ml hydrophobic interaction chromatography column (Perseptive Biosystems, HP) 
equilibrated in buffer B (50mM TRIS pH 7.3, 35% ImM DTT). Protein was
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eluted in a decreasing (NH4)2S0 4  gradient (100-0%) in butter B over 15 CV’s. As before the 
correct fraction was identified by SDS -  PAGE, Figure 6.5.
Protein concentration was assayed by the Bradford method (Bradford, 1976) and UV 
absorption at 280nm.
Figure 6.5: Coomassie blue stained SDS-PAGE displaying protein purity 
after subsequent purification steps.
Lane 1: Molecular markers (kDa)
Lane 2: Crude Rml A.
Lane 2: Post HQ Rml A.
Lane 4: Post HP Rml A.
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The protein ran as a single band on SDS-PAGE and was judged to be satisfactorily pure for 
crystallisation.
Protein was also overexpressed in terrific broth as opposed to LB. However, as the yield of 
soluble protein obtained was essentially the same (11.2 mgs from terrific broth and 10.4 mgs 
from LB) per litre of culture over expression was routinely performed in LB for cost 
effectiveness.
Dynamic Light Scattering
RmlA was concentrated to 5mg ml * under nitrogen pressure (Amicon) and dialysed 3 times 
against 20mM TRIS pH 7.3, 2mM DTT in preparation for analysis by dynamic light 
scattering. The results of which are shown in Table 6.1.
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Table 6.1: Dynamic light scattering results for Rml A. The average polydispersity
value as a function o f the hydrodynamic radius is 30.5%.
# Ampl. Differ.
Coeff.
Radius
(nm)
Polyd.
(nm)
Est.MW
kDa
Temp. Count
Rate
Base
Line
Poly
D%
1 0.807 533 4.2 1.450 96 22.3 109 1.023 34.5
2 0.827 547 4.1 1.197 91 21.8 105 1.003 29.1
3 0.815 522 4.2 1.242 99 22.1 109 1.023 29.5
4 0.806 514 4.3 1.268 104 22.3 110 1.029 29.4
5 0.823 512 4.4 1.517 100 22.1 109 1.006 35.2
6 0.835 520 4.4 1.551 106 22.3 109 1.015 35.2
7 0.837 504 4.2 1.744 109 22.2 110 1.021 41.5
8 0.844 533 4.3 1.476 96 22.4 106 1.005 35.1
9 0.846 522 4.2 1.513 100 22.2 107 1.004 36.0
10 0.842 540 4.1 1.205 92 22.2 105 1.003 29.3
Although the average polydispersity as a function of the hydrodynamic radius is slightly 
higher than one would like for crystallisation purposes, protein was routinely produced by 
this protocol and used in crystallisation trials.
Crystallisation o f Rml A
Unlike the crystallisation of UDP-galactopyranose mutase, the sitting drop method of 
crystallisation was employed for initial ciystallisation trials. Rather than ‘hanging’ in a 
sealed environment in the presence of the crystallising agent the protein ‘sits’ in an elevated 
well above the crystallising agent. The reason for the switch in approach was for purposes of 
convenience only. The plates used for this set up are available from Douglas Instruments 
and enable a more cost efficient approach to crystallisation.
After the final purification step protein was concentrated to 10 mg ml * and dialysed against 
three changes of 20mM TRIS pH 7.3, 2mM DTT. Ciystailisation trials were performed with 
2pi of protein solution and 2pl of precipitant and incubated at 20.5 C. As before the
218
crystallisation screens available from Hampton Research were used to screen for primary 
crystallisation conditions. All conditions tried are listed in Table 6.2, along with the results 
observed.
Table 6.2: Initial screens performed in crystallisation o f Rml A.
Precipitant pH
Protein 
Concentration 
mg ml'^
Mixing Crystals
PEG 6K No
PEG 6K /L iC l Yes
(NH4)2S04 4 ,5 , Yes
MPD 6, 7, 2 ,4  & 8 Yes No
NaCl 8 ,& 9 No
Hampton CS I No
Hampton CS II No
After 4 days small crystals (0.05 x 0.05 x 0.01mm) had grown from solutions equilibrated 
against 30 % PEG 6K / LiCl at pH units ranging from 6 - 9 .  To try and increase the size of 
the crystals the parameters around this condition were optimised. Thereafter the optimum 
size of ciystal was grown from a solution of 4mg ml * protein equilibrated with 23% PEG / 
l.OM LiCl, 0 .IM HEPES pH 6.5.
Encouraging results were also obtained from the initial screens with (NH4)2S0 4 . After 8 - 9  
days crystal nucléation sites were evident. As with the PEG / LiCl initial conditions, 
optimisation followed and crystallisation parameters were refined allowing hexagonal 
crystals to grow from a protein solution equilibrated against 2.8M (NH4)2S0 4 , O.IM MES 
pH 6.2 after 9 days, Figure 6.6. However, ciystal size was so small (0.05 x 0.05 x -0.01mm) 
that continued optimisation of the PEG / LiCl conditions took priority.
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Additive screens from Hampton Research were tried at this stage to see if they 
complimented crystal growth. O f the 72 different additives tested only Mn(Cl4)2 at 0.0IM 
appeared to enhance crystal growth. This was subsequently included in crystallisation 
experiments. Incubation of the protein with substrate (a-glucose-1 -phosphate) at 4 C and 
37°C prior to crystallisation did not promote the growth of larger crystals. The final size of 
the crystals was now 0.3 x 0.1 x 0.1mm and growth was complete after 4 days. Figure 6.7. 
Figure 6 .6 : Crystal o f  RmlA grown from 2.8M (NH^ ^ 0 4 , O.IM MES pH  6.2
Figure 6 .1: Crystals o f  RmlA grown from  23% PEG /  l.OM Li Cl, 0.01 M  Mn (CI4) 2, 
O.IM HEPES pH6.5
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Data Collection
A crystal was cryoprotected in a solution of mother liquor containing 15% glycerol and 
mounted in the ciyostream (IlOK). The crystal to detector distance was set to 200mm and 
an exposure time of 50 minutes per T oscillation employed. X-rays were generated using a 
FR-951 rotating anode (Enraf Nonius) with copper target and focussed with the MacScience 
mirror system. As data was only observable to 8Â indexing were impossible. However, a 
single image was recorded on PX 9.6 at the synchrotron source Daresbury, which showed 
diffraction to 3.5Â.
Preparation o f Selenomethionine Variant RmlB
DNA Extraction and Transformation into the Methionine Auxotroph B834 (DE3)
The method followed is exactly as outlined in Chapter 2, for the analogous experiment with 
UDP-galactopyranose mutase.
Overexpression and Purification o f B834 RmlB in Defined Medium.
Previous experiments with mutase to quantify the amount of soluble protein obtained using 
different expression media for the overexpression of selenomethionine variant protein 
showed no particular medium to excel. For this reason the same media (defined) used in 
over-expression of mutase was used here.
Single colonies were selected from an agar/ampicillin plate and used to inoculate 2 x 5ml of 
defined medium (Table 2.3) supplemented with Img L * thiamine. This starter culture was 
incubated at 37°C overnight with agitation and used to inoculate 2 x 500ml of defined
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medium. Incubation continued at 37 C 200rpm before addition of ImM IPTG at an OD^oo 
of 1.0 whereupon incubation continued for a further 16 hours before the cells were harvested 
by centrifugation (lOOOOg, 4 C, 15 minutes).
Purification o f Selenomethionine Variant RmlB
Purification of the selenomethionine variant RmlB was as the native enzyme (Giraud
personal communication). Experience in the purification of the selenomethionine variant
mutase suggested a concentration of 2mM DTT would be sufficient in preventing oxidation.
For this reason DTT concentrations were kept at this level to avoid any potential disruption
of the purification strategy. Sample homogeneity was judged by SDS-PAGE, Figure 6.8.
Figure 6 .8 : Silver stained SDS-PAGE ofSe-M et RmlB after hydrophobic interaction
chromatography. Lanel molecular markers (kDa), lanes 2&3 purified RmlB.
Mass Spectrometric Analysis o f RmlB
Selenium incorporation was confirmed by mass spectrometry to be 100%. Analysis of the 
selenomethionine protein revealed a peak at 40834 a.m.u, 154 a.m.u. higher than the peak 
displayed by native protein, which is correct for the substitution of three selenium’s in 
methionine.
Crystallisation o f Selenomethionine Variant RmlB.
As the crystallisation parameters for the native protein had been previously determined and 
optimised (O.IM MES pH 6.3, 1.5M LiSO^, 2mM DTT) screens around this condition were
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set up with selenomethionine RmlB in sitting drop trays. As with native enzyme, the protein
(3mg ml ') was incubated prior to crystallisation overnight with NAD^. Crystal growth was
complete after 14 days. The maximum crystal size was smaller than that for the native
enzyme at 0.4 x 0.15 x 0.15mm compared to 0.6 x 0.2 x 0.2 mm. Figure 6.9.
Figure 6.9: Selenomethionine RmlB crystallisedfrom a solution ofSm g mb^ protein 
equilibrated against 0.1M MES pH  6.3, Î.5M  LiSÜ4, 2mM DTT. Crystal 
dimensions 0.4 x 0.15 x 0.15mm.
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In-house Selenomethionine Variant RmlB Data Collection
A crystal of optimum size was cryoprotected in 15% glycerol and mounted in the cryostream 
at 11 OK. All diffraction data were collected using the Enraf-Nonius/MacScience D1P2000 
dual image plate. X-rays were generated (X=1.54À) using an Enraf-Nonius FR591 rotating 
anode generator and focussed using the MacScience mirror system. An oscillation range of 
r  was set, exposure time 25 minutes and the crystal to detector distance set at 150mm. The 
crystal diffracted weakly to 3.1 Â. As a result the exposure time was doubled and the image 
plate moved back to 200mm, 3.0Â at edge.
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90 degree’s of data were collected and processed using DENZO and SCALEPACK 
(Otwinowski & Minor, 1996), in space group C222] with unit cell dimensions a = 146.62Â, 
b = 168.92Â, c = 87.72Â, a  = (3 = y = 90^ .^ The data aie 85% complete from 26Â to 3.1Â, 
Emerge 11.9% and redundancy 2.6. Unfortunately the crystal iced during data acquisition 
preventing the collection of a more complete data set. Data collection and reduction 
statistics are shown in Table 6.3. The mosaic spread was fixed to 0.5 for scaling, as it 
proved unstable in refinement.
Table 6.3: Quality o f the selenomethionine variant protein data set o f RmlB 
collected in-house.
Resolution (A) No. Reflections % Complete R-Merge % Redundancy
40.00 -  6.67 1753 81.2 4.8 2.7
6 .67-5 .30 1784 86.0 9.7 2.7
5.30-4 .63 1786 87.3 8.6 2.7
4.63-4.21 1791 88.2 9.2 2.7
4 .21-3 .91 1746 85.5 12.5 2.6
3 .91-3 .68 1717 85.7 15.3 2.6
3.68 -  3.49 1760 87.6 18.7 2.6
3.49 -  3.34 1752 86.6 22.7 2.6
3.34-3.21 1749 88.1 27.9 2.5
3 .21-3 .10 1433 71.6 35.0 2.5
40.00 -  3.10 17271 84.8 11.9 2.6
6.4 Results and Discussion 
RmlA
RmlA from Streptococcus suis has successfully been overexpressed and purified in a form 
that is suitable for protein crystallisation. The protein migrates as a single band around 30 
kDa on denaturing gels. However, analysis by light scattering suggests a certain amount of 
heterogeneity may be present. Regardless, crystals have been reproducibly grown from 
solutions of PEG / LiCl and (NH4)2S0 4  by the sitting drop vapour diffusion method. The
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maximum crystal size currently obtainable is 0.3 x 0.1 x 0.1mm. Characterisation of the 
crystals by X-ray analysis shows diffraction to around 8Â in-house and 3.5Â on PX 9.6, 
Daresbury.
To obtain higher resolution data, crystals of better quality are required. Further optimisation 
of the current crystallisation conditions may yield better crystals and this should be pursued 
particularly with the ammonium sulphate conditions, which have not had much optimisation 
as yet. Alternatively, as analysis by dynamic light scattering shows some polydispersity, the 
purification protocol may require refinement. Before alteration of the purification protocol 
the protein should first be characterised by mass spectrometry. If any heterogeneity is 
apparent then optimisation of the purification protocol will then become the priority.
RmlB
A selenomethionine vaiiant of the protein has also been successfully overexpressed, purified 
and crystallised in a form suitable for X-ray data collection. Crystal growth characteristics 
are identical to the native protein, though the final crystal dimensions are approximately 25% 
smaller. 100% selenium incorporation has been confirmed by mass spectrometry making the 
crystals suitable for MAD analysis. A 85% data set, R e^rge = 11.9%, has been collected in- 
house using one of these crystals. As the structure of a 40% homologous structure has since 
been deposited in the PDB the need for a selenomethionine variant of the protein has been 
removed.
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6.5 Conclusions and Future Work 
RmlA
Parameters allowing the reproducible crystallisation of RmlA have been determined and 
improvement of crystal quality is the initial priority. Should crystals of higher quality be 
forthcoming then data collection should commence. As there is no protein structure 
currently exhibiting significant sequence similarity in the protein data bank 
(http://www.rcsb.org), phases will have to be deteimined experimentally. Transformation of 
the gene encoding for RmlA into B834 cells will allow overexpression of the 
selenomethionine variant of the protein where a high level of selenium incorporation would 
be expected. Purification and crystallisation should be highly similar to that of the native 
protein and yield crystals where selenium has replaced sulphur in the protein. Phases will 
then be determined from MAD methods.
RmlB
This structure is now likely to be solved by moleculai" replacement and others in the 
laboratory are actively pursuing this.
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Appendix I
Hampton Crystal Screen I
T ube Salt Tube B uffer Tube Precipitate
1. 0 .02M C aC l2 1. Na Acetate 1. 30% v/v MPD
2. None 2. None 2. 0.4M  K, Na tartrate
3. None 3. None 3. 0.4M  NH4  Phosphate
4. None 4. O.IM TRIS pH8.5 4. 2.0M  (NH)4 SO4
5. 0.2M  Na Citrate 5. O .IM N aH E FE S pH7.5 5. 30%v/v MPD
6. 0.2M  M gC lz 6. O.IM TRIS pH 8.5 6. 30% w/v PEG 4000
7. None 7. 0. J M Na Cacodylate pH6.5 7. 1.4M Na Acetate
8. 0.2M  Na Citrate 8. O.IM Na Cacodylate pH6.5 8. 30% v/v 2-propanol
9. 0.2M  NR» acetate 9. 0. IM Na Acetate pH 5.6 9. 30% w/v PEG4000
10. 0.2M  NH4  acetate 10. O.IM Na Acetate pH 4.6 10. 30% w/v PEG 4000
11. None 11. 0 .1M Na Citrate pH 5.6 11. 1 .OM NH4  Phosphate
12. 0.2M  M g CI2 12. O .IM N a HEPES pH 7.5 12. 30% v/v 2-propanol
13. 0.2M  Na Citrate 13. O.IM TRIS pH 8.5 13 30% v/v PEG 400
14. 0.2M  Ca CI2 14. O .IM N a HEPES pH 7.5 14. 28% v/v PEG 400
15. 0.2M  (NH )4  SO4 15. O.IM Na Cacodylate pH6.5 15. 30% w/v PEG8000
16. None 16. O .IM N a HEPES pH 7.5 16. 1 .5M L iSÜ 4
17. 0.2M  Li SO4 17. O.IM TRIS pH 8.5 17. 30% PEG 4000
18. 0.2M  M g Acetate 18. O.IM Na Cacodylate pH6.5 18. 20% PEG 8000
19. 0.2M  NH4  Acetate 19 O.IM TRIS pH 8.5 19. 30% v/v 2-propanol
20. 0.2M  (NH)4 SO4 20. O.IM Na Acetate pH 4.6 20. 25% w/v PEG 4000
21. 0.2M  Mg Acetate 21. O.IM Na Cacodylate pH6.5 21. 30% v/v MPD
22. 0.2M  Na Acetate 22. O.IM TRIS pH 8.5 22. 30% w/v PEG 4000
23. 0.2M M g CI2 23. O .IM N a HEPES pH 7.5 23. 30% v/v PEG 400
24. 0.2M  Ca CI2 24. O.IM Na Acetate pH4.6 24. 20% v/v 2-propanol
25. None 25. O.IM Imidazole pH 6.5 25. 1 .OM Na Acetate
26. 0.2M  NH4  Acetate 26. O.IM Na Citrate pH 5.6 26. 30% v/v MPD
27. 0.2M  Na Citrate 27. O .IM N a HEPES pH 7.5 27. 20% v/v 2-propanol
28. 0.2M  Na Acetate 28, O.IM Na Cacodylate pH6.5 28. 30% w/v PEG 8000
29. None 29. O .IM N a HEPES pH 7.5 29. 0.8M  K, Na Tartrate
30. 0.2M  NH4 SO4 30. None 30. 30%w/v PEG 8000
31. 0.2M  NH4  SO4 31. None 31. 30% w/v PEG 4000
32. None 32. None 32. 2.0M  (NH)4 SO4
33. None 33. None 33. 4.0M  Na Formate
34. None 34. O.IM Na Acetate pH 4.6 34. 2.0M  Na Formate
35. None 35. O .IM N a HEPES pH 7.5 35. 1.6M Na, K Phosphate
36. None 36. O.IM TRIS pH 8.5 36. 8%w/v PEG8000
37. None 37. 0.1 M Na Acetate pH 4.6 37. 8%w/v PEG4000
38. None 38. O .IM N a HEPES pH 7.5 38. 1.4M Na Citrate
39. None 39. O .IM N a HEPES pH 7.5 39. 2% v/v PEG 400 & 2.0M  NH4  S 0 4
40. None 40. O.IM Na Citrate pH5.6 40. 20% v/v 2-propanol & 20% PEG 400
41. None 41. O .IM N a HEPES pH 7.5 41. 10% v/v 2-propanol & 20% PEG 4000
42. 0.05M  K Phosphate 42. None 42. 20w /v PEG 8000
43. None 43. None 43. 30% v/v PEG 1500
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44. None 44. None 44. 0.2M  Mg Acetate
45. 0.2M  Zn Acetate 45. O.IM Na Cacodylate pH6.5 45. I8 %w/v PEG 8000
46. 0.2M  Ca Acetate 46. O.IM Na Cacodylate pH6.5 46. 18%w/v PEG 8000
47. None 47. 0 .1M Na Acetate pH 4.6 47. 2.0M  (NH )4  SO4
48. None 48. O.IM TRIS pH 8.5 48. 2 .0 M (NHL SO 4
49. 1.0M L iSO 4 49. None 49. 2%w/v PEG 8000
50. 0.5M  Li SO4  50. 
Hampton Crystal Screen II
None 50. 15%w/v PEG 8000
T ube Salt Tube B uffer T ube Precipitate
1.0 2M NaCl 1.0. None 1.0 10%w/v PEG 6000
2.0 O.IM acetyl(CHi)?NHBr 2.0 None 2.0 0.5M  NaCl 
0.01M M gC h.(O H )6
3.0 None 3.0 None 3.0 25% v/v Ethylene glycol
4.0 None 4.0 None 4.0 35% v/v Dioxane
5.0 2.0M  (NH ) 4  SO4 5.0 None 5.0 5% v/v isopropanol
6.0 None 6.0 None 6.0 l.OM imidazole pH 6.5
7.0 None 7.0 None 7.0 10% w/v PEG 1000 
10% w/v PEG 8000
8.0 1.5M NaCl 8.0 None 8.0 10% v/v Ethanol
9.0 None 9.0 O.IM Na Acetate pH 4.6 9.0 2.0M  Na Cl
10.0 0.2M  NaCl 10.0 O.IM Na Acetate pH 4.6 10.0 30% v/v MPD
11.0 O.OlMCoCl.(OH)fi 11.0 O.IM Na Acetate pH 4.6 11.0 l.OM 1,6 Hexanedio!
12.0 O .lM C dC h 12.0 O.IM Na Acetate pH 4.6 12.0 30% w /v PEG 400
13.0 0.2M  (NH )4  SO4 13.0 O.IM Na Acetate pH 4.6 13.0 30% w/v PEG 
monomethylether 2000
14.0 0.2M  K/Na Tartrate 14.0 O.IM N a Citrate pH 5.6 14.0 2.0M  (NHL SO 4
15.0 0.5M  (NH)4 SO4 15.0 O.IM Na Citrate pH 5.6 15.0 l.OM Lb SO4
16.0 0.5M  NaCl 16.0 O.IM Na Citrate pH 5.6 16.0 4% w/v Polyethyleneimine
17.0 None 17.0 O.IM Na Citrate pH 5.6 17.0 35% v/v tert'butanol
18.0 0.0 IM FeCl2.(0H)e 18.0 O.IM Na Citrate pH 5.6 18.0 10% v/v Jeffamine M -600
19.0 None 19.0 0 .1M Na Citrate pH 5.6 19.0 2.5M  1.6 Hexanediol
20.0 None 20.0 O.IM MES pH 6.5 20.0 1.6M MgSÜ4.(OH)7
21.0 0.1M NaPOr 
O.IM KPO4
21.0 O.IM MES pH 6.5 21.0 2.0M  NaCl
22.0 None 22.0 O.IM MES pH6.5 22.0 12% w /v PEG 20,000
23.0 1.6M (NH )4  SO4 23.0 O.IM MES pH6.5 23.0 10% v/v Dioxane
24.0 0.05M  CsCl 24.0 O.IM MES pH 6.5 24.0 30% Jeffamine M -600
25.0 O.OIMCoC1.(OH)6 25.0 O.IM MES pH 6.5 25.0 1.8M (NH4)2S04
26.0 0.2M  (NH4)2S04 26.0 O.IM MES p H 6.5 26.0 30% w/v PEG 
monomethylether 5000
27.0 0 .0 IM ZnS0 4 .(0 H )7 27.0 O.IM MES pH 6.5 27.0 25% v/v PEG 
monomethylether 550
28.0 None 28.0 None 28.0 1.6M Na Citrate pH6.5
29.0 0.5M  (NH4)2S04 29.0 O.IM HEPES pH 7.5 29.0 30% v/v MPD
30.0 None 30.0 O.IM HEPES pH 7.5 30.0 10% w/v PEG 6000
5% v/v MPD
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31.0 None 31.0 O.IM HEPES pH 7.5 31.0 20% v/v Jeffamine M -600
32.0 O.IM NaCl 32.0 O.IM HEPES pH 7.5 32.0 1.6M (NH4)2S04
33.0 None 33.0 O.IM HEPES pH 7.5 33.0 2.0M  (NH4) Formate
34.0 O.OSMCd S04.(0H )« 34.0 O.IM HEPES pH 7.5 34.0 I .OM Na Acetate
35.0 None 35.0 O.IM HEPES pH 7.5 35.0 70% v/v MPD
36.0 None 36.0 O.IM HEPES pH 7.5 36.0 4.3M  NaCl
37.0 None 37.0 O.IM HEPES pH 7.5 37.0 10% w/v PEG 8000  
8% v/v Ethylene glycol
38.0 None 38.0 O.IM HEPES pH 7.5 38.0 20% w/v PEG 10000
39.0 0.2M  M gCh. (0H )7 39.0 O.IM TRIS pH 8.5 39.0 3.4 M 1.6 Hexanediol
40.0 O.IM CaCl2 .(O H )2 40.0 O.IM TRIS pH 8.5 40.0 25% v/v tert'butanol
41.0 O.OlMNiCI. (OH)fi 41.0 O.IM TRIS pH 8.5 41.0 1.0M L i2SO 4
42.0 1.5M (NH4)2S04 42.0 O.IM TRIS pH 8.5 42.0 12% v/v Glycerol
43.0 0.2M  (NH4)P03 43.0 O .IM TRIS pH 8.5 43.0 50% v/v MPD
44.0 None 44.0 O.IM TRIS pH 8.5 44.0 20% v/v Ethanol
45.0 0 .0 IM NiCI. (OHL 45.0 O.IM TRIS pH 8.5 45.0 20% w /v PEG 
monomethylether 2000
46.0 O.IM NaCl 46.0 O.IM B icine pH 9.0 46.0 30% w/v PEG 
monomethyether 550
47.0 None 47.0 O.IM B icine pH9.0 47.0 2.0M  MgCl2.(OH)ft
48.0 2% v/v dioxane 48.0 O.IM Bicine pH 9.0 48.0 10% w/v PEG20000
JMac Crystal Screen
1.0 0.05M  CaCb 1.0 O.IM Acetate pH4.6 1.0 15% MPD
2,0 0.1M L Î2SO 4 2.0 0 .1M Acetate pH4.6 2.0 10% PEG 8K
3.0 0.2M  M g Ch 3.0 0 .1M Acetate pH4.6 3.0 30% PEG 8K
4.0 None 4.0 0 .1 M Acetate pH4.6 4.0 IM L izSO r
5.0 0.5M  (NH4>2 SO4 5.0 O.IM Acetate pH4.6 5.0 10% PE G 8K
6.0 0.5M  MgC12 6.0 0 .1M Acetate pH4.6 6.0 2M  (NHrJzSOr
7.0 0.2M  NaK Phosphate 7.0 0 .1M Acetate pH4.6 7.0 3M (NH4)2S04
8.0 None 8.0 0 .1 M Acetate pH4.6 8.0 IM Na tartrate
9.0 0. i M Na tartrate 9.0 0 .1 M Acetate pH 4 .6 9.0 20% PEG 8K
10.0 None 10.0 0 .1M Acetate pH 4.6 10.0 2M NaCl
11.0 O.IM Na tartrate 11.0 0 .1 M Acetate pH 4.6 11.0 10% MPD
12.0 0.2M  Li2 SO4 12.0 O.IM Acetate pH 4.6 12.0 20% PEG 8K
13.0 0.2M  NaCl 13.0 O.IM Acetate pH 4.6 13.0 30% MPD
14.0 None 14.0 0.1M Acetate pH 4.6 14.0 23M  Na / K phosphate
15.0 0.2M  Liz SO4 15.0 O.IM Na Citrate pH 5.6 15.0 20% PEG 8K
16.0 None 16.0 O.IM Na Citrate pH 5.6 16.0 30% PEG 8K
17.0 0.2M  Na tartrate 17.0 O.IM Na Citrate pH 5.6 17.0 2M (NH4>2 SO4
18.0 None 18.0 O.IM Na Citrate pH 5.6 18.0 10% PEG 8K
19.0 0.5M  (NH4)2 SO4 19.0 O.IM Na Citrate pH 5.6 19.0 10% PEG 8K
20.0 0.2M  Na Cl 20.0 O.IM Na Citrate pH 5.6 20.0 3M Na / K phosphate
21.0 0.2M  MgClz 21.0 O.IM Na Citrate pH 5.6 21.0 20% PEG 8K
22.0 0.2M  M g C12 22.0 O.IM Na Citrate pH 5.5 22.0 IM Na tartrate
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23.0 0.2M  Na/K phosphate23.0 O.IM Na Citrate pH 5.6 23.0 2M (NH4 )2  SO4
24.0 None 24.0 O.IM Na Citrate pH 5.6 24.0 2M Na Cl
25.0 0.5M  {NH4)2 SO4 25.0 O.IM Na Citrate pH 5.6 25.0 IM Liz SO4
26.0 O.IM Mg C h 26.0 O.IM Na Citrate pH 5.6 26.0 3M Na/K phosphate
27.0 0.2M U 2SO4 27.0 O.IM Na Citrate pH 5.6 27.0 3.0M  (NH4)z SO4
28.0 0.2M  Na/K phosphate28.0 O.IM Na Citrate pH 5.6 28.0 30% MPD
29.0 .None 29.0 0 .1 M Na Citrate pH 5.6 29.0 30% v/v MPD
30.0 None 30.0 O.IM MOPS pH6.5 30.0 20% PEG 8K
31.0 None 31.0 O.IM MOPS pH6.5 31.0 1M Na tartrate
32.0 0.2M Na tartrate 32.0 O.IM MOPS pH6.5 32.0 2M Na Cl
33.0 0.2M  Liz SO4 33.0 O.IM MOPS pH6.5 33.0 3M  Na/K phosphate
34.0 0.2M  NaCl 34.0 O.IM MOPS pH6.5 34.0 20% PEG 8K
35.0 None 35.0 O.IM MOPS pH6.5 35.0 2M (NH4)z SO4
36.0 None 36.0 O.IM MOPS pH6.5 36.0 3.0M  (NH4)2 SO4
37.0 0.2M  Na/K phosphate37.0 O.IM MOPS pH6.5 37.0 15% PEG 8K
38.0 0.2M  Na tartrate 38.0 O.IM MOPS pH6.5 38.0 10% PEG 8K
39.0 0.5M (NH4>2 SO4 39.0 O.IM MOPS pH6.5 39.0 20% PEG 8K
40.0 None 40.0 O.IM MOPS pH6.5 40.0 30% MPD
41.0 None 41.0 O.IM MOPS pH6.5 41.0 0.2M  CaClz
42.0 0.2M  Na/K phosphate42.0 O.IM MOPS pH6.5 42.0 2M NaCl
43.0 0.2M  MgCiz 43.0 O.IM MOPS pH6.5 43.0 30% MPD
44.0 None 44.0 O.IM MOPS pH6.5 44.0 IM Liz SO4
45.0 None 45.0 O.IM HEPES pH7.5 45.0 1M Liz SO4
46.0 O .lM C aC h 46.0 O.IM HEPES pH7.5 46.0 10% PE G 8K
47.0 0.2M NaCl 47.0 O.IM HEPES pH7.5 47.0 3M (NH4)z SO4
48.0 .None 48.0 O.IM HEPES pH7.5 48.0 20% PEG 8K
49.0 0.2M  Na tartrate 49.0 O.IM HEPES pH7.5 49.0 3M (NH4)z SO4
50.0 0.2M  U 2SO4 50.0 O.IM HEPES pH7.5 50.0 2M  (NH4)z SO4
51.0 0.5M  (NH4 )2  SO4 51.0 O.IM HEPES pH7.5 51.0 30% MPD
52.0 0.2M  Na tartrate 52.0 O.IM HEPES pH7.5 52.0 3M Na/K phosphate
53.0 0.2M Na/K phosphate 53 .0 O.IM HEPES pH7.5 53.0 IM N a tartrate
54.0 None 54.0 O.IM HEPES pH7.5 54.0 15% PEG 8K
55.0 None 55.0 O.IM HEPES pH7.5 55.0 2M NaCl
56.0 0.2M MgClz 56.0 O.IM HEPES pH7.5 56.0 19% PE G 8K
57.0 0.2M  U 2SO4 57.0 O.IM HEPES pH7.5 57.0 20% PEG 8K
58.0 0.2M  Na tartrate 58.0 O.IM HEPES pH7.5 58.0 1M ÜZ SO4
59.0 0.2M  Ü 2SO4 59.0 O.IM TRIS pH8.5 59.0 2M NaCl
60.0 0.2M  Na/Kphosphate 60.0 O.IM TRIS pH8.5 60.0 20% PEG 8K
61.0 0.2M  NaCl 61.0 O.IM TRIS pH8.5 61.0 20% PEG 8K
62.0 0.2M  NaCl 62.0 O.IM TRIS pH8.5 62.0 2M (NH4)z SO4
63.0 0.2M  Na tartrate 63.0 O .IM TRIS pH8.5 63.0 15% PE G 8K
64.0 None 64.0 O.IM TRIS pH8.5 64.0 1M Na tartrate
65.0 0.2M  Liz SO4 65.0 O.IM TRIS pH8.5 65.0 30% MPD
66.0 None 66.0 O.IM TRIS pH8.5 66.0 3.0M (NH4)z SO4
67.0 0.05M  CaClz 67.0 O.IM TRIS pH8.5 67.0 5% PEG SK
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68.0 None 68.0 O.IM TRIS pH8.5 68.0 3M Na/K phosphate
69.0 0.5M M gCb 69.0 O.IM TRIS pH8.5 69.0 10% P E G 8 K
70,0 Ü.5M (NH4)z SO4 70.0 O.IM TRIS pH8.5 70.0 30% MPD
71.0 O.IM U 2SO4 71.0 0 .1 M Acetate pH4.6 71.0 10% Me2K PEG
72.0 0.2M M gCb 72.0 0 .1 M Acetate pH4.6 72.0 15% M e2K PEG
73.0 0.2M  (NH4>2 SO4 73.0 0 .1 M Acetate pH4.6 73.0 20% Me2K PEG
74.0 None 74.0 0 .1M Acetate pH4.6 74.0 30% Me2K PEG
75.0 0.IMLÎ2SO4 75.0 0 .1M Acetate pH4.6 75.0 10% PEG 4K
76.0 O .lM M gC h 76.0 0 .1M Acetate pH4.6 76.0 15% PE G 4K
77.0 0.2M  (NH4)2 SO4 77.0 O.IM AcetatepH 4.6 77.0 20% PEG 4K
78.0 None 78.0 0 .1 M Acetate pH4.6 78.0 30% PEG 4K
79.0 O .IM U 2SO4 79.0 O.IM Citrate pH5.6 79.0 10% Me2K PEG
80.0 0.2M  MgClz 80.0 O.IM Citrate pH5.6 80.0 15% Me2KPEG
81.0 0.2M (NH4)2 SO4 81.0 O.IM CitratepH5.6 81.0 20% M e2k PEG
82.0 None 82.0 O.IM Citrate pH5.6 82.0 30% M e2K PEG
83.0 O.IM U 2SO4 83.0 O.IM CitratepH5.6 83.0 10% PEG 4K
84.0 0.2M  M gCb 84.0 0 .1M Citrate pH5.6 84.0 15% PE G 4K
85.0 0.2M  (NH4>2 SO4 85.0 O.IM Citrate pH5.6 85.0 20% PEG 4K
86.0 None 86.0 O.IM Citrate pH5.6 86.0 30% PEG 4K
87.0 0.IM LizSO 4 87.0 O.IM MOPS pH6..5 87.0 10% Me2K PEG
88.0 0.2M M gCh 88.0 O.IM MOPS pH6..5 88.0 15% M e2K PEG
89.0 0.2M  (NH 4 )2  SO4 89.0 O.IM MOPS pH6..5 89.0 20%  M e2K PEG
90.0 None 90.0 O.IM MOPS pH6..5 90.0 30% M e2K PEG
91.0 O.IM U 2SO4 91.0 O.IM MOPS pH6..5 91.0 10% PE G 4K
92.0 0.2M M gCh 92.0 O.IM MOPS pH6..5 92.0 15% PE G 4K
93.0 0.2M  (NH4)2 SO4 93.0 O.IM MOPS pH6..5 93.0 20% PEG 4K
94.0 None 94.0 O.IM MOPS pH6..5 94.0 30% PEG 4K
95.0 0.2M Liz SO 4 95.0 O.IM HEPES pH7.5 95.0 10% Me2K PEG
96.0 0.2M  M gCh 96.0 O.IM HEPES pH7.5 96.0 15% M e2K PEG
97.0 0.2M  (NH4 )2  SO4 97.0 O.IM HEPES pH7.5 97.0 20% M e2K PEG
98.0 None 98.0 O.IM HEPES pH7.5 98.0 30% M e2K PEG
99.0 O .IM L h SO4 99.0 O.IM HEPES pH7.5 99.0 I0% P E G 4K
100.0 0.2M  M gCh 90.0 O.IM HEPES pH7.5 90.0 15% PEG 4K
101.0 0.2M  (NH4)2 SO4 101.0 O.IM HEPES pH7.5 101.0 20% PEG 4K
102.0 None 102.0 O.IM HEPES pH7.5 102.0 25% PEG 4K
103.0 O.IM LhS04 103.0 O.IM TRIS pHB.S 103.0 10% Me2K PEG
104.0 0.2M  M gCh 104.0 O.IM TRIS pH8.5 104.0 15% M e2K PEG
105.0 0.2M  (NH4 )z SO4 105.0 O .IM TRIS pH8.5 105.0 20% Me2K PEG
106.0 None 106.0 O.IM TRIS pH8.5 106.0 30% Me2K PEG
107.0 Q.2M U 2SO4 107.0 O.IM TRIS pH8.5 107.0 10% PEG 4K
108.0 0.2M  M gCh 108.0 O.IM TRIS pH8.5 108.0 15% PEG 4K
109.0 0.2M  (NH4)2 SO4 109.0 O.IM TRIS pH8.5 109.0 20% PEG 4K
110.0 None 110.0 O.IM TRIS pH8.5 110.0 30% PEG 4K
111.0 0.2M  M gCh 111.0 O.IM TRIS pH8.5 111.0 30% PEG 4K
112.0 0.2M  M gCh 112.0 O.IM MOPS pH6.5 1120 20% PEG 8K
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113.0 0 .2M C aC h 113.0 O.IM TRIS pH8.5 113.0 30% PEG 4K
114.0 0.2M  CaCh 114.0 O.IM MOPS pH6.5 114.0 20% PEG 8K
Buffer pH is that o f  a I .OM stock prior to dilution with the other reagent components 
(MES is made as a 0.5M  stock).
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Appendix II
Additive ScreenI
I.0.1 M Barium chloride (Cation)
2. 0.1 M Cadmium chloride (Cation)
3. 0.1 M Calcium chloride (Cation)
4. 0.1 M Cobalt chloride (Cation)
5. 0.1 M Copper chloride (Cation)
6. 0.1 M Magnesium chloride (Cation)
7. 0.1 M Manganese chloride (Cation)
8. 0.1 M Strontium chloride (Cation)
9. 0.1 M Yterbium chloride (Cation)
10. 0.1 M Zinc chloride (Cation)
II. 30% Ethylene glycol (Organic)
12. 30% Glycerol (Organic)
13. 30% 1,6 Hexanediol (Organic)
14. 30% MPD (Organic)
15. 50% PEG 400 (Organic)
16. 0.1 M Trimethylamine HCl (Chaotrope)
17. 1.0 M Guanidine HCl (Chaotrope)
18. 0.1 M Urea (Chaotrope)
19. 15% 1,2,3 Heptanetriol (Amphiphile)
20. 20% Benzamidine HCl (Amphiphile)
21. 30% Dioxane (Organic)
22. 30% Ethanol (Organic)
23. 30% Isopropanol (Organic)
24. 30% Methanol (Organic)
Additive Screen II
1. 1.0 M Sodium iodide (Ion)
2. 0.1 M L-cysteine (Reducing Agent)
3. 0.1 M EDTA, sodium salt (Chelator)
4. 0.1 M b-Nicotinamide adenine dinucleotide (Co-factor)
5. 0.1 M Adenosine-50-triphosphate disodium salt (C-factor)
6. 30% w/v D(+)-Glucose (Carbohydrate)
7. 30% w/v D(+)-Sucrose (Carbohydrate)
8. 30% w/v Xylitol (Carbohydrate)
9. 0.1 M Spermidine (Polyamine)
10. 0.1 M Spermine-tetrahydrochloride (Polyamine)
11. 30% w/v 6-Aminocaproic acid (Linker)
12. 30% w/v 1,5-Diaminopentane dihydrochloride (Linker)
13. 30% v/v 1,6-Diaminohexane (Linker)
14. 30% w/v 1,8-Diaminooctane (Linker)
15. 1.0 M Glycine (Linker)
16. 0.3 M Glycyl-glycyl-glycine (Linker)
17. 0.1 M Hexaminecobalt trichloride (Polyamine)
18. 0.1 M Taurine (Linker)
19. 0.1 M Betaine monohydrate (Linker)
20. 5% w/v Polyvinylpyrrolidone K15 (Polymer)
21. 3.0 M Non-detergent suifo-betaine 195 (Solubilizing Agent)
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22. 2.0 M Non-detergent suiib-betaine 201 (Solubilizing Agent)
23. 0.1 M Phenol (Dissociating Agent)
24. 30% v/v Dimethyl sulfoxide (Chaotrope)
Detergent Screen
1. 1.0 M Ammonium sulfate (Salt)
2. 1.0 M Cesium chloride (Salt)
3. 1.0 M Potassium chloride (Salt)
4. 1.0 M Lithium chloride (Salt)
5. 2.0 M Sodium chloride (Salt)
6. 0.5 M Sodium fluoride (Salt)
7. 2.0 M Sodium thiocyanate (Salt)
8. 30% w/v Dextran sulfate, sodium salt (Polymer)
9. 50% v/v Jeffamine M-600 (Organic, non-volatile)
10. 40% v/v 2, 5 Hexanediol (Organic, non-volatile)
11. 40% v/v 1,3 Butanediol (Organic, non-volatile)
12. 40% v/v Polypropylene glycol P400 (Organic, non-volatile)
13. 40% v/v 1,4 Butanediol (Organic, non-volatile)
14. 40% v/v tert-Butanol (Organic, volatile)
15. 40% v/v 1,3 Propanediol (Organic, volatile)
16. 40% v/v Acetonitrile (Organic, volatile)
17. 40% v/v Gamma butyrolactone (Organic, volatile)
18. 40% v/v n-Propanol (Organic, volatile)
19. 5% v/v Ethyl acetate (Organic, volatile)
20. 40% v/v Acetone (Organic, volatile)
21. 2.5% v/v Dichloromethane (Organic, volatile)
22. 7% v/v n-Butanol (Organic, volatile)
23. 40% v/v 2,2,2-Trifluoroethanol (Organic, volatile)
24. 0.1 M 1,4-Dithio-DL-threitol (Reducing agent)
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UDP-galactopyranose mutase, the enzyme responsible for the 
conversion of UDP-galactopyranose to UDP-galactofuranose, 
has been crystallized in a form suitable for X-ray diffraction 
studies. UDP-galactofuranose is a key com ponent of m yco­
bacterial cell walls. Crystals o f both the native protein and a 
selenom ethionine variant have been grown by the vapour- 
diffusion method in hanging drops, and diffract to beyond  
3.0 Â  using synchrotron radiation. Equilibration was against a 
solution of 20% (w/v) polyethylene glycol (4K), 12%(v/v) 
2-propanol, 0.1 M  HEPES pH 7.6 at 293.5 K. Crystals grow as 
thin plates of dimensions 0.4 x  0.2 x  ~ 0 .02  mm. They are 
orthorhombic, space group F 2i, with unit-cell dimensions 
a =  71.12, b = 58.42, c = 96.38 À , j8= 96.38°. 92% (native) and 
94% (selenom ethionine) com plete data sets have been  
recorded to 2.9 Â  (Rmerge = 5.0%) and 3.0 Â  (Rmerge = 
6.9%), respectively. The Matthews coefficient is 2.35 Da"' 
for a dimer in the asymmetric unit, the solvent content being 
47%. Diffraction data have also been recorded on a putative 
platinum derivative to 3.5 A.
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1. Introduction
The alarming increase in the incidence of tuberculosis 
worldwide led to the World Health Organization (W HO) 
declaring a ‘global em ergency’ in 1993. It estimates that three 
million people die each year from tuberculosis and that this 
figure may rise to four million when the devastating link 
between tuberculosis and human immunodeficiency virus 
(HIV) is considered (Duncan, 1997). Being co-infected with 
HIV and M ycobacterium  tubercu losis  increases the risk of 
contracting a clinically significant disease from a 10% lifetime 
risk to around 10% a year (Young, 1995). Although in most 
cases of tuberculosis the present chemotherapy available is 
effective, it is apparent that more and more strains resistant to 
current therapeutic agents are emerging.
The cell wall o f mycobacteria is essential for cell growth and 
survival in the host. It confers on bacteria an extraordinary 
resistance to drugs, the host immune system, dehydration and 
acid treatment (Draper, 1982). Ethambutanol, one of the most 
successful front-line drugs currently used to treat tuberculosis, 
functions by inhibiting cell-wall assembly (Winford, 1982). The 
structure of the mycobacterial cell wall is elaborate, consisting 
of several unusual carbohydrate polymers (glycans). The 
arabinogalactan layer covalently attaches a highly imperme­
able layer of mycolic acids to a peptidoglycan layer and is thus 
a key com ponent of the cell wall. Arabinogalactan consists in 
part of alternating / - 1 ,5 and / - 1 ,6 gaiactofuranosyl residues. 
Galactofuranose is found only in bacteria and its synthesis is 
thus an intellectually appealing target for inhibition. The 
biosynthesis o f UDP-galactofuranose (G a l/ takes place by the
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direct conversion of UDP-galactopyranose by U D P-galacto­
pyranose mutase (mutase; Nassau et a i ,  1995). Highly hom o­
logous enzymes (40% sequence identity) are found in both 
Escherichia co li and K lebsiella  pneu m on ia  (Weston et a l ,  1998; 
Fig. 1). Analysis o f the primary sequences identifies a 
consensus (Rossmann fold) m otif consistent with
nucleotide sugar-binding enzymes. All three enzymes are 
known to incorporate flavin adenine dinucleotide (FA D ), and 
the enzyme from K. pn eu m on ia  has recently been shown to 
require nicotinamide adenine dinucleotide (phosphate) 
(N A D P) sugar-binding enzymes for activity (Koplin et a l ,  
1997). As the reaction carried out does not involve the net 
transfer of electrons, the mechanistic role of these cofactors is 
puzzling. In a program to study cell-wall biosynthesis, we have 
crystallized the native and selenom ethionine variant enzyme 
from E. coli. Our experiments suggest that the E. co li enzyme 
also incorporates N A D (P).
2. Protein purification
All chemicals were purchased from Sigma (Poole, U K ), except 
polyethylene glycol which was obtained from Fluka 
(Gillingham, UK). The clone for UDP-galactopyranose 
mutase was generously donated by Glaxo Wellcome.
5 ml of an enriched growth medium. Terrific Broth 
(Maniatis et a l ,  1982), containing ampicillin (200 pg m l"') was 
inoculated with a single colony of BL 21(D E 3)(pO R F6) and 
incubated overnight at 310 K with shaking. This was used to 
inoculate 500 ml of similarly treated media. Incubation 
continued under the same conditions until an OD^oo of 0.6 was 
reached. Isopropyl-/-D-thiogalactopyranoside (IPTG) was
added to a final concentration of 0.4 mM to initiate protein 
expression. A t this point the temperature was lowered to 
303 K and incubation was continued for a further 3 h, after 
which the cells were harvested by centrifugation (30 min, 
8000 rev m in"', 277 K). The use of an enriched media, lower 
induction temperatures and lower IPTG concentrations all 
served to increase the amount of soluble protein obtained.
Cells were resuspended in ice-cold sonication buffer 
[50 m M  tris(hydroxymethyl)aminome thane (Tris), 1 mM  
phenylmethysulfonyl fluoride (PM SF), 0.1 niM dithiothreitol 
(DTT)] at a concentration of 1.0 g cells per 1.0 ml buffer. 
Lysozyme was added (100 pg m l"') and the cells incubated at 
room temperature for 30 min. Sonication followed for 6 x  30 s 
intervals at 277 K. Cell debris was pelleted by centrifugation 
(30 min, 20000 rev m in"', 277 K). D eoxyribonuclease was 
added (20 ng m l"') and the cell extract filtered (0.02 pm).
The selenom ethionine variant of the protein was expressed  
by inhibition of m ethionine synthesis as described by D oublie  
(1997).
Crude extract was applied at 5 ml min"' to a 7.84 ml anion- 
exchange column (Perseptive Biosystems, H Q ) equilibrated in 
buffer A  (50 mM Tris pH 7.6 ,1  mM DTT) and eluted over a 0 -  
500 mM NaCl gradient over 15 column volumes. Protein 
elution was detected on-line at 280 and 420 nm. U D P-galac­
topyranose mutase was easily identified by its distinct yellow  
colour, a function of the FA D  co-factor. A 420 peaks from  
subsequent runs were pooled and concentrated under 
nitrogen pressure in an Am icon ultrafiltration cell. Pooled  
fractions from the anion-exchange column were brought to 
40% N H 4(S0 4 ) 2  saturation (2.4 g m l"') and applied at 
5 ml mill"' to a 7.84 ml hydrophobic interaction chromato-
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Figure 1
Alignment displaying the sequence homology between UDP-galactopyranose from E. coli, M. tuberculosis and K. pneumonia. The shaded area 
represents the amino acids common to each enzyme. Overall sequence homology is 40%.
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BM14 (À = 1.001 À ) using a M AR345, 18 cm mode image 
plate at the European Synchrotron Radiation Facility, 
Grenoble, France. Data were collected as 145 non-overlapping 
images in steps of 1° at a crystal-to-detector distance of 
242 mm. Diffraction was visible to 2.7 A ,  though weak below  
2.9 A  (Fig. 3). N o significant crystal decay was observed. Data  
were processed using D E N Z O  and S C A L E P A C K  (O tw i­
nowski, 1993) yielding 17660 unique reflections. The crystal 
was indexed in a monoclinic space group with unit-cell 
dimensions a = 71.12, b  = 58.42, c ~ 97.89 A , cr = y  = 90, 
/  = 96.38°. Analysis o f diffraction data identified systematic 
absences consistent with space group P 2\. Assuming a dimer 
of molecular mass 43 kDa for the monomer, V,„ is 
2.35 D a"' which falls in the allowed range for protein 
crystals (Matthews, 1968) and indicates a solvent content of  
47%. The data are 92% com plete from 15 to 2.9 A , with an 
Immerge of 5.0% and a redundancy of 2.5. For the highest 
resolution shell (3.0-2.9 A ), the data have a redundancy of 2.3 
with an R,nergc of 27%.
A s no hom ologous structure is known, we will need to 
determine phases experimentally. A  putative platinum-deri­
vative data set has also been recorded. A  crystal o f dimensions
0.4 xO.2 X ~0.03  mm was soaked in 3.5 mM K2PtCl6 for 9.5 h 
and back-soaked in cryoprotectant for 2 min before being 
rapidly transferred to the cold nitrogen stream (100 K). Data 
were collected as 298 non-overlapping images at 0.5° oscilla­
tion on station ID 14 EH3 at the ESRF using an M A R  CCD  
with a crystal-to-detector distance of 148 mm. The data are 
85% com plete to 3.5 Â  and have an R„iergc of 8.1% and a 
redundancy of 2.8. For the highest resolution shell (S.7-3.5 A ), 
the data have a redundancy of 2.9 with an Rmcr^c o f 14%. We 
were not able to locate the heavy-atom positions with this 
data. However, an EXAFS experiment did confirm the 
presence of platinum. In addition, a data set was collected with 
selenomethionine-variant protein. Data was again collected at 
100 K, X = 0.926 A , crystal-to-detector distance of 148 mm, 
using an M A R  CCD on ID14 EH3 at the ESRF. A  single 
crystal o f dimensions 0.4 x  0.25 x  —0.03 mm was used to 
record the entire data set in two sweeps of 25 s per 1° oscil­
lation. The data are 94% com plete (74% of the anomalous 
data) to 3.0 A. Rmcrge is 6.9% and the redundancy is 1.8. For
the highest resolution shell (3.16-3.0 A ), the data have a 
redundancy of 1.9 with an Rmergc o f 13.7%.
We expect structure determination to be aided by the 
presence of two m olecules within the asymmetric unit, 
allowing non-crystallographic averaging. We have extended  
our studies to the enzymes from K. pn eu m on ia  and M. 
tuberculosis. Small crystals o f the K. pneu m on ia  enzym e have 
been obtained. We expect to solve these structures by m ole­
cular replacement based on the E. co li structure.
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graphy column (Perseptive Biosystems. HP) equilibrated in 
buffer H (50 mM Tris. 40% I mM DTT]. Protein
was eluted in a decreasing N H 4(S0 4 ) 2  gradient (100-0% ) over 
15 column volumes. A 420 fractions were again combined and 
concentrated as before. Protein concentration was assayed by 
the method of Bradford (1976). l l i is  purification protocol 
yields highly homogenous protein for both the native and 
selenom ethionine versions, as judged by sodium dodecyl 
sulfate and isoelectric focusing polyacrylamide gel electro­
phoresis. A yield of 8 mg per litre of culture was obtained. 
Dynamic light-scattering studies showed the protein to be 
monodisperse with no polydispersity value measurable and a 
molecular weight of 96 kDa. which is consistent with a dimer 
of predicted mass 86 kDa. Mass spectroscopic studies (which 
confirmed selenium incorporation to be greater than 85%) 
suggest that, as isolated, only 50% of the protein contains both 
cofactors and about 10% contains neither cofactor.
Crystallization conditions for the native protein were 
arrived at after screening using the vapour-diffusion hanging- 
drop m ethodology ( Ducruix & Giegé. 1992). Two crystal forms 
were obtained. A single crystal o f dimensions 0.4 x 0.2 x  
0.05 mm was grown over one week from a solution of 
10 mg ml"' protein using 10% ( h / v ) polyethylene glycol (6K), 
100 mM HEPES (.V-2-hydroxyethylpiperazine-N'-2-ethane-
sulfonic acid; pH 7.0) as precipitant. The yellow crystal 
diffracted to 2.7 Â when fresh. The data was indexed using 
D E N Z O  (Otwinowski, 1993) in an orthorhombic space group 
{ F i l l ,  P2,2]2]. F 2 ,2 ,2  or P222,) with cell dimensions a = 56, 
h = 94, c -  134 A, Of = /  = y  = 90 . We have not been able to 
reproduce this form, despite extensive efforts. However, 
crystals grown over 5 d from a solution of 8 mg ml"' protein, 
100 mM HEPES pH 7.6, 20% (w/v) polyethylene glycol (4K), 
12% 2-propanol, 0.01 M L-cysteine have been consistently  
reproduced. Crystals are yellow diamond-shaped flat plates of 
dimensions 0.04 x 0.02 x  —0.002 mm. The second crystal­
lization conditions are identical for selenom ethionine protein 
with the addition of 1 mM DTT. Multiple seeding (2 d for each 
step, 5-t- steps being typical) is required to obtain crystals o f 0.5 
X 0.3 X <0.06 mm (Fig. 2) which are suitable for diffraction 
analysis. Preincubation with both cofactors substantially 
decreases the crystallization time and number of seeding steps 
required, although it has little effect on the final crystal size. 
Using the in-house Nonius rotating-anode and image-plate 
system, diffraction to 3.5 A  is observed. Conditions for cryo- 
protection of the crystals have been developed (15% glycerol 
or 15% methane pentanediol) allowing data collection at 
cryogenic temperatures.
r
( < o
(b)Figure 2
C rystals o f  I 'D P -g a la c to p y ra n o se  m u tase  (a )  b e fo re  and {h )  a fter  
seed in g . Ilte  d im en sio n s b efore  seed in g  are 0.()8 x  0 .04  x  ~ 0 .0 4  m m  and  
increase to  0.5 x  0..3 x < 0 .06  mm.
3. Data collection
A single crystal of UDP-galactopyranose mutase with 
dimensions 0.8 x 0.4 x —0.04 mm was cryoprotected (15% 
glycerol in mother liquor); soaking took place for approxi­
mately 2 min. The crystal was then scooped up with a rayon 
loop (Hampton Research) and rapidly transferred to the cold 
nitrogen stream (110 K). Diffraction data were collected on
Figure 3
S ec tio n  o f  a 1° o sc illa tio n  d iffraction  pattern  from  a crystal o f  U D P -  
ga la c to p y ra n o se  m u tase  tak en  at B M 14, E SR F, G ren o b le  record ed  w ith  
an M A R 3 4 5  im age p la te . T h e  reso lu tio n  at th e  e d g e  o f  th e ph otograp h  
corresp on d s to  2.8 A .
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1. Introduction
L-Rhamnose is a key com ponent o f the cell 
wall o f many pathogenic bacteria (Shibaev. 
1986; M cNeil et ai.. 1990). A  full listing of the 
established primary structures is available in 
the Com plex Carbohydrate Structure Data­
bank (http://www.ccrc.uga.edu). In myco­
bacteria, L-rhamnose is essential for cell-wall 
integrity as it connects the inner peptidoglycan 
layer to the arabinogalactan polysaccharides 
that are linked to the outer lipid layer of 
mycolic acids (M cNeil et a i .  1990). In Gram- 
negative bacteria. L-rhamnose is often found in 
the O-antigen part o f lipopolysaccharides. This 
portion o f the m olecule is o ften  responsible for 
resistance to com plem ent-m ediated serum 
killing (Joiner. 1988). In Streptococcus mutans. 
the rham nose-containing polysaccharide has 
been proposed to be responsible for the co lo­
nization of tooth surfaces (M ichalek et al.. 
1984) and adherence to heart, kidney and 
muscle tissues (Stinson et al.. 1980).
L-Rhamnose is incorporated in the m yco­
bacterial cell wall from a nucleoside diphos­
phate precursor. dTDP-L-rhamnose (M ikusova 
et a i .  1996). In G ram -negative bacteria such as 
Salm onella enterica (Jiang et al., 1991). Shigella 
fiexneri (Rajakumar e ta l..  1994), Xanthom onas 
cam pris (Koplin et al.. 1993) and Escherichia 
coli K12 (Stevenson et al.. 1994). as in Strep­
tococcus mutans and m ycobacteria (Tsukioka 
et al.. 1997: Ma et al.. 1997). four enzymes. 
Rm lA. RmlB. RmlC and Rm lD. are required 
to synthesize dTDP-L-rhamnose from 
ff-glucose-l-phosphate and dTTP (Fig. 1).
Because o f the importance of L-rhamnose in 
many pathogenic bacteria, all the enzym es 
involved in its synthesis are potential targets 
for the design of novel therapeutic inhibitors. 
To this end. we have initiated the structural 
study o f the four enzym es involved in its 
synthesis. H ere, we describe the purification, 
crystallization and preliminary structural 
studies o f dTDP-6-deoxy-D-xylo-4-hexulose  
3.5-epim erase (Rm lC). Bacterial Rm lC are not 
related in sequence to any other known 
epim erase.
2. RmlC over-expression and purification
Tlie open reading frame o f the gene encoding  
the dTDP-6-deoxy-D-xyIo-4-hexulose 3.5- 
epim erase (Rm lC) was amplified by PCR using 
primers that incorporated a 5' N d el  site and a 
S.s'/I site to facilitate cloning in the pET 30a(+) 
vector. Expression involves the IPTG-indu- 
cible T7 promoter and ribosom e-binding sites 
conferred by the vector, but uses the natural 
rm lC  initiation ATG  codon. The sequence o f 
the amplified and cloned gene was confirmed 
to be identical to the chrom osom al copy. The  
expressed protein is therefore strictly identical 
to the authentic product and carries no 
extensions or mutations. B L 21(D E 3) cells 
transformed with this plasmid were grown at 
310 K on Terrific Broth (M aniatis et al.. 1982) 
containing 80 pg m l" ’ kanamycin until the 
ODfioo reached 0.6-0.8. Overexpression was 
induced by addition of 1 m M  IPTG. A fter 3.5 h 
o f culture at 310 K. the cells were harvested by
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centrifugation (10 min. 6000,g. 277 K) and 
suspended in 100 m/W NaCl, 2 m/V/ DTT. 
5 m/W PMSF. 20 p.W lysozyme. 20 m/W Tris- 
HCl pH8.
After 20 min of incubation at room  
temperature, the viscosity o f the mixture was
dTTP + HO a-D -g lu c o se  1 - phosphate
o-p
R m lA PPi
HO d T D P -n -g lu coseHO'
OH o-TDP
R m lB + NA B
H3Ç dT D P-6-deoxy- D -xylo-4  
hexulose
OH O-TDP
R m lC
dT D P -6-deoxy- l  -ly  xo-4  
hexulose
RmlD
OH O-TDP
+ NADPH
J
OH
dTDP- L -rham nose
Figure 1
The dTDP-L-rhamnose biosynthetic pathway. RmlA. or-D-glucose- 
1-phosphate thymidylyltransterase: RmlB. dTDP-glucose 4.6-dehy- 
dratase; RmlC. dTDP-6-deoxy-D-xylo-4-hexulose 3.5-epimerase; 
RmlD. dTDP-6-deoxv-i.-xvlo-4-hexulose-4-reductase.
decreased by addition of DNAase  
(20 pg" ‘ ml) and by sonication (four cycles 
of 20 s interrupted by 1 min periods on ice). 
After addition o f 1 m/W EDTA. the mixture 
was centrifuged for 20 min at 20000g and 
277 K. Tlie supernatant was brought to 20% 
ammonium sulfate saturation 
and incubated for 1 h at 277 K. 
.After a second centrifugation 
(20 min. 20000g. 2~7 K). the 
supernatant was dialysed against 
three changes o f 2 1 of 50 mM  
NaCl. 20 m/W Tris-HCl pH 8.5. 
DTT was added to a final 
concentration of 2 m .\/ and the 
filtered supernatant passed 
through a POROS-HQ  HPLC 
column (BiocadSprint system). 
Proteins were eluted with a 50 -  
500 m/W NaCl gradient. A 
protein with a molecular weight 
corresponding to RmlC (.W^  ~
20.6 kD a) was found in a peak 
eluted at 250 m M  NaCl. Frac­
tions corresponding to this peak 
were pooled, concentrated with 
an Am icon filter and dialysed 
against two changes of 1 1 of 
20 m/W sodium  phosphate pH 
7.2. Am m onium  sulfate was 
added gradually to 20% satura­
tion and DTT was added to a 
final concentration of 2 m.W. The 
filtered protein sample was 
loaded on a POROS high- 
density phenyl HPLC column 
(BiocadSprint system) equili­
brated in buffer A (20% ammo­
nium sulfate. 20 m .\/ sodium  
phosphate pH 7.2). Elution was 
performed with an increasing 
gradient o f buffer B (20 m/W 
sodium phosphate pH 7.2): the
20.6 kDa protein was eluted at 
75% buffer B.
Figure 2
Photograph of an RmlC crystal.
3. Protein analysis
■After the two HPLC steps, the 
protein appeared to be pure as 
judged on an SDS silver-stained 
gel. Light-scattering experiments 
indicated the protein was 
m onodisperse with an apparent 
molecular weight of 42 kDa. 
consistent with a dimer. N- 
terminal sequencing confirmed 
that the protein was RmlC with 
an MMIVI N-terminal extremity, 
with less than 5% of the initi­
ating m ethionine removed. The
final yield of purification was 15 mg F  of 
Terrific Broth.
Protein concentration was estim ated by 
the Bradford m ethod (Bradford. 1976).
4. RmlC crystallization
After the final purification step. RmlC was 
dialysed against three changes of 2 1 of 
25 m .\/ Tris-HCl pH 7.75 and concentrated  
to 2.75 mg m F ‘. and DTT was then added to 
a final concentration of 5 m/W. Crystals were 
grown with 7 pi protein solution and 7 pi 
precipitant (1.6 M  ammonium sulfate. 0.1 M  
MES pH 6.1) using the sitting-drop vapour- 
diffusion m ethod (Ducruix & G iegé. 1992). 
Hexagonal shaped crystals grew in 6 d 
(Fig. 2).
5. Data collection
Data on frozen crystals (~ 0 .6  x 0.4 x 
0.4 mm) were obtained after a 20 min soak 
in cryoprotectant (20% glycerol. 2 M  
ammonium sulfate. 0.1 M MES pH 6.1).
2.65 À data were collected at 125 K using 
the Nonius/M acscience DIP2000 image 
plate. X-rays were generated at a wave­
length of 1.54 Â from a Nonius FR591 
rotating-anode generator and focused with 
M acScience mirrors. The crystal-to-detector 
distance was 150 mm. Data were recorded as 
62 non-overlapping 20 min F  oscillations.
2.17 A synchrotron data were recorded on 
a frozen crystal at 110 K at the ESR F BM14 
beamline at a wavelength of 0.979 Â  using a 
20 cm M AR Research image plate. The 
crystal-to-detector distance was 200 mm. 
Data were recorded as 26 non-overlapping 
1 min 1 oscillations.
Data on derivatives were recorded at 
Daresbury Laboratory at 125 K using a 
20 cm M AR Research image plate at 
beamline 9.5.
The reflections were indexed in a hexa­
gonal space group {a = b = 71.76.
c = 182.09 Â: O' = ^ = 90. y  = 120') with 
D E N Z O  and could be scaled in space 
groups P2,21 or P2i21 using S C A L E P A C K  
(O twinowski. 1992). The V,„ value 
(Matthews. 1968) was 2.2 Â ’ D a“ ' for two 
m olecules per asymmetric unit and 
2.4 Â ’ D a ~ ‘ for three m olecules per asym­
metric unit. The self-rotation function 
(Collaborative Computational Project. 
Number 4. 1994) has no peak for k = 120" 
but several peaks for k = 1 8 0 \ strongly 
suggesting that the asymmetric unit contains 
a dimer. Table 1 summarizes the two sets of 
data.
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Table 1
D a ta  c o l l e c t io n .
\  a lu e s  in  p a r e n th e s e s  r e f e r  to  th e  h ig h e s t  re s o lu t io n  sh e ll.
R e s o lu t io n  ( A )
H ig h e s t  r e s o lu t io n  s h e ll  ( A )
S p a c e  g ro u p
f  n it-c e ll  p a r a m e te r s  (A . )
T,„ ( tw o  m o le c u le s  p e r  a s y m m e tr ic  u n i t )  (A * D a " ')  
P e rc e n ta g e  s o lv e n t  
U n iq u e  r e lle c t io n s  
l td
A v e ra g e  re d u n d a n c y  
D a ta  c o m p le te n e s s  ( % )
( % )
^ /(merge = 5 2 5 1 / ( / ( ) ; - { / ( / i ) ) / 2 2 2 1 / < / ' ) / " l ie r e  lUi) 
o b serv atio n s.
D a ta  o b ta in e d  in -h o u s e
:5-:.b5
: .7 4 - : ,b 5
/ A . 21 o r  /A :2 1
ti = h  = 71 .5b , f  = 1X5.5:
u r =  d  =  ' / ( ) .  y  =  ! 2 0
5.5 
b4 .4  
16155
15.1 (2 .5 )
.VO (2 .0 )
97.1 (8 6 .2 )
7 .5 (2 7 .5 )
D a ta  o b ta in e d  a t th e  E S R F
4 0 -2 .1 7
2 .2 5 -2 .1 7
T 5 ,2 1  o r  P 5 C I
(1 =  6  =  71 .56 . c  = 185.5:
a  ~  fi = 90 . y  =  120
5.5
64 .4
27546
1 9 .5 (1 .9 )
2 .2 (2 .0 9 )
92.1 (8 0 .7 )
4 .7  (5 8 .4 )
th e  m e a su re d  d iffrac tio n  im en sitv  a n d  th e  su m m a tio n  includes all
6. Derivatization
A  partia l d ata  se t (5 0 % ) w as record ed  at 
D a resb u ry  L ab oratory  o n  a d er iva tive  
o b ta in ed  w ith  a 1 h so a k  in  1 m/V/ H gC L . 
T his d er iv a tiv e  had fou r  H g  a tom s b ou n d  
per un it c e ll w ith  a p h a sin g  p o w er  o f  1.6 and  
C ullis  R  factors o f  0 .64  for  acen tr ic  data  and
0.5 for  cen tr ic  data . W e h a v e  p rod u ced  o th er  
m ercu ry  d e r iv a tiv es  and se le n o m eth io n in e -  
en r ich ed  p r o te in  and w ill d e term in e  the  
R m lC  stru ctu re  shortly.
T lie  u se  o f  th e  C C L R C  D aresb u ry  
L ab o ra to ry  U K  and  E S R F -G re n o b le  fa c il­
ities  is g ra tefu lly  a ck n o w le d g e d . W e th ank
T h e W ellcom e Trust for  an  in tern ation a l 
travel grant.
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Abstract
C rystals h ave  b e e n  o b ta in ed  o f  su cc in y la ted  c o n ca n a v a lin  A  
c o m p le x e d  to  a n o v e l b id en ta te  sy n th etic  ligand. T lie  crystals  
are  th e  first ex a m p le  o f  a le c tin  w ith  a sy n th e tic  m u ltiv a len t  
ligan d  and  th e  first rep ort o f  c ry sta lliza tion  o f  su cc in y la ted  
c o n ca n a v a lin  A . T h e crysta ls  w ere  o b ta in ed  by s ittin g -d ro p  
vap ou r d iffu sio n  eq u ilib ra tin g  w ith  a so lu tio n  o f  20%  
p o ly e th y le n e  g ly co l, p H  5, 293 .5  K . C rystals are o r th o rh o m b ic , 
b e lo n g in g  to  sp ace  group  C 222; w ith  u n it-ce ll d im en sio n s  o f  
a  =  99 .1 , b  =  127.4, c  =  118.9 À . T h e  asym m e tr ic  u n it co n ta in s  a 
d im er, w ith  o v er  65%  o f  th e  v o lu m e  o ccu p ied  b y  w ater. T lie  
ligan d  cross  lin ks co n ca n a v a lin  A  m o n om ers. S u cc in y la ted  
c o n ca n a v a lin  A  is k n ow n  to  b e  a d im er  in so lu tio n , y e t  it is 
fo u n d  as th e  typ ica l co n ca n a v a lin  A  tetram er in  th e  crysta l. 
T lie  co n ta c ts  h o ld in g  to g e th er  the te tram er ap p ear  e x te n s iv e  
and  su g g e st th a t a fine b a lan ce  b e tw e e n  d im er and tetram ers  
exists. D a ta  to  2.65 Â  h a v e  b e e n  c o lle c ted  and th e  structure  
d e te rm in ed  b y  th e m o lecu la r  rep la cem en t m eth o d .
d isrupting or in ter fer in g  w ith  m o lecu la r  rec o g n itio n  p ro cesses  
rather than b e in g  cy to to x ic . O lig o sa cch a rid es  are p o o r  th er­
ap eu tics. h o w ev er , as tliey  are to o  po lar  for  sa tisfactory  u p tak e . 
M on osacch arid es, h o w ev e r , b in d  to o  w ea k ly  to  be o f  va lu e . 
O n e p o ssib le  so lu tio n  to  th is con u n d ru m  has b e e n  th e  u se  o f  
p o ly v a len t ligan ds. T h is is b a sed  o n  th e  o b serv a tio n  th a t in  
nature m any carb oh yd rate  p ro te in s  ap p ear  to  fu n c tio n  as 
oligom ers. C h em ica l sy n th esis  has p rod u ced  fa m ilie s  o f  su ch  
m u ltiva len t ligan ds, w h ich  o n  th e  b asis  o f  a g g lu tin a tio n  assays  
ap p ear  to  h a v e  d ram atic  resu lts  (K a n a i e t a l., 1997; S iga l e t a l., 
1996). S evera l stru ctu res are n o w  k n o w n  o f  lec tin s  c o m p le x e d  
to  naturally  occu rrin g  carb oh yd rates  that cross link  th e  p r o te in  
in  th e  crysta llin e  p h a se  (B o u rn e  e t al., 1994; D e s s e n  e t a l ,  1995; 
W right, 1992; W righ t &  H e ster , 1996). Im p ortan t q u estio n s  
rem ain  as to  th e  th erm o d y n a m ic  basis  o f  th ese  p o ly v a len t  
in teraction s (R o y , 1996; T o o n e , 1994). A s  part o f  a program  to  
co m b in e  ca lor im etery , crysta llograp h y  and ch em ica l sy n th es is  
w e rep ort th e  cry sta lliza tio n  and  structure d e te rm in a tio n  o f  th e  
first sy n th etic  m u ltiv a len t lig a n d -le c tin  com p lex .
1. Introduction
L ec tin s  com p rise  a varied  fam ily  o f  su gar-b in d in g  p ro te in s;  
th ey  are fou n d  in  all typ es  o f  organism s. P lan t lec tin s  in  
particu lar h ave  b e e n  o f  in ten se  in tere st , b eca u se  th ey  ex h ib it  
e x q u is ite  sp ecific ity  for  o lig o sa ccch a r id es  and  u n lik e  th eir  
m am m alian  cou n terp arts are m u ch  m o re  tractab le  to  char­
a c ter iza tio n  b y  a broad  ran ge  o f  b iop h ysica l tech n iq u es. T itus, 
th ese  p ro te in s , su ch  as th e  lec tin  from  C a n a va iia  e n s ifo rm is , 
co n ca n a v a lin  A  (co n  A ) ,  h a v e  serv ed  as m o d e ls  fo r  m o re  
c o m p le x  sp e c ie s  (R in i, 1995). In  con trast to  th e  e x q u is ite  
se le c tiv ity  at th e  o lig o sa cch a rid e  le v e l, th e  p ro te in s  are re la ­
tive ly  p ro m iscu o u s at th e  m o n o sa cch a r id e  le v e l, fa llin g  in to  
tw o  b road  c lasses; m a n n o se  sp ecific  and  g a la c to se  sp ecific . T h e  
affin ity  o f  th e  lectin  for m o n o sa cch a r id es  is co rre sp o n d in g ly  
low er, o f  th e  order = 1 x  10^ co m p a red  w ith  K a  =  
1 X 10* for o lig o sa cch a rid es  (C h erv en a k  & T o o n e , 1995; 
M andai e t a l., 1994; T o o n e , 1994). T h e  a d v en t o f  c a lo r im etr ic  
data  o n  le c tin  (e sp e c ia lly  c o n  A )  carb oh yd rate  c o m p le x e s  and  
th e  r ea lisa tio n  th at ab  in itio  m o d e llin g  m eth o d s  w ere  fa ilin g  to  
accu rately  m o d e l p r o te in -ca rb o h y d ra te  in tera ctio n s  h as re in ­
v ig o ra ted  th e  structural s tu d y  o f  le c tin -ca r b o h y d r a te  
co m p lex e s . A  nu m b er o f  o lig o sa c ch a r id e -p r o te in  c o m p le x e s  
h a v e  b e e n  d eterm in ed  (R in i. 1995 ). m o st r ec en tly  th e  stru c­
tu res o f  c o n  A  w ith  its c o g n a te  tr isacch arid e  and  p en ta ­
sacch arid e  (N a ism ith  & F ield , 1996: M o o th o o  & N a ism ith , 
1998).
P r o te in -sa cc h a r id e  in tera ctio n s are a p p ea lin g  th era p eu tic  
targets in m an y  d iseases , particu larly  th o se  in v o lv in g  in fec tio n  
and  in ap p rop ria te  im m u n e r esp o n se  (D w e k , 1996). T h er­
a p eu tics  d esig n ed  for  th is ta sk  w o u ld  p r in c ip a lly  b e  a im ed  at
L  1998 International Union of Crystallography 
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2. Crystallization and X-ray data collection
S u ccin y la ted  c o n  A  w as p u rch ased  from  S igm a (P o o le , U K ).  
T he syn th esis  o f  th e  b id en ta te  ligan d  [l,3 -d i-(A f-p ro p y lo x y -a -  
D -m an n op yran osy l)-carb om yl 5 -m eth y la z id o -b en zen e , F ig . 1] 
w ill be d escr ib ed  e lse w h e re . C rysta lliza tion  tr ia ls w ere  
p erform ed  b y  th e  m ea n s o f  th e  sittin g -d rop  va p o u r-d iffu sio n  
m eth o d  (D u cru ix  &  G ie g é , 1992). A  so lu tio n  o f  su cc in y la ted  
co n  A  (1 .2 m M )/lig a n d  (18  m M ) w as p rep ared  in  20  m M  I r is  
p H  7. 100 m M  N a C l, 1 m M  C aC l; and 1 m M  M nC lg and  
eq u ilib ra ted  aga in st 20%  p o ly e th y le n e  g lyco l (M , =  6 0 0 0 ), 
100 m M  citric acid , p H  5 in  sittin g -d rop  trays (C h a r les  Su p p er , 
U S A ) at 293.5 K . S m all crysta ls o f  d im en sio n s  0.1 x  0 .2  x  
0.2  m m  w ere  in itia lly  o b ta in ed . O p tim iza tio n  o f  th e  ligan d  
co n cen tra tio n  (5 m M ) y ie ld e d  b lo ck -sh a p e d  crysta ls  o f  u p  to
1.0 X 0.8  X 0 .6  m m . C rystal grow th  w as c o m p le te  in  14  d. 12 
crystals w ere  e x a m in e d , m o u n ted  in  a th in -w a lled  g la ss  c a p il­
OH  
(  OH
H O '
H O -
Fig. 1. The bivalent ligand [l,3-di-(Af-propyloxy-D!-D-mannopyranosyl)- 
carbomyl 5-m ethylazido-benzene] which cross links con A.
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lary. by e x p o su re  to  X -rays. T he reso lu tion  lim it var ied  from
2.65 to  3 .5 Â . A ll d iffraction  data  w ere c o lle c ted  at 293.5  K 
from  a s in g le  crystal (U.6 x  0.5 x  0.3 m m ) w hich  d iffrac ted  to  
th e h igh est r eso lu tion . L arger crystals d id  n o t g iv e  h igh er  
reso lu tio n  data. A ll d ata  w ere record ed  on  th e N o n iu s/  
M a cS cien ce  D IP200Ü  du al im age  p la te. X -rays w ere  g en era ted  
u sin g  a E n r a f-N o n iu s  F R 951 rota tin g -an od e g en era to r  and  
fo cu sed  u sin g  th e M a cS cien ce  m irror system , th rou gh  a 0.5 m m  
co llim a tor. D a ta  w ere c o lle c ted  as 92 n o n -o v er la p p in g  25 min  
1 o sc illa tio n s  w ith  a c ry sta l-to -d etec to r  d istan ce  o f  140 m m . 
T h e reso lu t io n  lim it o f  th e data  w as 2.65 A and n o  sign ifican t  
crysta l d e ca y  w as o b se rv ed  during data co lle c t io n . T lie  
program s D E N Z O  and S C A L E P A C K  {O tw in ow sk i. 1993) 
w ere  u sed  to  p ro cess  th e data. T he crystal w as in d ex e d  in a 
cen tred  o r th o rh o m b ic  sp a ce  grou p  w ith u n it-ce ll d im en sio n s  
n =  99.1. b  = 127.4. c -  118.9 A . A n a ly sis  o f  d iffraction  data  
id en tified  sy stem a tic  a b se n ces  co n s isten t w ith  sp a ce  group  
C 2 2 2 |. A  d im er o f  m o lecu la r  m ass 49  k D a . g ives rise to  a F„, 
(M atth ew s. 1968) o f  3 .8  D a " ' and in d ica tes  a so lv en t  
c o n te n t o f  o v e r  65% . T h e d ata  are 96%  co m p le te  from  26 to
2.65 Â . w ith  an  /?merge 7.2%  w ith  a red u n d an cy  o f  2.2  and a 
to ta l o f  84%  o f  p o ssib le  d a ta  are g rea ter  th an  l a .  For th e  h igh- 
reso lu tio n  sh e ll (2 .7 5 -2 .6 5  Â ) ,  the corresp on d in g  v a lu es  are 
98%  co m p le te , Rmerge 20 .2% . red u n d an cy  2.2 and 83%  grea ter  
th an  la .
3. S tru cture so lu tio n
T lie  stru ctu re  w as so lv ed  by m olecu lar  rep la cem en t, u sin g  
A M o R e  (N a v a za . 1994) as im p le m e n te d  in th e  C C P 4 p ack age  
(C o lla b o ra tiv e  C o m p u ta tio n a l P roject. N u m b er 4. 1994). T lie  
c o n v en tio n a l co n  A  d im er (m on om ers A  and  B )  from  th e  
tr im an n osid e  co m p le x  o f  co n  A  (I C V N ) str ip p ed  o f  m eta ls , 
w aters an d  sugars w as u sed  as th e  search  m o d el. T h e  ro ta tion  
fu n ction  fou n d  a sin g le  so lu tio n  w ith  a c o rre la tio n  co effic ien t  
o f  0.28  and th e  tran sla tion  fu n ctio n  p rod u ced  a final so lu tio n  
w ith  a c o rre la tio n  co e ffic ie n t o f  0.84. A  tran sla tion  search  in  
C 222 g a v e  n o  so lu tio n . In ord er  to  v isu a lize  the in tera ctio n  o f  
th e ligan d  w ith  ea ch  p ro te in  m on om er, the asym m etr ic  unit 
w as r ed efin e d  su ch  th at o n e  m o n o m er  o f  th e  c o n  A  d im er  
(m o n o m e r  A )  w as lin k ed  v ia  th e  ligan d to  a n o th er  m o n o m er
monomer B
c ro s s  lin k
m o n o m e r  C
m o n o m e r  v4
Fig. 2. Tlie conventional dimer of con A is formed by monomer A  and 
monomer B. the ligand cross links monomer A  to monomer C. 
Monomer C is related by the crystaiiographic transformation (1 — .v. 
1 — y, Ï 4- 4) to monomer B. Tlie cross-linking ligand is shown a 
straight line between the two sugar-binding sites.
(m o n o m er  O .  M o n o m er  C w as g en e ra ted  by ap p ly in g  the  
sym m etry tran sform ation  (4 — .v. 4 — y, z 4 -4 ) to  m o n o m er  B  
(F ig. 2). O th er  crysta iiograp h ic  op era to rs  gen era te  th e typical' 
con  A  tetram er. T lie  in itial free  R  factor was 38%  to  2.65 Â . 
R ig id -b od y  refin em en t o f  th e m o n o m ers gave a free R  factor o f  
30% . C lear d en sity  is v is ib le  for th e  m eta l io n s  and ligand. T he  
ligand is currently b e in g  bu ilt in to  th is e le c tro n  d en sity  and a 
stereo ch em ica l d ic tion ary  con stru cted . O n ce  th e ligan d  has  
b e e n  bu ilt in to  den sity , refin em en t w ill reco m m en ce . A  fu lly  
refined  structure w ill be rep orted  e lsew h ere .
Til at su ccin y la ted  co n  A  is fou n d  as a te tram er in th is  
crysta l is puzzling; the e lectro n  d en s ity  sh ow s e v id e n c e  o f  
su ccin y ia tion  on  tw o  ly s in e  residu es. D im er iza tio n  o f  the  
dim ers o cclu d es  4300  Â" o f  surface area  w hich  co m p a res  to  
5200  A" for n ative  co n  A  (D e a c o n  e î a l., 1997; R e e k e  e t al.. 
1975) and 4800  for th e  m a n n o se  co n  A  co m p le x  (N a ism ith  
et al.. 1994). T h ere  are 120 p r o te in -p r o te in  c o n ta c ts  le ss  than
4.0  A  b etw een  th e tw o  d im ers in  th is structure, co m p a red  w ith  
260  for th e na tive  and 160 for th e  m a n n o se  co m p lex . A lth o u g h  
th is tetram er is c lea r ly  less  tigh tly  p a ck e d  than th e  o th er  tw o. 
by a standard set o f  s tandard  cry sta llograp h ers’ criteria  (b u ried  
surface area  and co n ta c ts ) o n e  w ou ld  id en tify  th e  p ro te in  to  b e  
a fu n ction a l tetram er. H o w ev er , so lu tio n  stu d ies  sh o w  u n a m ­
b igu ou sly  that su cc in y la ted  co n  A  is a d im er  (G u n th er  e t al., 
1973). It appears th at th e  en erg y  barrier b e tw e e n  d im ers and  
tetram ers for su cc in y la ted  co n  A  is sm all e n o u g h  th at crysta l- 
pack in g  forces  can  d rive fo rm a tio n  o f  th e  tetram er. W e fee l  
th is resu lt p o ses  an in terest in g  te s t for th o se  w h o  w ish  to  d e v ise  
au tom atic  m e th o d s o f  id en tify in g  p ro te in  o lig o m er iz a tio n  s ta te  
from  static  crystal structures.
JH N  ack n o w led g es  B B S R C  su p p ort (B 0 8 3 0 7 ) an d  w e  th ank  
John  H elliw ell for e n co u ra g em en t.
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